

Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021

KEY WORDS: adults; evidence-based medicine; guidelines; sepsis; septic shock

INTRODUCTION

Sepsis is life-threatening organ dysfunction caused by a dysregulated host response to infection (1). Sepsis and septic shock are major healthcare problems, impacting millions of people around the world each year and killing between one in three and one in six of those it affects (2–4). Early identification and appropriate management in the initial hours after the development of sepsis improve outcomes.

The recommendations in this document are intended to provide guidance for the clinician caring for adult patients with sepsis or septic shock in the hospital setting. Recommendations from these guidelines cannot replace the clinician's decision-making capability when presented with a unique patient's clinical variables. These guidelines are intended to reflect best practice (Table 1).

(References 5–24 are referred to in the Methodology section which can be accessed at Supplemental Digital Content: Methodology.)

SCREENING AND EARLY TREATMENT

Recommendation

1. For hospitals and health systems, we **recommend** using a performance improvement program for sepsis, including sepsis screening for acutely ill, high-risk patients and standard operating procedures for treatment.

Strong recommendation, moderate quality of evidence for screening.

Strong recommendation, very low-quality evidence for standard operating procedures.

Screening for Patients With Sepsis and Septic Shock

Rationale

Sepsis performance improvement programs generally consist of sepsis screening, education, measurement of sepsis bundle performance, patient outcomes, and actions for identified opportunities (25, 26). Despite some inconsistency, a meta-analysis of 50 observational studies on the effect of performance improvement programs showed that these programs were associated with better adherence to sepsis bundles along with a reduction in mortality (OR, 0.66; 95% CI, 0.61–0.72) in patients with sepsis and septic

Laura Evans¹
 Andrew Rhodes²
 Waleed Alhazzani³
 Massimo Antonelli⁴
 Craig M. Coopersmith⁵
 Craig French⁶
 Flávia R. Machado⁷
 Lauralyn McIntyre⁸
 Marlies Ostermann⁹
 Hallie C. Prescott¹⁰
 Christa Schorr¹¹
 Steven Simpson¹²
 W. Joost Wiersinga¹³
 Fayeze Alshamsi¹⁴
 Derek C. Angus¹⁵
 Yaseen Arabi¹⁶
 Luciano Azevedo¹⁷
 Richard Beale¹⁸
 Gregory Beilman¹⁹
 Emilie Belley-Cote²⁰
 Lisa Burry²¹
 Maurizio Cecconi²²
 John Centofanti²³
 Angel Coz Yataco²⁴
 Jan De Waele²⁵
 R. Phillip Dellinger²⁶

This article is being simultaneously published in *Critical Care Medicine* (DOI: <https://doi.org/10.1097/CCM.0000000000005337>) and *Intensive Care Medicine* (DOI: <https://doi.org/10.1007/s00134-021-06506-y>).

Copyright © 2021 by the Society of Critical Care Medicine and the European Society of Intensive Care Medicine. All Rights Reserved.

shock (27). The specific components of performance improvement did not appear to be as important as the presence of a program that included sepsis screening and metrics.

Sepsis screening tools are designed to promote early identification of sepsis and consist of manual methods or automated use of the electronic health record (EHR). There is wide variation in diagnostic accuracy of these tools with most having poor predictive values, although the use of some was associated with improvements in care processes (28–31). A variety of clinical variables and tools are used for sepsis screening, such as systemic inflammatory response syndrome (SIRS) criteria, vital signs, signs of infection, quick Sequential Organ Failure Score (qSOFA) or Sequential Organ Failure Assessment (SOFA) criteria, National Early Warning Score (NEWS), or Modified Early Warning Score (MEWS) (26, 32). Machine learning may improve performance of screening tools, and in a meta-analysis of 42,623 patients from seven studies for predicting hospital acquired sepsis the pooled area under the receiving operating curve (SAUROC) (0.89; 95% CI, 0.86–0.92); sensitivity (81%; 95% CI, 80–81), and specificity (72%; 95% CI, 72–72) was higher for machine learning than the SAUROC for traditional screening tools such as SIRS (0.70), MEWS (0.50), and SOFA (0.78) (32).

Screening tools may target patients in various locations, such as in-patient wards, emergency departments, or ICUs (28–30, 32). A pooled analysis of three RCTs did not demonstrate a mortality benefit of active screening (RR, 0.90; 95% CI, 0.51–1.58) (33–35). However, while there is wide variation in sensitivity and specificity of sepsis screening tools, they are an important component of identifying sepsis early for timely intervention.

Standard operating procedures are a set of practices that specify a preferred response to specific clinical circumstances (36). Sepsis standard operating procedures, initially specified as Early Goal Directed Therapy have evolved to “usual care” which includes a standard approach with components of the sepsis bundle, early identification, lactate, cultures, antibiotics, and fluids (37). A large study examined the association between implementation of state-mandated sepsis protocols, compliance, and mortality. A retrospective cohort study of 1,012,410 sepsis admissions to 509 hospitals in the United States in a retrospective cohort examined mortality before (27 months) and after (30 months) implementation of New York state sepsis regulations, with a concurrent control population from four other states (38). In this comparative interrupted time series, mortality was lower in hospitals with higher compliance with achieving the sepsis bundles successfully.

Lower resource countries may experience a different effect. A meta-analysis of two RCTs in Sub-Saharan Africa found higher mortality (RR, 1.26; 95% CI, 1.00–1.58) with standard operating procedures compared with usual care, while it was decreased in one observational study (adjusted hazard ratio [HR]; 95% CI, 0.55–0.98) (39).

Kent Doi²⁷
 Bin Du²⁸
 Elisa Estenssoro²⁹
 Ricard Ferrer³⁰
 Charles Gomersall³¹
 Carol Hodgson³²
 Morten Hylander Møller³³
 Theodore Iwashyna³⁴
 Shevin Jacob³⁵
 Ruth Kleinpell³⁶
 Michael Klompas³⁷
 Younsuck Koh³⁸
 Anand Kumar³⁹
 Arthur Kwizera⁴⁰
 Suzana Lobo⁴¹
 Henry Masur⁴²
 Steven McGloughlin⁴³
 Sangeeta Mehta⁴⁴
 Yatin Mehta⁴⁵
 Mervyn Mer⁴⁶
 Mark Nunnally⁴⁷
 Simon Oczkowski⁴⁸
 Tiffany Osborn⁴⁹
 Elizabeth Papathanassoglou⁵⁰
 Anders Perner⁵¹
 Michael Puskarich⁵²
 Jason Roberts⁵³
 William Schweickert⁵⁴
 Maureen Seckel⁵⁵
 Jonathan Sevransky⁵⁶
 Charles L. Sprung⁵⁷
 Tobias Welte⁵⁸
 Janice Zimmerman⁵⁹
 Mitchell Levy⁶⁰

Recommendation

- We **recommend against** using qSOFA compared with SIRS, NEWS, or MEWS as a single screening tool for sepsis or septic shock.

Strong recommendation, moderate-quality evidence.

TABLE 1.
Table of Current Recommendations and Changes From Previous 2016 Recommendations

Recommendations 2021	Recommendation Strength and Quality of Evidence	Changes From 2016 Recommendations
1. For hospitals and health systems, we recommend using a performance improvement program for sepsis, including sepsis screening for acutely ill, high-risk patients and standard operating procedures for treatment.	Strong, moderate-quality evidence (for screening) Strong, very low-quality evidence (for standard operating procedures)	Changed from Best practice statement “We recommend that hospitals and hospital systems have a performance improvement program for sepsis including sepsis screening for acutely ill, high-risk patients.”
2. We recommend against using qSOFA compared with SIRS, NEWS, or MEWS as a single-screening tool for sepsis or septic shock.	Strong, moderate-quality evidence	NEW
3. For adults suspected of having sepsis, we suggest measuring blood lactate.	Weak, low quality of evidence	
INITIAL RESUSCITATION		
4. Sepsis and septic shock are medical emergencies, and we recommend that treatment and resuscitation begin immediately.	Best practice statement	
5. For patients with sepsis induced hypoperfusion or septic shock we suggest that at least 30 mL/kg of IV crystalloid fluid should be given within the first 3 hr of resuscitation.	Weak, low quality of evidence	DOWNGRADE from Strong , low quality of evidence “We recommend that in the initial resuscitation from sepsis-induced hypoperfusion, at least 30 mL/kg of IV crystalloid fluid be given within the first 3 hr”
6. For adults with sepsis or septic shock, we suggest using dynamic measures to guide fluid resuscitation, over physical examination, or static parameters alone.	Weak, very low quality of evidence	
7. For adults with sepsis or septic shock, we suggest guiding resuscitation to decrease serum lactate in patients with elevated lactate level, over not using serum lactate.	Weak, low quality of evidence	
8. For adults with septic shock, we suggest using capillary refill time to guide resuscitation as an adjunct to other measures of perfusion.	Weak, low quality of evidence	NEW
MEAN ARTERIAL PRESSURE		
9. For adults with septic shock on vasopressors, we recommend an initial target mean arterial pressure (MAP) of 65 mm Hg over higher MAP targets.	Strong, moderate-quality evidence	
ADMISSION TO INTENSIVE CARE		
10. For adults with sepsis or septic shock who require ICU admission, we suggest admitting the patients to the ICU within 6 hr.	Weak, low quality of evidence	

Recommendations 2021	Recommendation Strength and Quality of Evidence	Changes From 2016 Recommendations
INFECTION		
11. For adults with suspected sepsis or septic shock but unconfirmed infection, we recommend continuously re-evaluating and searching for alternative diagnoses and discontinuing empiric antimicrobials if an alternative cause of illness is demonstrated or strongly suspected.	Best practice statement	
12. For adults with possible septic shock or a high likelihood for sepsis, we recommend administering antimicrobials immediately, ideally within 1 hr of recognition.	Strong, low quality of evidence (Septic shock) Strong, very low quality of evidence (Sepsis without shock)	CHANGED from previous: “We recommend that administration of intravenous antimicrobials should be initiated as soon as possible after recognition and within one hour for both a) septic shock and b) sepsis without shock” strong recommendation, moderate quality of evidence
13. For adults with possible sepsis without shock, we recommend rapid assessment of the likelihood of infectious versus noninfectious causes of acute illness.	Best practice statement	
14. For adults with possible sepsis without shock, we suggest a time-limited course of rapid investigation and if concern for infection persists, the administration of antimicrobials within 3 hr from the time when sepsis was first recognized.	Weak, very low quality of evidence	NEW from previous: “We recommend that administration of IV antimicrobials should be initiated as soon as possible after recognition and within 1 hr for both a) septic shock and b) sepsis without shock” strong recommendation, moderate quality of evidence
15. For adults with a low likelihood of infection and without shock, we suggest deferring antimicrobials while continuing to closely monitor the patient.	Weak, very low quality of evidence	NEW from previous: “We recommend that administration of IV antimicrobials should be initiated as soon as possible after recognition and within 1 hr for both a) septic shock and b) sepsis without shock” strong recommendation, moderate quality of evidence
16. For adults with suspected sepsis or septic shock, we suggest against using procalcitonin plus clinical evaluation to decide when to start antimicrobials, as compared to clinical evaluation alone.	Weak, very low quality of evidence	
17. For adults with sepsis or septic shock at high risk of MRSA, we recommend using empiric antimicrobials with MRSA coverage over using antimicrobials without MRSA coverage.	Best practice statement	NEW from previous: “We recommend empiric broad-spectrum therapy with one or more antimicrobials for patients presenting with sepsis or septic shock to cover all likely pathogens (including bacterial and potentially fungal or viral coverage.” Strong recommendation, moderate quality of evidence

Downloaded from http://journals.lww.com/ccmjournal by BHDMM5ePHKav1ZEumt1QIN4a+kJLhEz9psIH04XM10hCy WCX1AWN7YQpI0I0HD33D00dRy7TVSF4C3VC4QAVpDDa8K2+YabH515KE on 09/11/2024

Recommendations 2021	Recommendation Strength and Quality of Evidence	Changes From 2016 Recommendations
18. For adults with sepsis or septic shock at low risk of MRSA, we suggest against using empiric antimicrobials with MRSA coverage, as compared with using antimicrobials without MRSA coverage.	Weak , low quality of evidence	NEW from previous: “We recommend empiric broad-spectrum therapy with one or more antimicrobials for patients presenting with sepsis or septic shock to cover all likely pathogens (including bacterial and potentially fungal or viral coverage.” Strong recommendation , moderate quality of evidence
19. For adults with sepsis or septic shock and high risk for multidrug resistant (MDR) organisms, we suggest using two antimicrobials with gram-negative coverage for empiric treatment over one gram-negative agent.	Weak , very low quality of evidence	
20. For adults with sepsis or septic shock and low risk for multidrug resistant (MDR) organisms, we suggest against using two gram-negative agents for empiric treatment, as compared to one gram-negative agent.	Weak , very low quality of evidence	
21. For adults with sepsis or septic shock, we suggest against using double gram-negative coverage once the causative pathogen and the susceptibilities are known.	Weak , very low quality of evidence	
22. For adults with sepsis or septic shock at high risk of fungal infection, we suggest using empiric antifungal therapy over no antifungal therapy.	Weak , low quality of evidence	NEW from previous: “We recommend empiric broad-spectrum therapy with one or more antimicrobials for patients presenting with sepsis or septic shock to cover all likely pathogens (including bacterial and potentially fungal or viral coverage.” Strong recommendation , moderate quality of evidence
23. For adults with sepsis or septic shock at low risk of fungal infection, we suggest against empiric use of antifungal therapy	Weak , low quality of evidence	NEW from previous: “We recommend empiric broad-spectrum therapy with one or more antimicrobials for patients presenting with sepsis or septic shock to cover all likely pathogens (including bacterial and potentially fungal or viral coverage. “ Strong recommendation , moderate quality of evidence
24. We make no recommendation on the use of antiviral agents.	No recommendation	
25. For adults with sepsis or septic shock, we suggest using prolonged infusion of beta-lactams for maintenance (after an initial bolus) over conventional bolus infusion.	Weak , moderate-quality evidence	

Recommendations 2021	Recommendation Strength and Quality of Evidence	Changes From 2016 Recommendations
26. For adults with sepsis or septic shock, we recommend optimising dosing strategies of antimicrobials based on accepted pharmacokinetic/pharmacodynamic (PK/PD) principles and specific drug properties.	Best practice statement	
27. For adults with sepsis or septic shock, we recommend rapidly identifying or excluding a specific anatomical diagnosis of infection that requires emergent source control and implementing any required source control intervention as soon as medically and logistically practical.	Best practice statement	
28. For adults with sepsis or septic shock, we recommend prompt removal of intravascular access devices that are a possible source of sepsis or septic shock after other vascular access has been established.	Best practice statement	
29. For adults with sepsis or septic shock, we suggest daily assessment for de-escalation of antimicrobials over using fixed durations of therapy without daily reassessment for de-escalation.	Weak, very low quality of evidence	
30. For adults with an initial diagnosis of sepsis or septic shock and adequate source control, we suggest using shorter over longer duration of antimicrobial therapy.	Weak, very low quality of evidence	
31. For adults with an initial diagnosis of sepsis or septic shock and adequate source control where optimal duration of therapy is unclear, we suggest using procalcitonin AND clinical evaluation to decide when to discontinue antimicrobials over clinical evaluation alone.	Weak, low quality of evidence	
HEMODYNAMIC MANAGEMENT		
32. For adults with sepsis or septic shock, we recommend using crystalloids as first-line fluid for resuscitation.	Strong, moderate-quality evidence	
33. For adults with sepsis or septic shock, we suggest using balanced crystalloids instead of normal saline for resuscitation.	Weak, low quality of evidence	<p>CHANGED from weak recommendation, low quality of evidence.</p> <p>“We suggest using either balanced crystalloids or saline for fluid resuscitation of patients with sepsis or septic shock”</p>
34. For adults with sepsis or septic shock, we suggest using albumin in patients who received large volumes of crystalloids.	Weak, moderate-quality evidence	
35. For adults with sepsis or septic shock, we recommend against using starches for resuscitation.	Strong, high-quality evidence	

Downloaded from http://journals.lww.com/ccmjournal by BHDMM5ePHKav1ZEoum1tIQN4a+KJLHEZg0sIH04XM10nCy on 09/11/2024

Recommendations 2021	Recommendation Strength and Quality of Evidence	Changes From 2016 Recommendations
36. For adults with sepsis and septic shock, we suggest against using gelatin for resuscitation.	Weak , moderate-quality evidence	UPGRADE from weak recommendation , low quality of evidence “We suggest using crystalloids over gelatins when resuscitating patients with sepsis or septic shock.”
37. For adults with septic shock, we recommend using norepinephrine as the first-line agent over other vasopressors.	Strong Dopamine. <i>High-quality evidence</i> Vasopressin. <i>Moderate-quality evidence</i> Epinephrine. <i>Low quality of evidence</i> Selepressin. <i>Low quality of evidence</i> Angiotensin II. <i>Very low-quality evidence</i>	
38. For adults with septic shock on norepinephrine with inadequate mean arterial pressure levels, we suggest adding vasopressin instead of escalating the dose of norepinephrine.	Weak , moderate quality evidence	
39. For adults with septic shock and inadequate mean arterial pressure levels despite norepinephrine and vasopressin, we suggest adding epinephrine.	Weak , low quality of evidence	
40. For adults with septic shock, we suggest against using terlipressin.	Weak , low quality of evidence	
41. For adults with septic shock and cardiac dysfunction with persistent hypoperfusion despite adequate volume status and arterial blood pressure, we suggest either adding dobutamine to norepinephrine or using epinephrine alone.	Weak , low quality of evidence	
42. For adults with septic shock and cardiac dysfunction with persistent hypoperfusion despite adequate volume status and arterial blood pressure, we suggest against using levosimendan.	Weak , low quality of evidence	NEW
43. For adults with septic shock, we suggest invasive monitoring of arterial blood pressure over noninvasive monitoring, as soon as practical and if resources are available.	Weak , very low quality of evidence	
44. For adults with septic shock, we suggest starting vasopressors peripherally to restore mean arterial pressure rather than delaying initiation until a central venous access is secured.	Weak , very low quality of evidence	NEW

Recommendations 2021	Recommendation Strength and Quality of Evidence	Changes From 2016 Recommendations
<p>45. There is insufficient evidence to make a recommendation on the use of restrictive versus liberal fluid strategies in the first 24 hr of resuscitation in patients with sepsis and septic shock who still have signs of hypoperfusion and volume depletion after the initial resuscitation.</p>	<p>No recommendation</p>	<p>NEW</p> <p>“We suggest using either balanced crystalloids or saline for fluid resuscitation of patients with sepsis or septic shock”</p> <p>Weak recommendation, low quality of evidence</p> <p>“We suggest using crystalloids over gelatins when resuscitating patients with sepsis or septic shock.”</p> <p>Weak recommendation, low quality of evidence</p>
<p>VENTILATION</p>		
<p>46. There is insufficient evidence to make a recommendation on the use of conservative oxygen targets in adults with sepsis-induced hypoxemic respiratory failure.</p>	<p>No recommendation</p>	
<p>47. For adults with sepsis-induced hypoxemic respiratory failure, we suggest the use of high flow nasal oxygen over noninvasive ventilation.</p>	<p>Weak, low quality of evidence</p>	<p>NEW</p>
<p>48. There is insufficient evidence to make a recommendation on the use of noninvasive ventilation in comparison to invasive ventilation for adults with sepsis-induced hypoxemic respiratory failure.</p>	<p>No recommendation</p>	
<p>49. For adults with sepsis-induced ARDS, we recommend using a low tidal volume ventilation strategy (6 mL/kg), over a high tidal volume strategy (> 10 mL/kg).</p>	<p>Strong, high-quality evidence</p>	
<p>50. For adults with sepsis-induced severe ARDS, we recommend using an upper limit goal for plateau pressures of 30 cm H₂O, over higher plateau pressures.</p>	<p>Strong, moderate-quality evidence</p>	
<p>51. For adults with moderate to severe sepsis-induced ARDS, we suggest using higher PEEP over lower PEEP.</p>	<p>Weak, moderate-quality evidence</p>	
<p>52. For adults with sepsis-induced respiratory failure (without ARDS), we suggest using low tidal volume as compared with high tidal volume ventilation.</p>	<p>Weak, low quality of evidence</p>	
<p>53. For adults with sepsis-induced moderate-severe ARDS, we suggest using traditional recruitment maneuvers.</p>	<p>Weak, moderate-quality evidence</p>	
<p>54. When using recruitment maneuvers, we recommend against using incremental PEEP titration/strategy.</p>	<p>Strong, moderate-quality evidence</p>	
<p>55. For adults with sepsis-induced moderate-severe ARDS, we recommend using prone ventilation for greater than 12 hr daily.</p>	<p>Strong, moderate-quality evidence</p>	

Downloaded from http://journals.lww.com/ccmjournal by BHDMSepHKav1Zcum1tQIN4a+kLHeZg0sH0d4XM0hCy on 09/11/2024

Recommendations 2021	Recommendation Strength and Quality of Evidence	Changes From 2016 Recommendations
56. For adults with sepsis induced moderate-severe ARDS, we suggest using intermittent NMBA boluses, over NMBA continuous infusion.	Weak , moderate-quality evidence	
57. For adults with sepsis-induced severe ARDS, we suggest using Venovenous (VV) ECMO when conventional mechanical ventilation fails in experienced centers with the infrastructure in place to support its use.	Weak , low quality of evidence	NEW
ADDITIONAL THERAPIES		
58. For adults with septic shock and an ongoing requirement for vasopressor therapy we suggest using IV corticosteroids.	Weak , moderate-quality evidence	UPGRADE from Weak recommendation , low quality of evidence “We suggest against using IV hydrocortisone to treat septic shock patients if adequate fluid resuscitation and vasopressor therapy are able to restore hemodynamic stability (see goals for Initial Resuscitation). If this is not achievable, we suggest IV hydrocortisone at a dose of 200 mg/day.”
59. For adults with sepsis or septic shock we suggest against using polymyxin B hemoperfusion.	Weak , low quality of evidence	NEW from previous: “We make no recommendation regarding the use of blood purification techniques”
60. There is insufficient evidence to make a recommendation on the use of other blood purification techniques.	No recommendation	
61. For adults with sepsis or septic shock we recommend using a restrictive (over liberal) transfusion strategy.	Strong , moderate-quality evidence	
62. For adults with sepsis or septic shock we suggest against using IV immunoglobulins.	Weak , low quality of evidence	
63. For adults with sepsis or septic shock, and who have risk factors for gastrointestinal (GI) bleeding, we suggest using stress ulcer prophylaxis.	Weak , moderate-quality evidence	
64. For adults with sepsis or septic shock, we recommend using pharmacologic venous thromboembolism (VTE) prophylaxis unless a contraindication to such therapy exists.	Strong , moderate-quality evidence	
65. For adults with sepsis or septic shock, we recommend using low molecular weight heparin over unfractionated heparin for VTE prophylaxis	Strong , moderate-quality evidence	
66. For adults with sepsis or septic shock, we suggest against using mechanical VTE prophylaxis, in addition to pharmacological prophylaxis, over pharmacologic prophylaxis alone.	Weak , low quality of evidence	

Recommendations 2021	Recommendation Strength and Quality of Evidence	Changes From 2016 Recommendations
67. In adults with sepsis or septic shock and AKI, we suggest using either continuous or intermittent renal replacement therapy.	Weak , low quality of evidence	
68. In adults with sepsis or septic shock and AKI, with no definitive indications for renal replacement therapy, we suggest against using renal replacement therapy.	Weak , moderate-quality evidence	
69. For adults with sepsis or septic shock, we recommend initiating insulin therapy at a glucose level of ≥ 180 mg/dL (10 mmol/L).	Strong , moderate-quality evidence	
70. For adults with sepsis or septic shock we suggest against using IV vitamin C.	Weak , low quality of evidence	NEW
71. For adults with septic shock and hypoperfusion-induced lactic acidemia, we suggest against using sodium bicarbonate therapy to improve hemodynamics or to reduce vasopressor requirements.	Weak , low quality of evidence	
72. For adults with septic shock and severe metabolic acidemia (pH ≤ 7.2) and acute kidney injury (AKIN score 2 or 3), we suggest using sodium bicarbonate therapy	Weak , low quality of evidence	
73. For adult patients with sepsis or septic shock who can be fed enterally, we suggest early (within 72 hr) initiation of enteral nutrition.	Weak , very low quality of evidence	
LONG-TERM OUTCOMES AND GOALS OF CARE		
74. For adults with sepsis or septic shock, we recommend discussing goals of care and prognosis with patients and families over no such discussion.	Best practice statement	
75. For adults with sepsis or septic shock, we suggest addressing goals of care early (within 72 hr) over late (72 hr or later).	Weak , low quality of evidence	
76. For adults with sepsis or septic shock, there is insufficient evidence to make a recommendation on any specific standardized criterion to trigger goals of care discussion.	No recommendation	
77. For adults with sepsis or septic shock, we recommend that the principles of palliative care (which may include palliative care consultation based on clinician judgement) be integrated into the treatment plan, when appropriate, to address patient and family symptoms and suffering.	Best practice statement	
78. For adults with sepsis or septic shock, we suggest against routine formal palliative care consultation for all patients over palliative care consultation based on clinician judgement.	Weak , low quality of evidence	

Downloaded from http://journals.lww.com/ccmjournal by BHDMD5epPHKavIzEoumT1QIN4a+kKJLhEZgbsIHo4XMM0nCy on 09/11/2024

Recommendations 2021	Recommendation Strength and Quality of Evidence	Changes From 2016 Recommendations
79. For adult survivors of sepsis or septic shock and their families, we suggest referral to peer support groups over no such referral.	Weak , very low quality of evidence	
80. For adults with sepsis or septic shock, we suggest using a handoff process of critically important information at transitions of care over no such handoff process.	Weak , very low quality of evidence	
81. For adults with sepsis or septic shock, there is insufficient evidence to make a recommendation on the use of any specific structured handoff tool over usual handoff processes.	No recommendation	
82. For adults with sepsis or septic shock and their families, we recommend screening for economic and social support (including housing, nutritional, financial, and spiritual support), and make referrals where available to meet these needs.	Best practice statement	
83. For adults with sepsis or septic shock and their families, we suggest offering written and verbal sepsis education (diagnosis, treatment, and post-ICU/post-sepsis syndrome) prior to hospital discharge and in the follow-up setting.	Weak , very low quality of evidence	
84. For adults with sepsis or septic shock and their families, we recommend the clinical team provide the opportunity to participate in shared decision making in post-ICU and hospital discharge planning to ensure discharge plans are acceptable and feasible.	Best practice statement	
85. For adults with sepsis and septic shock and their families, we suggest using a critical care transition program, compared with usual care, upon transfer to the floor.	Weak , very low quality of evidence	
86. For adults with sepsis and septic shock, we recommend reconciling medications at both ICU and hospital discharge.	Best practice statement	
87. For adult survivors of sepsis and septic shock and their families, we recommend including information about the ICU stay, sepsis and related diagnoses, treatments, and common impairments after sepsis in the written and verbal hospital discharge summary.	Best practice statement	
88. For adults with sepsis or septic shock who developed new impairments, we recommend hospital discharge plans include follow-up with clinicians able to support and manage new and long-term sequelae.	Best practice statement	

Recommendations 2021	Recommendation Strength and Quality of Evidence	Changes From 2016 Recommendations
89. For adults with sepsis or septic shock and their families, there is insufficient evidence to make a recommendation on early post-hospital discharge follow-up compared with routine post-hospital discharge follow-up.	No recommendation	
90. For adults with sepsis or septic shock, there is insufficient evidence to make a recommendation for or against early cognitive therapy.	No recommendation	
91. For adult survivors of sepsis or septic shock, we recommend assessment and follow-up for physical, cognitive, and emotional problems after hospital discharge.	Best practice statement	
92. For adult survivors of sepsis or septic shock, we suggest referral to a post-critical illness follow-up program if available.	Weak, very low quality of evidence	
93. For adult survivors of sepsis or septic shock receiving mechanical ventilation for > 48hr or an ICU stay of > 72 hr, we suggest referral to a post-hospital rehabilitation program.	Weak, very low quality of evidence	

Rationale

The qSOFA uses three variables to predict death and prolonged ICU stay in patients with known or suspected sepsis: a Glasgow Coma Score < 15, a respiratory rate ≥ 22 breaths/min and a systolic blood pressure ≤ 100 mm Hg. When any two of these variables are present simultaneously, the patient is considered qSOFA positive. Data analysis used to support the recommendations of the Third International Consensus Conference on the Definitions of Sepsis identified qSOFA as a predictor of poor outcome in patients with known or suspected infection, but no analysis was performed to support its use as a screening tool (5). Since that time numerous studies have investigated the potential use of the qSOFA as a screening tool for sepsis (40–42). The results have been contradictory as to its usefulness. Studies have shown that qSOFA is more specific but less sensitive than having two of four SIRS criteria for early identification of infection induced organ dysfunction (40–43). Neither SIRS nor qSOFA are ideal screening tools for sepsis and the bedside clinician needs to understand the limitations of each. In the original derivation study, authors found that only

24% of infected patients had a qSOFA score 2 or 3, but these patients accounted for 70% of poor outcomes (5). Similar findings have also been found when comparing against the National Early warning Score (NEWS) and the Modified Early warning Score (MEWS) (44). Although the presence of a positive qSOFA should alert the clinician to the possibility of sepsis in all resource settings; given the poor sensitivity of the qSOFA, the panel issued a strong recommendation against its use as a single screening tool.

Recommendation
3. For adults suspected of having sepsis, we suggest measuring blood lactate. <i>Weak recommendation, low-quality evidence.</i>

Rationale

The association of lactate level with mortality in patients with suspected infection and sepsis is well established (45, 46). Its use is currently recommended as part of the SSC Hour-1 sepsis bundle for those patients with sepsis (47, 48), and an elevated

Downloaded from http://journals.lww.com/ccmjournal by BHDMDM5ePHKav1ZEoum1tIQN4a+kLhEz9sIH04XM0h0Cy on 09/11/2024

lactate is part of the Sepsis-3 definition of septic shock (49). It has been suggested that lactate can also be used to screen for the presence of sepsis among undifferentiated adult patients with clinically suspected (but not confirmed) sepsis. Several studies have assessed the use of lactate in this context (50–52).

The lactate cutoffs determining an elevated level ranged from 1.6–2.5 mmol/L, although diagnostic characteristics were similar regardless of the cutoff. Sensitivities range from 66–83%, with specificities ranging from 80–85%. Pooled positive and negative likelihood ratios from the three studies are 4.75 and 0.29, respectively. Studies showed an association between the use of point-of-care lactate measurements at presentation and reduced mortality; however, the results are inconsistent (53). In summary, the presence of an elevated or normal lactate level significantly increases or decreases, respectively, the likelihood of a final diagnosis of sepsis in patients with suspected sepsis. However, lactate alone is neither sensitive nor specific enough to rule-in or rule-out the diagnosis on its own. Lactate testing may not be readily available in many resource-limited settings (54–61). Therefore, we issued a weak recommendation favoring the use of serum lactate as an adjunctive test to modify the pretest probability of sepsis in patients with suspected but not confirmed sepsis.

Initial Resuscitation

Recommendations

4. Sepsis and septic shock are medical emergencies, and we **recommend** that treatment and resuscitation begin immediately.

Best practice statement.

5. For patients with sepsis induced hypoperfusion or septic shock we **suggest** that at least 30 mL/kg of IV crystalloid fluid should be given within the first 3 hours of resuscitation.

Weak recommendation, low-quality evidence.

6. For adults with sepsis or septic shock, we **suggest** using dynamic measures to guide fluid resuscitation over physical examination or static parameters alone.

Weak recommendation, very low-quality evidence.

Remarks:

Dynamic parameters include response to a passive leg raise or a fluid bolus, using stroke volume (SV), stroke volume variation (SVV), pulse pressure variation (PPV), or echocardiography, where available.

7. For adults with sepsis or septic shock, we **suggest** guiding resuscitation to decrease serum lactate in patients with elevated lactate level, over not using serum lactate.

Weak recommendation, low-quality evidence.

Remarks:

During acute resuscitation, serum lactate level should be interpreted considering the clinical context and other causes of elevated lactate.

8. For adults with septic shock, we **suggest** using capillary refill time to guide resuscitation as an adjunct to other measures of perfusion.

Weak recommendation, low-quality evidence.

Rationale

Timely, effective fluid resuscitation is crucial for the stabilization of sepsis-induced tissue hypoperfusion in sepsis and septic shock. Previous guidelines recommend initiating appropriate resuscitation immediately upon recognition of sepsis or septic shock and having a low threshold for commencing it in those patients where sepsis is not proven but is suspected. Although the evidence stems from observational studies, this recommendation is considered a best practice and there are no new data suggesting that a change is needed.

The 2016 SSC guideline issued a recommendation for using a minimum of 30 mL/kg (ideal body weight) of IV crystalloids in initial fluid resuscitation. This fixed volume of initial resuscitation was based on observational evidence (62). There are no prospective intervention studies comparing different volumes for initial resuscitation in sepsis or septic shock. A retrospective analysis of adults presenting to an emergency department with sepsis or septic shock showed that failure to receive 30 mL/kg of crystalloid fluid therapy within 3 hours of sepsis onset was associated with increased odds of in-hospital mortality, delayed resolution of hypotension and increased length of stay in ICU, irrespective of comorbidities, including end-stage kidney disease and heart failure (63). In the PROCESS (64), ARISE (65) and PROMISE (66) trials, the average volume of fluid received pre-randomization was also in the range of 30 mL/kg, suggesting that this fluid volume has been adopted in routine clinical practice (67).

Most patients require continued fluid administration following initial resuscitation. Such administration needs to be balanced with the risk of fluid

accumulation and potential harm associated with fluid overload, especially prolonged ventilation, progression of acute kidney injury (AKI) and increased mortality. One of the most important principles of managing complex septic patients is the need for a detailed initial assessment and ongoing re-evaluation of the response to treatment. To avoid over- and under-resuscitation, fluid administration beyond the initial resuscitation should be guided by careful assessment of intravascular volume status and organ perfusion. Heart rate, central venous pressure (CVP) and systolic blood pressure alone are poor indicators of fluid status. Dynamic measures have demonstrated better diagnostic accuracy at predicting fluid responsiveness compared with static techniques. Dynamic measures include passive leg raising combined with cardiac output (CO) measurement, fluid challenges against stroke volume (SV), systolic pressure or pulse pressure, and increases of SV in response to changes in intrathoracic pressure. In a systematic review and meta-analysis, dynamic assessment to guide fluid therapy was associated with reduced mortality (RR, 0.59; 95% CI, 0.42 to 0.83), ICU length of stay (MD -1.16 days; 95% CI, -1.97 to -0.36), and duration of mechanical ventilation (-2.98 hours; 95% CI, -5.08 to -0.89) (3). However, in one other meta-analysis, there was no significant difference in mortality between septic patients resuscitated with a volume responsiveness-guided approach compared with standard resuscitative strategies (68). Most data arise from high income settings and a paucity of evidence exists in resource-limited settings to guide optimal titration of fluid resuscitation as well as the appropriate safety endpoints. An RCT in patients with sepsis and hypotension in Zambia showed that early protocolized resuscitation with administration of IV fluids guided by jugular venous pressure, respiratory rate, and arterial oxygen saturation only, was associated with significantly more fluid administration in the first 6 hours (median 3.5 L [IQR, 2.7–4.0] versus 2.0 L [IQR, 1.0–2.5]) and higher hospital mortality (48.1% versus 33%) than standard care (69).

If fluid therapy beyond the initial 30 mL/kg administration is required, clinicians may use repeated small boluses guided by objective measures of SV and/or CO. In post-cardiac surgery patients, fluid challenges of 4 mL/kg compared to 1 to 3 mL/kg increased the sensitivity of detecting fluid responders and nonresponders based on measurement of CO (70). In resource-limited

regions where measurement of CO or SV may not be possible, a >15% increase in pulse pressure could indicate that the patient is fluid responsive utilizing a passive leg-raise test for 60–90 seconds (71, 72).

Serum lactate is an important biomarker of tissue hypoxia and dysfunction, but is not a direct measure of tissue perfusion (73). Recent definitions of septic shock include increases in lactate as evidence of cellular stress to accompany refractory hypotension (1). Previous iterations of these guidelines have suggested using lactate levels as a target of resuscitation in the early phases of sepsis and septic shock, based on earlier studies related to goal-directed therapy and meta-analyses of multiple studies targeting reductions in serum lactate in comparison with “standard care” or increases in central venous oxygen saturation (74, 75). The panel recognizes that normal serum lactate levels are not achievable in all patients with septic shock, but these studies support resuscitative strategies that decrease lactate toward normal. Serum lactate level should be interpreted considering the clinical context and other causes of elevated lactate. As with sepsis screening, lactate measurement may not always be available in some resource-limited settings.

When advanced hemodynamic monitoring is not available, alternative measures of organ perfusion may be used to evaluate the effectiveness and safety of volume administration. Temperature of the extremities, skin mottling and capillary refill time (CRT) have been validated and shown to be reproducible signs of tissue perfusion (76, 77). The ANDROMEDA-SHOCK study evaluated whether a resuscitation strategy targeting CRT normalization was more effective than a resuscitation strategy aiming at normalization or decreasing lactate levels by 20% every 2 hours in the first 8 hours of septic shock (58). At day 3, the CRT group had significantly less organ dysfunction as assessed by SOFA score (mean SOFA score 5.6 [SD 4.3] versus 6.6 [SD 4.7]; $p = 0.045$). Twenty-eight-day mortality was 34.9% in the peripheral perfusion group and 43.4% in the lactate group, but this difference did not reach statistical significance (HR, 0.75; 95% CI, 0.55–1.02). Despite the absence of a clear effect on mortality, using CRT during resuscitation has physiologic plausibility and is easily performed, noninvasive, and no cost. However, this approach should be augmented by careful, frequent, and comprehensive patient evaluation to predict or recognize fluid overload early, particularly

where critical care resources are constrained. Relevant consideration of the background pathology or pathological processes pertinent to the patient should also inform management (69, 78).

Mean Arterial Pressure

Recommendation

9. For adults with septic shock on vasopressors, we **recommend** an initial target mean arterial pressure (MAP) of 65 mm Hg over higher MAP targets.
Strong recommendation, moderate-quality evidence.

Rationale

MAP is a key determinant of mean systemic filling pressure, which in turn is the major driver of venous return and CO. Increasing MAP therefore usually results in increased tissue blood flow and augments the supply side of tissue perfusion. While some tissues, such as the brain and kidneys have the ability to autoregulate blood flow, MAPs below a threshold, usually understood to be approximately 60 mm Hg, are associated with decreased organ perfusion, which tracks linearly with MAP (79). Previous SSC guidelines recommended targeting a MAP of greater than 65 mm Hg for initial resuscitation. The recommendation was based principally on a RCT in septic shock comparing patients who were given vasopressors to target a MAP of 65–70 mm Hg, versus a target of 80–85 mm Hg (80). This study found no difference in mortality, although a subgroup analysis demonstrated a 10.5% absolute reduction in renal replacement therapy (RRT) with higher MAP targets among patients with chronic hypertension. Additionally, targeting higher MAP with vasopressors was associated with a higher risk of atrial fibrillation. A limitation of this study was that the average MAP in both arms exceeded the targeted range. A meta-analysis of two RCTs on this topic supported that higher MAP targets did not improve survival in septic shock (RR, 1.05; 95% CI, 0.90–1.23) (81).

A recent RCT, monitored to ensure protocol and MAP target compliance, compared a “permissive hypotension” (MAP 60–65 mm Hg) group with a “usual care” group that received vasopressors and MAP targets set by the treating physician in patients aged 65 years and older with septic shock (82, 83). The intervention group in this study achieved a mean MAP of 66.7 mm Hg, compared with 72.6 mm Hg in the usual

care group. Among 2,463 analyzed patients, there was significantly less exposure to vasopressors in the intervention group, measured by duration of vasopressor infusion and total vasopressor doses expressed in nor-epinephrine equivalents. Ninety-day mortality in the permissive hypotension and usual care groups was similar (41.0% vs 43.8%).

Given the lack of advantage associated with higher MAP targets and the lack of harm among elderly patients with MAP targets of 60–65 mm Hg, the panel recommends targeting a MAP of 65 mm Hg in the initial resuscitation of patients with septic shock who require vasopressors.

Admission to Intensive Care

Recommendation

10. For adults with sepsis or septic shock who require ICU admission, we **suggest** admitting the patients to the ICU within 6 hours.
Weak recommendation, low-quality evidence.

Rationale

The outcome of critically ill patients depends on timely application of critical care interventions in an appropriate environment. Outside the ICU, septic patients are typically seen in the emergency department (ED) and hospital wards. Delayed admissions of critically ill patients from ED are associated with decreased sepsis bundle compliance and increased mortality, ventilator duration, and ICU and hospital length of stay (84). Data on the optimal time for transfer to the ICU stem from observational studies and registry databases.

In an observational study of 401 ICU patients, authors reported an increase in ICU mortality of 1.5% for each hour delay of ED to ICU transfer (85). A retrospective observational study of 14,788 critically ill patients in the Netherlands showed a higher hospital mortality for the higher ED to ICU time quintiles (2.4–3.7 hr and > 3.7 hr) compared with the lowest ED to ICU time quintile (< 1.2 hr) (86). When adjusted for severity of illness, an ED to ICU time > 2.4 hr was associated with increased hospital mortality in patients with higher illness severity (ORs of 1.20 [95% CI, 1.03–1.39]). Patients with sepsis were not studied separately.

Another study evaluated 50,322 ED patients admitted to 120 US ICUs (87). Mortality increased when ED stay exceeded 6 hours (17% vs 12.9%, $p < 0.001$).

Among hospital survivors, the delayed admission group had a longer hospital stay, higher mortality, and higher rates of mechanical ventilation and central venous catheterization. Similarly, another study of 12,380 ward patients in 48 hospitals in the United Kingdom showed that (88) delayed admission to ICU led to higher 90-day mortality and further physiological deterioration.

Based on existing data, timely admission of critically ill patients to an ICU environment may result in better patient outcomes. There is also evidence of improved patient satisfaction, increased patient safety, better patient flow and improved staff morale (89). However, although critical care services are likely best delivered in an ICU environment, there are multiple reasons why immediate transfer of critically ill patients with sepsis to an ICU may not always be possible, in particular in lower- and middle-income countries (LMIC), where ICU bed availability can be limited. In this case, regular assessment, evaluation, and appropriate treatment should not be delayed, independent of patient location.

INFECTION

Diagnosis of Infection

Recommendation

- 11. For adults with suspected sepsis or septic shock but unconfirmed infection, we **recommend** continuously re-evaluating and searching for alternative diagnoses and discontinuing empiric antimicrobials if an alternative cause of illness is demonstrated or strongly suspected.
Best practice statement.

Rationale

In previous versions of these guidelines, we highlighted the importance of obtaining a full screen for infectious agents prior to starting antimicrobials whenever it is possible to do so in a timely fashion (12, 13). As a best practice statement, we recommended that appropriate routine microbiologic cultures (including blood) should be obtained before starting antimicrobial therapy in patients with suspected sepsis and septic shock if it results in no substantial delay in the start of antimicrobials (i.e., < 45 min). This recommendation has not been updated in this version but remains as valid as before.

The signs and symptoms of sepsis are nonspecific and often mimic multiple other diseases (90–92).

Because there is no “gold standard” test to diagnose sepsis, the bedside provider cannot have a differential diagnosis of sepsis alone in a patient with organ dysfunction. Indeed, a third or more of patients initially diagnosed with sepsis turn out to have noninfectious conditions (90, 93, 94). Best practice is to continually assess the patient to determine if other diagnoses are more or less likely, especially because a patient’s clinical trajectory can evolve significantly after hospital admission, increasing or decreasing the likelihood of a diagnosis of sepsis. With this uncertainty, there can be significant challenges in determining when it is “appropriate” to de-escalate or discontinue antibiotics.

Another major challenge is implementing a system that reminds clinicians to focus on the fact that the patient is still receiving antibiotics each day, especially as providers rotate in and out of the care team. Systems that promote such reassessment by automatic stop orders, electronic prompts, or mandatory check lists all seem useful in theory, but each has disadvantages in terms of provider acceptance or assuring that providers thoughtfully assess the need for antibiotics rather than checking a box in the electronic record or reflexively acknowledging a prompt, without considering its underlying rationale (95).

We did not identify any direct or indirect evidence assessing this important issue. Thus, clinicians are strongly encouraged to discontinue antimicrobials if a non-infectious syndrome (or an infectious syndrome that does not benefit from antimicrobials) is demonstrated or strongly suspected. Since this situation is not always apparent, continued reassessment of the patient should optimize the chances of infected patients receiving antimicrobial therapy and non-infected patients avoiding therapy that is not indicated.

Time to Antibiotics

Recommendations

- 12. For adults with possible septic shock or a high likelihood for sepsis, we **recommend** administering antimicrobials immediately, ideally within one hour of recognition.
Strong recommendation, low quality of evidence (septic shock)
Strong recommendation, very low quality of evidence (sepsis without shock)

13. For adults with possible sepsis without shock, we **recommend** rapid assessment of the likelihood of infectious versus non-infectious causes of acute illness.

Best practice statement.

Remarks:

Rapid assessment includes history and clinical examination, tests for both infectious and non-infectious causes of acute illness and immediate treatment for acute conditions that can mimic sepsis. Whenever possible this should be completed within 3 hours of presentation so that a decision can be made as to the likelihood of an infectious cause of the patient's presentation and timely antimicrobial therapy provided if the likelihood of sepsis is thought to be high.

14. For adults with possible sepsis without shock, we suggest a time-limited course of rapid investigation and if concern for infection persists, the administration of antimicrobials within 3 hours from the time when sepsis was first recognized.

Weak recommendation, very low quality of evidence.

15. For adults with a low likelihood of infection and without shock, we suggest deferring antimicrobials while continuing to closely monitor the patient.

Weak recommendation, very low quality of evidence.

Rationale

Early administration of appropriate antimicrobials is one of the most effective interventions to reduce mortality in patients with sepsis (96–98). Delivering antimicrobials to patients with sepsis or septic shock should therefore be treated as an emergency. The imperative to provide antimicrobials as early as possible, however, must be balanced against the potential harms associated with administering unnecessary antimicrobials to patients without infection (99, 100). These include a range of adverse events such as allergic or hypersensitivity reactions, kidney injury, thrombocytopenia, *Clostridioides difficile* infection, and antimicrobial resistance (101–106). Accurately diagnosing sepsis is challenging as sepsis can present in subtle ways, and some presentations that first appear to be sepsis turn out to be noninfectious conditions (90, 93, 107, 108). Evaluating the likelihood of infection and severity of illness for each patient with suspected sepsis should inform the necessity and urgency of antimicrobials (99, 100).

The mortality reduction associated with early antimicrobials appears strongest in patients with septic shock, where studies have reported a strong association between time to antibiotics and death in patients with septic shock but weaker associations in patients

without septic shock (98, 109, 110). In a study of 49,331 patients treated at 149 New York hospitals, each additional hour of time from ED arrival to administration of antimicrobials was associated with 1.04 increased odds of in-hospital mortality, $p < 0.001$ (1.07 (95% CI, 1.05–1.09) for patients receiving vasopressors vs. 1.01 (95% CI, 0.99–1.04) for patients not on vasopressors) (98). In a study of 35,000 patients treated at Kaiser Permanente Northern California, each additional hour of time from ER arrival to administration of antimicrobials was associated with 1.09 increased odds of in-hospital mortality (1.07 for patients with “severe” sepsis [lactate ≥ 2 , at least one episode of hypotension, required noninvasive or invasive mechanical ventilation or has organ dysfunction] and 1.14 for patients with septic shock); which equated to a 0.4% absolute mortality increase for “severe” sepsis and a 1.8% absolute increase for septic shock (110). Finally, in a study of 10,811 patients treated in four Utah hospitals, each hour delay in time from ED arrival to administration of antimicrobials was associated with 1.16 increased odds of in-hospital and 1.10 increased odds of 1-year mortality (1.13 in patients with hypotension vs 1.09 in patients without hypotension) (111). Other studies, however, did not observe an association between antimicrobial timing and mortality (112–117). It should be noted that all the aforementioned studies were observational analyses and hence at risk of bias due to insufficient sample size, inadequate risk adjustment, blending together the effects of large delays until antibiotics with short delays, or other study design issues (118).

In patients with sepsis without shock, the association between time to antimicrobials and mortality within the first few hours from presentation is less consistent (98, 110). Two RCTs have been published (119, 120); one failed to achieve a difference in time-to-antimicrobials between arms (120) and the other found no significant difference in mortality despite a 90-minute difference in median time interval to antimicrobial administration (119). Observational studies do, however, suggest that mortality may increase after intervals exceeding 3–5 hours from hospital arrival and/or sepsis recognition (98, 111, 119, 120). We therefore suggest initiating antibiotics in patients with possible sepsis without shock as soon as sepsis appears to be the most likely diagnosis, and no later than 3 hours after sepsis was first suspected if concern for sepsis persists at that time.

Overall, given the high risk of death with septic shock and the strong association of antimicrobial timing and mortality, the panel issued a strong recommendation to administer antimicrobials immediately, and within one hour, in all patients with potential septic shock. Additionally, for patients with confirmed/very likely sepsis, we recommend antimicrobials be administered immediately (Figure 1). For patients with possible sepsis without shock, we recommend a rapid assessment of infectious and noninfectious etiologies of illness be undertaken to determine, within 3 hours, whether antibiotics should be administered or whether antibiotics should be deferred while continuing to monitor the patient closely.

Limited data from resource-limited settings suggest that timely administration of antimicrobials in patients with sepsis and septic shock is beneficial and potentially feasible (121–126). Access and availability of a wide range of antimicrobials in such settings may however vary (54, 55, 57, 59, 61). The availability and turnaround time for laboratory testing, rapid infectious diagnostic, imaging, etc. varies widely by regions and settings. As such, the rapid assessment of infectious and non-infectious etiologies of illness will differ across settings, depending on what is feasible to achieve. Recent recommendations pertaining to the use of antimicrobials in patients with sepsis and septic shock in resource-limited settings are in line with the current recommendations (123).

Biomarkers to Start Antibiotics

Recommendation

16. For adults with suspected sepsis or septic shock, we **suggest against** using procalcitonin plus clinical evaluation to decide when to start antimicrobials, as compared to clinical evaluation alone.

Weak recommendation, very low quality of evidence.

Rationale

Procalcitonin is undetectable in healthy states, but rises rapidly in response to pro-inflammatory stimuli, especially bacterial infections (127). In theory, procalcitonin levels in combination with clinical evaluation may facilitate the diagnosis of serious bacterial infections and prompt early initiation of antimicrobials. In a meta-analysis of 30 studies (3,244 patients), procalcitonin had a pooled sensitivity of 77% and specificity of 79% for sepsis in critically ill patients (128).

We identified direct evidence from three RCTs that compared procalcitonin-guided protocols for antibiotic initiation vs usual care (129–131). A meta-analysis of the three trials ($n = 1,769$ ICU patients) found no difference in short-term mortality (RR, 0.99; 95% CI, 0.86 to 1.15), length of ICU stays (MD, 0.19 days; 95% CI, -0.98 to 1.36) or length of hospitalization (MD, 7.00 days; 95% CI, -26.24 to 12.24). Long-term mortality, readmission rates, and hospital-free days were not reported in any of the trials,

and no relevant studies on the costs associated with use of procalcitonin were found. In general, knowledge about the undesirable effects was lacking, and the quality of evidence was very low. Published guidelines for the management of community acquired pneumonia recommend initiation of antimicrobials for patients with community acquired pneumonia regardless of procalcitonin level (132).

With no apparent benefit, unknown costs, and




Figure 1. Recommendations on timing of antibiotic administration.

limited availability in some settings including LMICs, the panel issued a weak recommendation against using procalcitonin to guide antimicrobial initiation in addition to clinical evaluation.

Antimicrobial Choice

Recommendations

17. For adults with sepsis or septic shock at high risk of methicillin-resistant *Staphylococcus aureus* (MRSA), we **recommend** using empiric antimicrobials with MRSA coverage over using antimicrobials without MRSA coverage.
Best practice statement.
18. For adults with sepsis or septic shock at low risk of MRSA, we **suggest against** using empiric antimicrobials with MRSA coverage, as compared with using antimicrobials without MRSA coverage.
Weak recommendation, low quality of evidence.

Rationale

The decision on whether to include an antibiotic active against MRSA in an empiric treatment regimen for sepsis and septic shock depends upon 1) the likelihood that the patient's infection is caused by MRSA; 2) the risk of harm associated with withholding treatment for MRSA in a patient with MRSA; and 3) the risk of harm associated with MRSA treatment in a patient without MRSA.

MRSA accounts for approximately 5% of culture-positive infections among critically ill patients (133), and may be decreasing according to some reports (134, 135). The incidence of MRSA varies, however, by region (ranging from ~2% in Western Europe to 10% in North America) and by patient-related characteristics (133, 136, 137). Patient-related risk factors for MRSA include prior history of MRSA infection or colonization, recent IV antibiotics, history of recurrent skin infections or chronic wounds, presence of invasive devices, hemodialysis, recent hospital admissions and severity of illness (136, 138–142).

Observational data on the impact of including MRSA coverage in empiric regimens vary. Some studies focus on patients with documented MRSA infections, while others evaluate the impact of MRSA coverage in undifferentiated patients. Among patients with documented MRSA infections, delays of > 24–48 hours until antibiotic administration are associated with increased mortality in some studies (143–147),

but not in others (148–154). Among undifferentiated patients with pneumonia or sepsis, broad-spectrum regimens including agents active against MRSA were associated with higher mortality, particularly among patients without MRSA (137, 151, 155, 156). The undesirable effects associated with unnecessary MRSA coverage are also supported by studies showing an association between early discontinuation of MRSA coverage and better outcomes in patients with negative nares or bronchoalveolar lavage (BAL) MRSA PCR (157–159).

Failure to cover for MRSA in a patient with MRSA may be harmful, but unnecessary MRSA coverage in a patient without MRSA may also be harmful. Data from RCTs, including the evaluation of nasal swab testing to withhold therapy for MRSA, are warranted, and studies on rapid diagnostic tools and clinical prediction rules for MRSA are needed.

Recommendations

19. For adults with sepsis or septic shock and high risk for multidrug resistant (MDR) organisms, we **suggest** using two antimicrobials with gram-negative coverage for empiric treatment over one gram-negative agent.
Weak recommendation, very low quality of evidence.
20. For adults with sepsis or septic shock and low risk for MDR organisms, we **suggest against** using two gram-negative agents for empiric treatment, compared with one gram-negative agent.
Weak recommendation, very low quality of evidence.
21. For adults with sepsis or septic shock, we **suggest against** using double gram-negative coverage once the causative pathogen and the susceptibilities are known.
Weak recommendation, very low quality of evidence.

Rationale

Considering the increasing frequency of MDR bacteria in many parts of the world and associations between delays in active therapy and worse outcomes, the initial use of multidrug therapy is often required to ensure the empiric regimen includes at least one effective agent that is active against the offending organism (12, 13). In the empiric phase—before causative agent(s) and susceptibilities are known, the optimal choice of antibiotic therapy depends on the local prevalence of resistant organisms, patient risk factors for resistant organisms, and the severity of illness. In the directed/targeted phase, once causative agent(s) and susceptibilities are

known, sustained double gram-negative coverage is rarely necessary except for patients with highly resistant organisms.

This was borne out in a recent systematic review with meta-analysis of 10 RCTs, no differences in mortality or other patient-important outcomes between empiric mono- vs. combination antibiotic therapy in adult ICU patients with severe sepsis or septic shock were observed, also when taking disease severity into consideration (160). Results from the largest RCT included in the meta-analysis (a comparison of sustained courses of moxifloxacin and meropenem vs meropenem alone in a low endemic resistance setting) were consistent with the findings from the meta-analysis (161).

Recommendations about the use of more than one gram-negative agent for empiric treatment over one gram-negative agent are challenging given clinical heterogeneity, including patient characteristics, source of infection, causative agents, and antibiotic resistance patterns. Local information about the resistance patterns of the most common causative agents of sepsis is essential to choose the most appropriate empiric antibiotic therapy. For this reason, we refrained from proposing recommendations regarding double gram-negative coverage in patients with sepsis or septic shock overall, but instead recommend tailoring the use of double coverage based on patients' risk of MDR pathogens. Factors to guide this decision include: proven infection or colonization with antibiotic-resistant organisms within the preceding year, local prevalence of antibiotic-resistant organisms, hospital-acquired/healthcare-associated (versus community-acquired infection), broad-spectrum antibiotic use within the preceding 90 days, concurrent use selective digestive decontamination (SDD), travel to a highly endemic country within the preceding 90 days (see <https://resistancemap.cddep.org/>) and hospitalization abroad within the preceding 90 days (162–164). In the directed/targeted phase, once causative agent(s) and susceptibilities are known, sustained double gram-negative coverage is not necessary except possibly for patients with highly resistant organisms with no proven safe and efficacious therapeutic option.

Overall quality of evidence was very low, and the direct costs of antibiotics can increase with the routine use of multiple agents for treatment. This may specifically have an impact in resource-limited settings.

In general, in patients at high risk for MDR organisms, we suggest using two gram negative agents for empiric treatment to increase the likelihood of adequate coverage, while in patients with a low risk for MDR organisms, we suggest using a single agents for empiric treatment, as there are no apparent benefits of using two agents and the a risk of antimicrobial-associated undesirable effects, including direct toxicity, *Clostridioides difficile* infection and development of antibiotic resistance (165). Empiric double coverage of gram-negative bacilli is most important in patients at high risk for resistant organisms with severe illness, particularly septic shock.

Antifungal Therapy

Recommendations

22. For adults with sepsis or septic shock at high risk of fungal infection, we **suggest** using empiric antifungal therapy over no antifungal therapy.

Weak recommendation, low quality of evidence.

23. For adults with sepsis or septic shock at low risk of fungal infection, we **suggest against** empiric use of antifungal therapy.

Weak recommendation, low quality of evidence.

Rationale

Sepsis and septic shock due to fungi are most commonly observed in ICUs and are associated with poor outcomes (166–170). Some observational studies suggested that prompt initiation of appropriate empiric antifungal therapy may be associated with a reduction in mortality, however these studies do not prove a causal relationship between antifungal therapy and outcome, nor do they clarify the role of timing of treatment, and some other studies have failed to show this association (167, 171–173).

In an updated meta-analysis of empiric antifungal therapy versus no antifungal therapy in adult critically ill patients, no difference in short-term mortality was observed. In the largest and most recent RCT-EMPIRICUS—there was also no difference in outcome between patients receiving empiric antifungal therapy (micafungin) and patients receiving placebo (174). The overall quality of evidence was low, and treatment with empiric antifungals may be associated with increased costs.

While patients with sepsis or septic shock may not in general benefit from empiric antifungals, some patients with particular risk factors for fungal infection

may, for example patients with febrile neutropenia who fail to defervesce after 4–7 days of broad-spectrum antibacterial therapy are at increased risk of having fungal disease (Table 2) (175, 176). The risk of *Candida* sepsis or septic shock for other immunosuppressed populations is highly disease- and therapy-specific. Importantly, the decision to start empiric antifungal therapy depends on the type and number of risk factors, along with the local epidemiology of fungal infections.

Accordingly, we suggest using empiric antifungal therapy in patients at high risk of fungal infection, while we suggest avoiding this if the risk is low. The choice of antifungal agent for empiric therapy depends on multiple issues including host factors, prior colonization and infection, prior exposure to prophylactic or therapeutic antifungal therapy, comorbidities, and the toxicities and drug interactions of the therapeutic options.

Antiviral Therapy

Recommendation

- 24. We make no recommendation on the use of antiviral agents.

Rationale

Viral infections encompass a broad spectrum of pathogens and diseases in humans but—apart from specific clinical situations such as epidemics/pandemics—are rarely the primary cause of sepsis. In a recent large international point prevalence study, viruses were documented in less than 4% of infections (133).

Historically, influenza has been one of the more common viral causes of sepsis. However, it is unclear to what extent the primary viral infection as opposed to bacterial pneumonia co-infection is the cause of organ dysfunction in these patients (219–222). More recently, SARS-CoV-2 (causing COVID-19) is now responsible for many cases of infection and sepsis (223). The ongoing pandemic due to SARS-CoV-2 has resulted in the understanding of this condition changing very rapidly (224).

While there appears to be no overall effect of neuraminidase inhibitors on mortality in patients with influenza-related pneumonia, there may be an effect when administered early in the course of the disease (225).

TABLE 2.
Examples of Risk Factors for Fungal Infection

Risk Factors for <i>Candida</i> Sepsis
Candida Colonization at Multiple Sites (177–179)
Surrogate Markers Such as Serum Beta-D-Glucan Assay (177)
Neutropenia (180, 181)
Immunosuppression (173, 180, 181)
Severity of Illness (High APACHE score) (182, 183)
Longer ICU Length of Stay (183)
Central Venous Catheters and Other Intravascular Devices (168, 180, 181, 184)
Persons Who Inject Drugs (185)
Total Parenteral Nutrition (186)
Broad Spectrum Antibiotics (178, 187)
Gastrointestinal Tract Perforations and Anastomotic Leaks (186, 188–190)
Emergency Gastrointestinal or Hepatobiliary Surgery (190)
Acute Renal Failure and Hemodialysis (186, 188)
Severe Thermal Injury (191–193)
Prior Surgery (186)
Risk Factors for Endemic Yeast (<i>Cryptococcus</i> , <i>Histoplasma</i> , <i>Blastomyces</i> , <i>Coccidioidomycosis</i>)
Antigen Markers Such as Cryptococcal, Histoplasma or Blastomyces assays (194–196)
HIV Infection (197–200)
Solid Organ Transplantation (199, 201–203)
High Dose Corticosteroid Therapy (199)
Hematopoietic Stem Cell Transplantation (204)
Certain Biologic Response Modifiers (205, 206)
Diabetes Mellitus (207)
Risk Factor for Invasive Mold Infection
Neutropenia (204, 208)
Surrogate Markers Such as Serum or Bronchoalveolar Lavage Galactomannan Assay (209–211)
Hematopoietic Stem Cell Transplantation (204, 208, 212)
Solid Organ Transplantation (202, 212–214)
High Dose Corticosteroid Therapy (215, 216)
Certain Biologic Response Modifiers (206, 217, 218)

The decision to start empirical antifungal therapy depends on the type and number of risk factors, along with the locale epidemiology of fungal infections.

For detailed information on specific antiviral therapy, including for influenza and SARS CoV-2, please refer to dedicated clinical practice guidelines (226–228).

Immunocompromised patients are particularly vulnerable to viral infections, including patients with neutropenia, human immunodeficiency virus (HIV) infection, hematological malignancies and hematopoietic stem cell transplantation or solid organ transplants; in these patients herpes simplex virus, Epstein-Barr virus, cytomegalovirus, and respiratory viruses such as adenoviruses, can cause severe disease (229). Tropical and subtropical regions have endemic and epidemic outbreaks of zoonotic viral infections including those caused by Dengue, Ebola, Lassa, Marburg, Sin Nombre, and Chikungunya virus. Many of these can manifest with clinical signs of sepsis, particularly in their early stages. Unfortunately, effective therapies are lacking for most of these viruses.

The desirable effects of empiric antiviral therapy are unknown, and as for other antimicrobial agents there is a risk of undesirable effects (165). Data on cost effectiveness were not available.

Due to the rapidly changing position related to antiviral therapies in critically ill patients presenting with several acute respiratory failure, this panel decided not to issue a recommendation on antiviral therapies and to refer the reader to more specific guidelines (226).

Delivery of Antibiotics

Recommendation

25. For adults with sepsis or septic shock, we **suggest** using prolonged infusion of beta-lactams for maintenance (after an initial bolus) over conventional bolus infusion.

Weak recommendation, moderate quality of evidence.

Rationale

Beta-lactam antibiotics may be subject to changes in important pharmacokinetic parameters in the setting of sepsis and septic shock resulting in sub-therapeutic concentrations (230, 231). As opposed to conventional intermittent infusion (infusion ≤ 30 minutes), administration by prolonged IV infusion, either as an extended infusion (antibiotic infused over at least half of the dosing interval) or as a continuous infusion, results in sustained beta-lactam concentrations which align with the pharmacodynamics of these drugs.

Two meta-analyses reported similar results supporting reduced short-term mortality (RR, 0.70; 95% CI, 0.57–0.87) with prolonged infusion of beta-lactams

(232, 233). No trials assessed the undesirable effects of continuous infusion, and the desirable effects were deemed important, while the overall quality of evidence was moderate. Prolonged infusion is a feasible intervention if suitable IV access is present, and resources are available to ensure the beta-lactam is infused over the necessary duration. The latter may be an issue in some resource limited settings, including LMICs.

Administration of a loading dose of antibiotic before prolonged infusion is essential to avoid delays to achieving effective beta-lactam concentrations (234). Over the course of therapy, both extended and continuous infusions will occupy a venous catheter/lumen more than an intermittent infusion and drug-stability and drug-drug compatibility considerations are important to ensure effectiveness of antibiotic and other IV drug therapies (235).

The reduction in short-term mortality from prolonged infusion of beta-lactams is significant with the intervention being feasible with negligible cost implications and no data suggesting inferior outcomes with prolonged infusion. Accordingly, we suggest prolonged infusion of beta-lactams over conventional bolus infusion in patients with sepsis and septic shock if the necessary equipment is available. Further research is needed on long-term outcomes, on the effect on emergence of antimicrobial resistance, and on costs of prolonged versus bolus infusion of beta-lactams (236).

Pharmacokinetics and Pharmacodynamics

Recommendation

26. For adults with sepsis or septic shock, we **recommend** optimizing dosing strategies of antimicrobials based on accepted pharmacokinetic/pharmacodynamic (PK/PD) principles and specific drug properties.

Best practice statement.

Rationale

Antibiotics are subject to changes in PK/PD parameters in sepsis and septic shock where resultant concentrations may be too low risking clinical failure, or too high leading to toxicity (Table 3) (237–239). Augmented renal clearance (240), AKI (241), hypoalbuminemia (242), RRT (243, 244), and extracorporeal membrane oxygenation (245, 246) are examples of common scenarios that affect the concentrations of some antibiotics. Administration of antibiotics using an approach that adheres to PK/

TABLE 3.
Guidance for PK/PD-Based Dosing for Specific Drug Classes

Drug or Drug Class	PK/PD Index Associated With Bacterial Killing or Efficacy	Drug Concentration Target	Considerations for Optimized Dosing*	Reference Number
Antibacterials				
Aminoglycosides	AUC_{0-24}/MIC ; C_{max}/MIC	AUC 70–100 C_{max}/MIC 8–10	Use extended interval dosing with patient weight and kidney function	237
Beta-lactams	$fT_{>MIC}$	$C_{min} > MIC$	Use prolonged infusions, consider patient weight and kidney function	253
Colistin	AUC_{0-24}/MIC	Unspecified	Use patient weight and kidney function	259
Daptomycin	AUC_{0-24}/MIC ; C_{max}/MIC	$AUC_{0-24}/MIC > 200$	Use patient weight and kidney function	237
Fluoroquinolones	AUC_{0-24}/MIC ; C_{max}/MIC	AUC_{0-24}/MIC 80–125	Use kidney function	237
Vancomycin	AUC_{0-24}/MIC	AUC_{0-24}/MIC 400	Use patient weight and kidney function	260
Antifungals				
Fluconazole	AUC_{0-24}/MIC	AUC_{0-24}/MIC 100	Use patient weight and kidney function	261
Posaconazole	AUC_{0-24}/MIC	C_{min} 1–4 mg/L	Use formulation-specific dose	261
Voriconazole	AUC_{0-24}/MIC	C_{min} 2–6 mg/L	Use patient weight	261

*Other considerations than those listed may have been listed in studies in critically ill patient subpopulations.

AUC_{0-24} —ratio of area under the concentration-time curve from 0–24 hours; MIC—minimum inhibitory concentration; $fT_{>MIC}$ —time over-dosing interval that free (unbound) drug is maintained above the MIC; C_{max} —maximum concentration in a dosing interval; C_{min} —minimum concentration in a dosing interval.

Note: use of therapeutic drug monitoring has been described for all drugs, although it is not widely available for most.

PD principles and using dosing regimens developed in patients with sepsis and septic shock is more likely to result in effective and safe drug concentrations compared to use of dosing recommendations provided in the manufacturer's product information (247).

We did not identify any relevant data quantifying the value of dosing based on PK/PD principles in adults with sepsis and septic shock. Although there are no data on this topic directly derived from adults with sepsis and septic shock, data from a broader patient population, critically ill patients, support an increased likelihood of achieving effective and safe antibiotic concentrations when applying PK/PD principles to dosing (248). The application of PK/PD principles can be aided by clinical pharmacists (249). Some studies in critically ill patients have reported benefits in terms of clinical cure (237, 250–253).

Applying a PK/PD approach to antibiotic dosing requires support from knowledgeable clinician team members (254), use of a patient population-specific guideline document (255), use of therapeutic drug monitoring (256), and/or use of dosing software (238, 248). Some of these potential approaches to application of PK/PD-based dosing require extra resources, some of which may not be available in all settings, in which

case freely available resources such as dosing nomograms can be used (234, 257, 258). Guidance on how to apply a PK/PD approach for specific drug classes have been described elsewhere (237). Additional research is needed on short- and long-term mortality outcomes, effect on emergence of antimicrobial resistance, impact on drug stability within prolonged infusions, and health economics of different PK/PD-based approaches to dosing. (Table 3). Use of therapeutic drug monitoring has been described for all drugs, although it is not widely available for most.

Source Control

Recommendation

27. For adults with sepsis or septic shock, we **recommend** rapidly identifying or excluding a specific anatomical diagnosis of infection that requires emergent source control and implementing any required source control intervention as soon as medically and logistically practical.
Best practice statement.

Rationale

Appropriate source control is a key principle in the management of sepsis and septic shock (12, 13).

Source control may include drainage of an abscess, debriding infected necrotic tissue, removal of a potentially infected device, or definitive control of a source of ongoing microbial contamination (262). Foci of infection readily amenable to source control include intra-abdominal abscesses, gastrointestinal perforation, ischemic bowel or volvulus, cholangitis, cholecystitis, pyelonephritis associated with obstruction or abscess, necrotizing soft tissue infection, other deep space infection (e.g., empyema or septic arthritis), and implanted device infections (262).

Source control of infectious foci was associated with improved survival in recent observational and cluster randomized studies (120, 263, 264). Source control should be achieved as soon as possible following initial resuscitation (265, 266). While there are limited data to conclusively issue a recommendation regarding the timeframe in which source control should be obtained, smaller studies suggest that source control within 6 to 12 hours is advantageous (265–271). Studies generally show reduced survival beyond that point. The failure to show benefit with source control implemented in less than 6 hours may be a consequence of the limited number of patients and the heterogeneity of the intervention. Therefore, any required source control intervention in sepsis and septic shock should ideally be implemented as soon as medically and logistically practical after the diagnosis is made (120). Clinical experience suggests that without adequate source control, many severe presentations will not stabilize or improve despite rapid resuscitation and provision of appropriate antimicrobials. In view of this fact, prolonged efforts at medical stabilization in lieu of source control for severely ill patients, particularly those with septic shock, are generally not advised (272).

The selection of optimal source control methods must weigh the benefits and risks of the specific intervention, the patient's preference, clinician's expertise, availability, risks of the procedure, potential delays, and the probability of the procedure's success. In general, the least invasive option that will effectively achieve source control should be pursued. Open surgical intervention should be considered when other interventional approaches are inadequate or cannot be provided in a timely fashion. Surgical exploration may also be indicated when diagnostic uncertainty persists despite radiologic evaluation, when the probability of success with a percutaneous procedure is uncertain, or when the undesirable effects of a failed procedure are

high. Logistic factors unique to each institution, such as surgical or interventional staff availability, may also play a role in the decision. Future research is needed to investigate the optimal timing and method of source control in patients with sepsis and septic shock with a source of infection amenable to drainage.

Recommendation

28. For adults with sepsis or septic shock, we **recommend** prompt removal of intravascular access devices that are a possible source of sepsis or septic shock after other vascular access has been established.

Best practice statement.

Rationale

Removal of a potentially infected intravascular access device is considered a part of adequate source control (262). An intravascular device suspected to be a source of sepsis should be removed after establishing another site for vascular access and following successful initial resuscitation (265, 266). In the absence of septic shock or fungemia, some implanted tunneled catheter infections may be treated effectively with prolonged antimicrobial therapy if removal of the catheter is not practical (273). However, catheter removal with adequate antimicrobial therapy is definitive and is the preferred treatment in most cases.

We identified one relevant RCT (274) and two observational studies (275, 276). There was no evidence of a difference in mortality, however, the studies were hampered by significant limitations, including risk of confounding by indication (the observational studies) and imprecision (the RCT), which is why the results should be interpreted cautiously. The quality of evidence was very low.

De-escalation of Antibiotics

Recommendation

29. For adults with sepsis or septic shock, we **suggest** daily assessment for de-escalation of antimicrobials over using fixed durations of therapy without daily reassessment for de-escalation.

Weak recommendation, very low quality of evidence.

Rationale

Antimicrobial exposure is linked to the development of antimicrobial resistance and efforts to reduce both the number of antibiotics administered and their spectrum

of therapy are therefore important strategies in patients with sepsis and septic shock (165). This is particularly relevant in empiric therapy where broad-spectrum therapy is recommended, as the causative pathogen has not yet been identified. Once both the pathogen(s) and susceptibilities are known, antimicrobial de-escalation—i.e., stopping an antimicrobial that is no longer necessary (in case of combination therapy) or changing an antimicrobial to narrow the spectrum is encouraged. Given the adverse societal and individual risks to continued unnecessary antimicrobial therapy, thoughtful de-escalation of antimicrobials based on adequate clinical improvement is appropriate even if cultures are negative. Early discontinuation of all antimicrobial therapy if infection is ruled out is advisable (277). Antimicrobial de-escalation should ideally be done as soon as possible, and rapid diagnostic techniques may facilitate this.

We identified direct evidence from 13 studies (1,968 patients) (277), including one RCT (278). In our meta-analysis, we observed improved short-term mortality in patients who were de-escalated (RR, 0.72; 95% CI, 0.57 to 0.91) (Supplemental Digital Content: Appendix 2). Long-term mortality was evaluated in one study only and did not demonstrate a difference (RR, 0.99; 95% CI, 0.64 to 1.52). De-escalation was associated with shorter length of stay in the hospital (MD -5.56 days; 95% CI, -7.68 to -3.44), but not in the ICU (MD -2.6 days; 95% CI, -5.91 to 0.72).

Most studies were observational, and there are concerns that de-escalation is used primarily in patients who are getting better, which is why the reported improved short-term mortality should be interpreted with caution (277, 279).

De-escalation is in generally safe, may offer cost savings when unnecessary antibiotics are discontinued, and reduced risk of antimicrobial resistance and reduced toxicity and side-effects may be important (280). Based on the overall very low quality of evidence, RCTs are warranted along with more studies on antimicrobial resistance.

Duration of Antibiotics

Recommendation

30. For adults with an initial diagnosis of sepsis or septic shock and adequate source control, we **suggest** using shorter over longer duration of antimicrobial therapy.
Weak recommendation, very low quality of evidence.

Rationale

Restricting antimicrobial therapy to the shortest course associated with better outcomes is an important part of antimicrobial stewardship (281–285). The optimal duration of antimicrobial therapy for a given patient with sepsis or septic shock depends on many factors, including host, microbe, drug, and anatomical site (Table 2) (99, 100).

There have been considerable efforts over the past two decades to clarify the optimal duration of antimicrobial therapy by comparing “short” courses with traditional (“longer”) courses. There are data from RCTs in specific conditions such as pneumonia (286–289), urinary tract infections (290), bacteremia (291, 292), and intraabdominal infections (293). In many of the trials, the shorter course was just as effective as the longer course but associated with fewer adverse consequences. Very few trials, however, focused exclusively on critically ill patients with sepsis or septic shock, and the overall quality of evidence was very low.

Given the lack of definitive and generalizable data regarding the optimal duration of therapy for patients who are critically ill, it is not surprising that there is considerably practice variation (281, 294). Specialist consultation appears to be associated with improved patient outcomes for a variety of infectious syndromes (295–300). This has generally been ascribed to improvements in microbial appropriateness of the empiric antimicrobial regimen provided. However, it is also possible that reducing the duration of unnecessary therapy may account for at least part of the benefit.

Thus, for adults with an initial diagnosis of sepsis or septic shock and adequate source control, we suggest a shorter course of antibiotics, as this is less costly, has fewer undesirable effects without impacting adversely on outcomes (Table 4).

Biomarkers to Discontinue Antibiotics

Recommendation

31. For adults with an initial diagnosis of sepsis or septic shock and adequate source control where optimal duration of therapy is unclear, we **suggest** using procalcitonin AND clinical evaluation to decide when to discontinue antimicrobials over clinical evaluation alone.
Weak recommendation, low quality of evidence.

TABLE 4.
Planned Duration of Empirical Antimicrobial Therapy in RCTs of Shorter vs Longer Duration of Therapy According to Clinical Syndrome

Population/Syndrome	RCT/Systemic Review (Data Extracted From)	Shorter Duration	Longer Duration	Outcomes
Pneumonia	Capellier 2012 (301)	8 days	15 days	No difference
	Chastre 2003 (301, 302)	8 days	15 days	No difference
	El Moussaoui 2006 (302)	3 days	8 days	No difference
	Fekih Hassen 2009 (301–303)	7 days	10 days	No difference
	File 2007 (302, 303)	5 days	7 days	No difference
	Kollef 2012 (302, 303)	7 days	10 days	No difference
	Leophonte 2002 (302, 303)	5 days	10 days	No difference
	Medina 2007 (301)	8 days	12 days	No difference
	Siegel 1999 (302, 303)	7 days	10 days	No difference
	Tellier 2004 (302, 303)	5 days	7 days	No difference
Bacteremia	Chaudhry 2000 (302)	5 days	10 days	No difference
	Runyon 1991 (302)	5 days	10 days	No difference
	Yahav 2018 (304)	7 days	14 days	No difference
Intra-abdominal infection	Montravers 2018 (305)	8 days	15 days	No difference
	Sawyer 2015 (293)	Max. 5 days	Max. 10 days	No difference
Urinary tract infection	Peterson 2008 (290)	5 days	10 days	No difference

Rationale

Shorter durations of antimicrobial therapy are in general recommended; however, critically ill patients often receive antimicrobials for more days than necessary (288, 301, 306). While typically clinical evaluation alone is used to decide duration, biomarkers could offer additional information. C-reactive protein is often used in this regard. Procalcitonin has been studied most extensively both in critically ill and non-critically ill patients, both for initiation and discontinuation of therapy (307).

We identified direct evidence from 14 RCTs (*n* = 4,499 patients) that assessed use of procalcitonin to guide antimicrobial treatment duration in patients with sepsis (two trials included critically ill patients in general) (308–321). A meta-analysis suggested improved mortality in patients who were managed using procalcitonin versus control (RR, 0.89; 95% CI, 0.80 to 0.99), while there was no effect on length of stay in ICU or hospital. Antibiotic exposure was consistently lower in patients who were managed with procalcitonin and clinical evaluation, however, in many trials the total duration of therapy was still 7 days or

longer in the intervention group. Also, the algorithms for antimicrobial therapy, frequency of procalcitonin monitoring and the thresholds (or percentage change in procalcitonin concentration) for discontinuation differed across the trials. Therefore, the overall quality of evidence was judged to be low.

The undesirable effects of using procalcitonin along with clinical evaluation to decide when to discontinue antimicrobials are considered minimal, and do not outweigh the potential benefits (322). Limited data on the cost-effectiveness are available, although a single-center study reported decreased hospital costs associated with PCT-guided antibiotic in medical ICU patient with undifferentiated sepsis (323). Procalcitonin testing may not be available in all countries and healthcare settings, including LMICs.

Based on apparent benefit and no obvious undesirable effects, we suggest using procalcitonin along with clinical evaluation to decide when to discontinue antimicrobials in adults with an initial diagnosis of sepsis or septic shock and adequate source control, if the optimal duration of therapy is unclear and if procalcitonin is available.

Downloaded from http://journals.lww.com/ccmjournal by BMDM5ePHKav1Zcum1tQIN4a+kLhEz9sIH04XM0h0Cy wCX1AWmYQp/ll0tHD33D00dRy7T5F4C3VC4QAVpDDa8K2+YabH5t5KE = on 09/11/2024

HEMODYNAMIC MANAGEMENT

Fluid Management

Recommendations

- | | |
|-----|--|
| 32. | For adults with sepsis or septic shock, we recommend using crystalloids as first-line fluid for resuscitation.
<i>Strong recommendation, moderate quality of evidence.</i> |
| 33. | For adults with sepsis or septic shock, we suggest using balanced crystalloids instead of normal saline for resuscitation.
<i>Weak recommendation, low quality of evidence.</i> |
| 34. | For adults with sepsis or septic shock, we suggest using albumin in patients who received large volumes of crystalloids over using crystalloids alone.
<i>Weak recommendation, moderate quality of evidence.</i> |
| 35. | For adults with sepsis or septic shock, we recommend against using starches for resuscitation.
<i>Strong recommendation, high quality of evidence.</i> |
| 36. | For adults with sepsis and septic shock, we suggest against using gelatin for resuscitation.
<i>Weak recommendation, moderate quality.</i> |

Rationale

Fluid therapy is a key part of the resuscitation of sepsis and septic shock. Crystalloids have the advantage of being inexpensive and widely available. The absence of clear benefit following the administration of colloids compared to crystalloid solutions supports the use of crystalloid solutions in the resuscitation of patients with sepsis and septic shock (324). The optimal fluid remains a subject of debate. For decades, the administration of normal saline solution (0.9% sodium chloride) has been common practice (325), but potential adverse effects that include hyperchloremic metabolic acidosis, renal vasoconstriction, increased cytokine secretion and concern about acute kidney injury (AKI) have led to increased interest in chloride-restrictive solutions, known as balanced or buffered solutions (326–330). Subsequently, a network meta-analysis of 14 RCTs of patients with sepsis showed in an indirect comparison that balanced crystalloids were associated with decreased mortality, compared to saline (331).

There have been a number of recent RCTs assessing the question of which crystalloid may be most beneficial in patients with sepsis. In the SPLIT multicenter, double-blinded clinical trial, the comparison

between balanced solutions and normal saline yielded no differences in mortality or AKI (332). The modest volume of infused fluid, the predominance of surgical patients, and the low number of septic patients (4%) precludes generalizability of the results. In 2016, the SALT pilot trial ($n = 974$) compared balanced solutions versus normal saline; with septic patients comprising 25% and 28% of the population, respectively (333). The primary outcome, a composite outcome including mortality, new RRT or persistent renal dysfunction (major adverse kidney event within 30 days, MAKE30), was similar between groups (24.6% vs. 24.7%). Subsequently, the SMART trial was published in 2018, a single-center, multiple-crossover study including 15,802 patients who received balanced solutions or normal saline, alternating on a monthly basis (334). In the pre-specified subgroup of patients admitted with sepsis in all participating ICUs, 30-day mortality was lower in those receiving balanced solutions, compared to normal saline (OR, 0.80; 95% CI, 0.67–0.94). Likewise, in a secondary analysis including only the 1,641 patients admitted to medical ICUs with a diagnosis of sepsis, balanced solutions were associated with reduced 30-day hospital mortality (OR, 0.74; 95% CI, 0.59–0.93) and MAKE30, and increased vasopressor- and RRT-free days (335).

The SMART trial was a single-center study without individual patient randomization and no blinded assignment of the intervention, it exposed participants to moderate amount of fluid volume, identification of sepsis subgroups was based on ICD-10 codes, and it used a composite outcome which may not be as relevant as a patient-centered outcome (336). However, the use of balanced solutions in sepsis may be associated with improved outcomes compared with chloride-rich solutions. No cost-effectiveness studies compared balanced and unbalanced crystalloid solutions. Therefore, we considered the desirable and undesirable consequences to favor balanced solutions, but as the quality of the evidence is low, we issued a weak recommendation. Two ongoing large RCTs will provide additional data and inform future guideline updates (337, 338).

Although albumin is theoretically more likely to maintain oncotic pressure than crystalloids (339), it is more costly and there is no clear benefit with its routine use. Since the publication of the 2016 guidelines (12),

two single-center trials and two meta-analyses have been published on this topic (324, 340–342). A Cochrane review including RCTs with 12,492 patients comparing albumin versus crystalloids found no difference in 30-day (RR, 0.98; 95% CI, 0.92–1.04) or 90-day mortality (RR, 0.98; 95% CI, 0.92–1.04) or need for RRT between groups (RR, 1.11; 95% CI, 0.96–1.27) (324). This meta-analysis included patients with critical illness, and while the main solution included in the analysis was albumin, some studies in other analyses included fresh frozen plasma. A second meta-analysis, which also included critically ill patients, found lower static filling pressures (MD, -2.3 cm H₂O; 95% CI, 3.02–1.05) and mean arterial pressure (MAP) (MD, -3.53 mmHg; 95% CI, -6.71 to -0.36) with crystalloid use, but no difference in mortality at 28 days (RR, 1.0; 95% CI, 0.92–1.10) or 90 days (RR, 1.32; 95% CI, 0.76–2.29) (340). The largest clinical trial in sepsis, the ALBIOS trial comparing a combination of albumin and crystalloids to crystalloids alone in 1,818 patients with sepsis or septic shock did not demonstrate a difference in 28-day (RR, 1.0; 95% CI, 0.87–1.14) or 90-day mortality (RR, 0.94; 95% CI, 0.85–1.05) (339). Of note, in this trial, albumin was given as a 20% solution, with a treatment goal of a serum albumin concentration of 30 g/L until ICU discharge or 28 days. A meta-analysis of studies including septic patients did not show a significant difference in mortality (RR, 0.98; 95% CI, 0.89–1.08). In addition, the risk of new organ failures (RR, 1.02; 95% CI, 0.93 to 1.11), ventilator-free days or vasopressor-free days did not differ. Although albumin use resulted in a larger treatment effect in the septic shock subgroup (RR, 0.88; 95% CI, 0.77–0.99) than in the sepsis subgroup (RR, 1.03; 95% CI, 0.91–1.17), the subgroup analysis did not detect a subgroup effect (P-interaction = 0.19).

The lack of proven benefit and higher cost of albumin compared to crystalloids contributed to our strong recommendation for the use of crystalloids as first-line fluid for resuscitation in sepsis and septic shock. The suggestion to consider albumin in patients who received large volumes of crystalloids is informed by evidence showing higher blood pressure at early and later time points (339), higher static filling pressures (340), and lower net fluid balance (339) with albumin. Limited data precludes a cutoff value for crystalloid

infusion above which albumin might be considered as part of resuscitation.

In the 2016 SSC guidelines, a strong recommendation was issued against using hydroxyethyl starch (HES) (12). No new data were identified. A previous meta-analysis of RCTs in septic patients showed a higher risk of RRT with the use of HES 130/0.38–0.45 (RR, 1.36; 95% CI, 1.08–1.72) and a higher risk of death in a pre-defined analysis of low risk of bias trials (RR, 1.11; 95% CI, 1.0–1.2) (343). A network meta-analysis of patients with sepsis or septic shock also demonstrated a higher risk of death (OR, 1.1; 95% CI, 0.99–1.30) and need for RRT (OR, 1.39; 95% CI, 1.17–1.66) (331) with starches in a direct comparison with crystalloids. Therefore, the 2016 recommendation against the use of HES in resuscitation of patients with sepsis or septic shock did not change (331, 343).

Gelatin is a synthetic colloid used as a resuscitation fluid; there is a lack of powered well-designed studies supporting its administration in sepsis and septic shock. Included studies are generally small and include mostly postoperative, non-critically ill patients. In an indirect comparison, a four-node network meta-analysis conducted in patients with sepsis, showed no clear effect on mortality when compared with crystalloids (OR, 1.24; 95% credible interval [CrI] 0.61–2.55) (331). Similarly, another RCT did not find an effect on mortality with gelatin use (RR, 0.87; 95% CI, 0.66–1.12) (344). Adverse effects of gelatin have been reviewed in a network meta-analysis, which demonstrated higher risk of RRT with gelatin use compared with normal saline (OR, 1.27; 95% CrI, 0.44–3.64) and balanced crystalloids (OR, 1.50; 95% CrI 0.56–3.96) (345). Overall, the quality of evidence was moderate, due to imprecision and indirectness. In a systematic review of RCTs including patients with hypovolemia, gelatin use increased the risk of anaphylaxis (RR, 3.01; 95% CI, 1.27–7.14) in comparison with crystalloids use (346). Furthermore, gelatins may affect hemostasis and the effect on blood transfusions was unclear (RR, 1.10; 95% CI, 0.86–1.41). Therefore, in the face of inconclusive effect on mortality, increased adverse effects, and higher costs, the panel issued a weak recommendation against the use of gelatin for acute resuscitation. More high-quality studies are needed to inform future guideline updates.

Vasoactive Agents

Recommendations

37. For adults with septic shock, we **recommend** using norepinephrine as the first-line agent over other vasopressors. *Strong recommendation*

Dopamine. *High quality evidence*

Vasopressin. *Moderate-quality evidence*

Epinephrine. *Low-quality evidence*

Selepressin. *Low-quality evidence*

Angiotensin II. *Very low-quality evidence*

Remark:

In settings where norepinephrine is not available, epinephrine or dopamine can be used as an alternative, but we encourage efforts to improve the availability of norepinephrine. Special attention should be given to patients at risk for arrhythmias when using dopamine and epinephrine.

38. For adults with septic shock on norepinephrine with inadequate MAP levels, we **suggest** adding vasopressin instead of escalating the dose of norepinephrine. *Weak recommendation, moderate-quality evidence.*

Weak recommendation, moderate-quality evidence.

Remark:

In our practice, vasopressin is usually started when the dose of norepinephrine is in the range of 0.25–0.5 $\mu\text{g}/\text{kg}/\text{min}$.

39. For adults with septic shock and inadequate MAP levels despite norepinephrine and vasopressin, we **suggest** adding epinephrine. *Weak recommendation, low-quality evidence.*

Weak recommendation, low-quality evidence.

40. For adults with septic shock, we **suggest against** using terlipressin. *Weak recommendation, low quality of evidence.*

Weak recommendation, low quality of evidence.

Rationale

Norepinephrine is a potent α -1 and β -1 adrenergic receptors agonist, which results in vasoconstriction and increased MAP with minimal effect on heart rate. Dopamine acts in a dose-dependent fashion on dopamine-1, α -1 and β -1 adrenergic receptors. At lower dosages, dopamine causes vasodilation via dopamine-1 receptor activity in the renal, splanchnic, cerebral, and coronary beds. With higher dosages, dopamine's α -adrenergic receptor activity predominates resulting in vasoconstriction and increased systemic vascular resistance (SVR); its β -1 adrenergic receptor activity can lead to dose-limiting arrhythmias. Norepinephrine is more potent than dopamine as a vasoconstrictor. In a systematic review and meta-analysis of 11 RCTs, norepinephrine resulted in a lower mortality (RR, 0.89; 95% CI, 0.81–0.98) and lower risk of arrhythmias (RR, 0.48; 95% CI, 0.40–0.58) compared with dopamine (347).

Although the β -1 activity of dopamine may be useful in patients with myocardial dysfunction, the higher risk of arrhythmias limits its use (348).

Epinephrine's action is also dose-dependent with potent β -1 adrenergic receptor activity and moderate β -2 and α -1 adrenergic receptor activity. The activity of epinephrine, at low doses, is primarily driven by its action on β -1 adrenergic receptors, resulting in increased cardiac output (CO), decreased systemic vascular resistance (SVR) and variable effects on MAP. At higher doses, however, epinephrine administration results in increased SVR and CO. Potential adverse effects of epinephrine include arrhythmias and impaired splanchnic circulation (349). Epinephrine may increase aerobic lactate production via stimulation of skeletal muscle β -2 adrenergic receptors, making the use of serum lactate to guide resuscitation challenging (350). A randomized blinded study comparing epinephrine with norepinephrine in patients with shock showed no difference in 90-day mortality (HR, 0.88; 95% CI, 0.63–1.25) and vasopressor-free days (351). The panel issued a strong recommendation for norepinephrine as the first-line agent over other vasopressors (**Figure 2**).

Vasopressin is an endogenous peptide hormone produced in the hypothalamus and stored and released by the posterior pituitary gland. Its mechanism for vasoconstrictive activity is multifactorial and includes binding of V_1 receptors on vascular smooth muscle resulting in increased arterial blood pressure. Studies show that vasopressin concentration is elevated in early septic shock but decreases to normal range in most patients between 24 and 48 hours as shock continues (352, 353). This finding has been called "relative vasopressin deficiency" as, in the presence of hypotension, vasopressin would be expected to be elevated. The significance of this finding is unknown. Unlike most vasopressors, vasopressin is not titrated to response, but it is usually administered at a fixed dose of 0.03 units/min for the treatment of septic shock. In clinical trials, vasopressin was used up to 0.06 units/min (354). Higher doses of vasopressin have been associated with cardiac, digital, and splanchnic ischemia (355).

The VANISH trial directly compared the use of vasopressin versus norepinephrine by randomizing patients with septic shock in a factorial 2×2 design aiming to also assess the role of hydrocortisone. There was no significant difference between the vasopressin and norepinephrine groups in 28-day mortality (30.9%




Figure 2. Summary of vasoactive agents recommendations.

vs 27.5%; RR, 1.13 [95% CI, 0.85–1.51]). Although there was no difference with respect to kidney injury (RR, 0.89; 95% CI, 0.72–1.11), vasopressin use reduced the risk of RRT (RR, 0.71; 95% CI 0.53–0.97) (354).

As for combination therapy, the main study (the VASST trial) comparing norepinephrine alone to

norepinephrine plus vasopressin (0.01–0.03 U/min) showed no improvement in 28-day mortality (39.3% vs 35.4%, $P = 0.26$) (356). However, in a subgroup analysis, patients with less severe shock receiving norepinephrine $< 15 \mu\text{g}/\text{min}$ had improved survival with the addition of vasopressin (26.5% vs. 35.7%, $P = 0.05$). Both VANISH and VASST demonstrated a catecholamine-sparing effect of vasopressin; as such, the early use of vasopressin in combination with norepinephrine may help reduce the adrenergic burden associated with traditional vasoactive agents (357). In our systematic review of 10 RCTs, vasopressin with norepinephrine reduced mortality as compared with norepinephrine alone (RR, 0.91; 95% CI, 0.83–0.99) but did not reduce the need for RRT (RR, 0.79; 95% CI, 0.57–1.10). There was no difference in the risks of digital ischemia (RR, 1.01; 95% CI, 0.33–9.84) or arrhythmias (RR, 0.88; 95% CI, 0.63–1.23). The threshold for adding vasopressin varied among studies and remains unclear. Starting vasopressin when norepinephrine dose is in the range of 0.25–0.5 $\mu\text{g}/\text{kg}/\text{min}$ seems sensible (354). Another meta-analysis of RCTs on distributive shock showed a lower risk of atrial fibrillation with the combination of vasopressin and norepinephrine compared to norepinephrine alone (358). However, a recent individual patient data meta-analysis of patients with septic shock from 4 RCTs showed that vasopressin alone or in combination with norepinephrine led to higher risk of digital ischemia (risk difference [RD] 1.7%; 95% CI, 0.3–3.2) but lower risk of arrhythmia (RD, -2.8%; 95% CI, -0.2 to -5.3) compared with norepinephrine alone (359).

The evidence regarding the optimal therapeutic strategy for shock requiring high dose vasopressors is scant (360). Epinephrine has been suggested as second or third-line vasopressor for patients with septic shock. With the use of norepinephrine at elevated concentrations, the α_1 receptors may already be saturated and downregulated (361). Thus, the use of another drug such as epinephrine that targets the same receptors may be of limited utility and vasopressin could be more adequate in this scenario. In an indirect comparison, a network meta-analysis did not find any significant difference between epinephrine and vasopressin in terms of mortality (RR, 0.94; 95% CI, 0.47–1.88) (362). Epinephrine might be useful in refractory septic shock patients with myocardial dysfunction.

Thus, we considered the desirable and undesirable consequences of these vasopressors and issued a strong

recommendation to use norepinephrine as a first line agent instead of dopamine, vasopressin, epinephrine and selepressin and angiotensin II in patients with septic shock as a first-line agent, and a weak recommendation over selepressin and angiotensin II. Although some evidence suggests that vasopressin might be superior to norepinephrine in terms of clinical outcomes, the panel took into consideration its higher costs and lower availability and have issued a strong recommendation to use norepinephrine as first line agent instead of vasopressin. We also consider the potential benefit and undesirable consequences of using the combination of norepinephrine and vasopressin and issue a weak recommendation for adding vasopressin instead of escalating the dose of norepinephrine. Further evidence is needed to properly address the role of combination therapy of vasopressors in septic shock.

The panel also recognized that availability of, and experience with, norepinephrine may vary. As part of the global campaign for universal healthcare, the World Health Organization (WHO) essential medicines and health products program works to increase global access to essential, high-quality, safe, effective, and affordable medical products. If norepinephrine is unavailable, either dopamine or epinephrine can be used with special attention given to the risk of arrhythmias.

Selepressin is a highly selective V1 agonist, inducing vasoconstriction via stimulation of vascular smooth muscle. It does not share the typical V1b and V2 receptor effects of vasopressin (increased pro-coagulant factors, salt, and water retention, nitric oxide, and corticosteroid release) and has, therefore, been postulated as a potentially attractive non-catecholamine vasopressor alternative to norepinephrine. Selepressin has been studied in two randomized trials in septic shock. The first, a double-blind, randomized, placebo-controlled phase IIa trial, compared three ascending doses of selepressin (1.25, 2.5, and 3.75 ng/kg/min) in maintaining blood pressure, with open-label norepinephrine (363). Selepressin at a dose of 2.5 ng/kg/min was demonstrated to be effective in maintaining MAP > 60 mm Hg without norepinephrine in about 50% of patients at 12 hours and about 70% of patients at 24 hours. A follow-on phase IIb/phase III trial using an adaptive design, initially comparing three doses (1.7, 2.5, and 3.5 ng/kg/min) with the potential to add a further 5 ng/kg/min dose group (364). The study was stopped for futility after enrollment of 828 patients,

with no significant differences between any of the key endpoints (ventilator- and vasopressor-free days, 15.0 [selepressin] versus 14.5 [placebo], $P = 0.30$; 90-day all-cause mortality, 40.6% vs 39.4%, $P = 0.77$; 30-day RRT-free days, 18.5 vs 18.2, $P = 0.85$; 30-day ICU-free days, 12.6 vs 12.2, $P = 0.41$); adverse event rates were also similar between groups. The meta-analysis of the two studies did not show significant difference in mortality (selepressin: 41.8% vs norepinephrine: 40.45%; RR, 0.99 [95% CI, 0.84–1.18]). As selepressin failed to demonstrate clinical superiority over norepinephrine, we considered the desirable and undesirable consequences to be in favor of norepinephrine and issued a weak recommendation against the use of selepressin as a first-line therapy. Furthermore, it is not currently commercially available.

Angiotensin II is a naturally occurring hormone with marked vasoconstrictor effects, triggered through stimulation of the renin-angiotensin system. A synthetic human preparation has recently become available for clinical use and has been studied in two clinical trials. After a small, short-term pilot of 20 patients with vasodilatory (septic) shock (10 patients in each group) which showed physiological efficacy without obvious safety issues (365), a larger RCT of 344 patients was performed in patients with vasodilatory shock (approximately 90% confirmed or presumed sepsis) (366). The primary endpoint, an increase of MAP of at least 10 mm Hg or to at least 75 mm Hg, was achieved in 114 of 163 patients in the angiotensin II group and in 37 of 158 patients in the placebo group (69.9% vs 23.4%, $P < 0.001$). A meta-analysis found no difference in mortality rates between angiotensin II and norepinephrine (46.2% vs 54.2%; RR, 0.85 [95% CI, 0.69–1.06]; very low quality). There was no clear increase in adverse events with the use of angiotensin II. As the available evidence is of very low quality, and clinical experience in sepsis and, therefore, demonstration of safety remains limited, the panel considered that angiotensin should not be used as a first-line agent, but having demonstrated physiological effectiveness, it may have a role as an adjunctive vasopressor therapy.

Terlipressin is a prodrug and is converted to lysine vasopressin by endothelial peptidases, producing a “slow release” effect and giving an effective half-life of around 6 hours. Terlipressin is more specific for the V1 receptors and it has been studied in nine clinical trials of patients with sepsis, with or without cirrhosis,

involving 950 patients in total. Our meta-analysis showed no difference in mortality (terlipressin: 42.9% vs 49.0%; RR, 0.89 [95% CI, 0.70–1.13]; low quality) but an increase in adverse events. The largest of these studies enrolled 617 patients with septic shock, in a randomized, blinded fashion, with terlipressin (or placebo) added at a dose of between 20 mcg/hr to 160 mcg/hr to a standard norepinephrine-based approach, to achieve a MAP of 65–75 mmHg (367). The primary outcome was death from any cause at 28 days. The 28-day mortality in the two groups was 40% for terlipressin and 38% for norepinephrine (OR, 0.93; 95% CI, 0.55–1.56, $P = 0.80$), and there were no differences in SOFA score at day 7 or vasopressor-free days. More patients who received terlipressin had serious adverse events; 33 of 260 patients (12%) experienced digital ischemia after receiving terlipressin, versus only one patient who received norepinephrine ($P < 0.0001$); diarrhea was also more common in the terlipressin group (2.7% versus 0.35%, $P = 0.037$). There were three cases of mesenteric ischemia in the terlipressin group versus one in the norepinephrine group. Therefore, the panel considered that the undesirable consequences are higher with the use of terlipressin and issued a weak recommendation against its use in patients with septic shock.

Inotropes

Recommendations

41. For adults with septic shock and cardiac dysfunction with persistent hypoperfusion despite adequate volume status and arterial blood pressure, we **suggest** either adding dobutamine to norepinephrine or using epinephrine alone.

Weak recommendation, low quality of evidence.

42. For adults with septic shock and cardiac dysfunction with persistent hypoperfusion despite adequate volume status and arterial blood pressure, we **suggest against** using levosimendan.

Weak recommendation, low quality of evidence.

Rationale

Sepsis-induced myocardial dysfunction is recognized as a major contributor to the hemodynamic instability and is associated with worse outcomes of patients with septic shock (368). Inotropic therapy can be used in patients with persistent hypoperfusion after adequate fluid resuscitation, and in patients with

myocardial dysfunction, based on suspected or measured low CO and elevated cardiac filling pressures. Dobutamine and epinephrine are the most commonly used inotropes. Physiologic studies demonstrate that dobutamine increases CO and oxygen transport, increases splanchnic perfusion and tissue oxygenation, improves intramucosal acidosis and hyperlactatemia (369). However, these effects may not be predictable (370). Dobutamine infusion may produce severe vasodilation and result in lower MAP. In addition, the inotropic response may be blunted in sepsis with a preserved chronotropic effect causing tachycardia without an increase in stroke volume (SV) (370). No RCTs compared dobutamine to placebo in this population. Indirect comparison from network meta-analysis showed that dobutamine with norepinephrine had no clear impact on mortality when compared to no inotropic agents (OR, 0.69; 95% CI, 0.32 to 1.47) (362). None of the trials directly compared dobutamine combined with norepinephrine to norepinephrine alone. In an observational study of 420 patients with septic shock, the use of an inotropic agent (dobutamine, levosimendan, epinephrine, or milrinone) was independently associated with increased 90-day mortality (OR, 2.29; 95% CI, 1.33 to 3.94) even after propensity score adjustment (371). However, the analysis adjusted only to baseline characteristics, without accounting for time-varying confounders including the patient condition at the time of initiating inotropes which may explain the association with mortality. The panel considered the network meta-analysis as a higher quality than observational studies and issued a suggestion to use inotropes only in selected situations.

No evidence supports the superiority of dobutamine over epinephrine. Epinephrine is commonly available especially in low-resource settings (372). In an indirect comparison of dobutamine versus epinephrine, a network meta-analysis showed no clear effect on mortality (OR, 1.18; 95% CI, 0.47–3.97) (362). Therefore, we considered the desirable and undesirable consequences to be comparable for both drugs and issued a weak recommendation to use either one for patients with septic shock and cardiac dysfunction with persistent hypoperfusion despite adequate fluid status and MAP. Both should be discontinued in the absence of improvement in hypoperfusion or in the presence of adverse events. Further evidence derived from high quality RCTs is needed to properly address the role of inotropes in sepsis.

Levosimendan is a calcium-sensitizing drug with inotropic and vasodilatory properties. It has been evaluated in septic shock (373). A meta-analysis of three RCTs ($n = 781$) showed that levosimendan, compared with no inotropic agents, did not impact mortality (RR, 0.87; 95% CI, 0.59 to 1.28). Data from the LeoPARDS trial ($n = 515$) showed that levosimendan versus no inotropic agents was associated with a lower likelihood of successful weaning from mechanical ventilation and a higher risk of supraventricular tachyarrhythmia (373). A meta-analysis of seven RCTs comparing levosimendan with dobutamine showed that levosimendan was not superior to dobutamine in adults with sepsis in terms of mortality (OR, 0.80; 95% CI, 0.48, 1.33; $p = 0.39$) (374). Thus, the panel issued a weak recommendation against the use of levosimendan based on the lack of benefit, in addition to the safety profile, cost and the limited availability of the drug.

Monitoring and Intravenous Access

Recommendations

43. For adults with septic shock, we **suggest** using invasive monitoring of arterial blood pressure over noninvasive monitoring, as soon as practical and if resources are available.

Weak recommendation, very low quality of evidence.

44. For adults with septic shock, we **suggest** starting vasopressors peripherally to restore MAP rather than delaying initiation until a central venous access is secured.

Weak recommendation, very low quality of evidence.

Remark:

When using vasopressors peripherally, they should be administered only for a short period of time and in a vein in or proximal to the antecubital fossa.

Rationale

Estimation of blood pressure using a noninvasive cuff tends to be inaccurate and the discrepancy more pronounced in shock states (375–379). Insertion of an arterial catheter permits safe, reliable and continuous measurement of arterial pressure and allows real time analysis so that therapeutic decisions can be based on immediate and accurate blood pressure information (380). A systematic review of observational studies showed that the risk of limb ischemia and bleeding was less than 1% for radial catheters, and the risk of limb ischemia and bleeding was less than 1% and 1.58%, respectively for femoral catheters. The most common

complication was localized hematoma, 14% for radial and 6% for femoral catheters (381). Ultrasound guidance may increase the first attempt success rate and decrease the complication rate (382, 383). A systematic review showed higher risk of infections when femoral arterial catheters were used compared to radial artery catheters (RR, 1.93; 95% CI, 1.32–2.84), and the overall pooled incidence of bloodstream infection was 0.96 per 1,000 catheter days (384). In the previous version of these guidelines, a weak recommendation was issued for using invasive monitoring of arterial blood pressure over noninvasive monitoring (12). Since then, no new relevant evidence became available. Large, randomized trials that compare arterial blood pressure monitoring versus noninvasive methods are still lacking. In view of the low complication rate and likely higher accuracy of blood pressure measurement, the benefits of arterial catheters probably outweigh the risks. However, the potentially limited resources in some countries and the lack of high-quality studies need to be considered. Therefore, the panel issued a weak recommendation in favor of arterial catheter placement. Arterial catheters should be removed as soon as continuous hemodynamic monitoring is no longer required to minimize the risk of complications.

The prompt initiation of vasopressors to restore blood pressure is an integral component of the management of septic shock. Vasopressors have been traditionally administered via a central venous access due to concerns of extravasation, local tissue ischemia and injury if administered peripherally. However, the process of securing central venous access can be time consuming and requires specialized equipment and training that may not be available in under resourced settings even in high income countries, leading to a delayed initiation of vasopressors (385). Large, randomized trials that compare central and peripheral catheters for initial infusion of vasopressor are lacking. A small study ($n = 263$) randomly allocated patients to receive peripheral vascular access or a central access (386). The need for vasopressor was the indication for venous access in 70% of the patients. The incidence of major catheter-related complications was higher in those randomized to peripheral venous lines with no significant difference in the incidence of minor catheter-related complication. The most common peripheral venous line complication was difficulty in placement. Almost half of the patients assigned to the

peripheral access group did not need a central line throughout their ICU stay. Other authors also showed that central lines could be avoided by peripheral line insertion (387). The administration of vasopressors through peripheral IV catheters is generally safe. A recent systematic review showed that extravasation occurred in 3.4% (95% CI, 2.5–4.7%) of patients with no reported episodes of tissue necrosis or limb ischemia (388). Most of the studies reported no need for active treatment of the extravasation, and a systematic review concluded that most patients who experience extravasation events have no long-term sequelae (389). Extravasation may occur more frequently if vasopressors are infused distally to the antecubital fossa; a meta-analysis showed that 85% of reported extravasation events occurred when vasopressors were infused by a catheter that was located distal to the antecubital fossa (389). The occurrence of local tissue injury may be more likely with prolonged administration of vasopressors. Administration of vasopressors for a short period of time (< 6 hours) in a well-placed peripheral catheter proximal to the antecubital fossa is unlikely to cause local tissue injury (389).

The time to initiation of vasopressors may be shorter if peripheral access is used. A post-hoc analysis of the ARISE trial showed that 42% of patients had vasopressors initiated via a peripheral catheter with a shorter time to initiation of vasopressors (2.4 [1.3–3.9] vs. 4.9 hours [3.5–6.6], $p < 0.001$) (385). Moreover, most patients who had vasopressors started peripherally achieved a MAP > 65 mmHg within 1 hour. Delay in vasopressor initiation and achieving MAP of 65 is associated with increased mortality (390, 391).

Given the low complication rate of peripheral vasopressors and the possibility of restoring blood pressure faster, the benefits of initiating vasopressors for a short period of time in a vein proximal to the antecubital fossa probably outweigh the risks. Therefore, we issued a weak recommendation in favor of the rapid initiation of vasopressors peripherally. If the infusion of vasopressors is still needed after a short period of time, as soon as practical and if resources are available, they should be infused through a central venous access to minimize the risk of complications. The lack of availability and expertise in placement of central venous catheters in different settings is an important consideration (55). Though data are generally sparse on the latter, a study of mostly senior resident doctors

in Nigeria concluded that knowledge of central venous catheter placement was limited (392). Though the panel suggests peripheral administration of norepinephrine as a temporizing measure until a central venous catheter can be placed, its longer-term central administration may not be possible in some settings. Larger prospective studies are needed to provide better evidence on the adequacy and safety of peripheral lines in this scenario.

Fluid Balance

Recommendation

45. There is insufficient evidence to make a recommendation on the use of restrictive versus liberal fluid strategies in the first 24 hours of resuscitation in patients with sepsis and septic shock who still have signs of hypoperfusion and volume depletion after initial resuscitation.

Remark:

Fluid resuscitation should be given only if patients present with signs of hypoperfusion.

Rationale

The current literature does not provide clear guidance about the best fluid strategy following the initial resuscitation bolus of fluids. The four largest clinical trials in sepsis resuscitation used moderate to large amounts of fluids in the first 72 hours. Although Rivers (393) administered over 13 L of fluids, ProCESS (64), ARISE (65) and ProMISe (66) administered approximately 7 to 8 L in the usual care groups with a reported low mortality rate. However, recent evidence suggests that IV fluids used to restore organ perfusion may damage vascular integrity and lead to organ dysfunction (394). Data from observational studies have shown an association of high-volume fluid resuscitation and increased mortality, but these studies are likely affected by unmeasured variables (i.e., the administration of higher amounts of fluids to sicker patients) (395, 396). Recent data emerging from Africa showed that higher volume fluid resuscitation in adults was associated with increased mortality, but the generalizability of these data is limited due to the high prevalence of HIV/AIDS and malnutrition in the patients enrolled and the resource-scarce conditions with limited access to ICUs (69).

The current evidence evaluating a restrictive IV fluid strategy in the management of septic patients

varies with respect to the inclusion criteria, the definition of restrictive and liberal fluid strategies, the criteria guiding the administration of additional IV fluids (e.g., perfusion parameters vs. hemodynamic variables), and the duration of the interventions (397–401). Moreover, the primary outcomes were mostly related to IV fluid volumes administered during the study period and given the small sample sizes, they were not powered to identify differences in patient-centered outcomes. The ongoing Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis (CLOVERS) trial and the Conservative vs liberal fluid therapy in septic shock (CLASSIC) trial will shed some light to this matter (402, 403). Given the quality of the evidence and the variability among existing studies, the panel issued no recommendation for either restrictive or liberal fluid management in the first 24 hours of resuscitation after the initial fluid bolus in patients with sepsis and septic shock. However, it is important to emphasize this discussion does not affect the recommendation for the initial IV fluid bolus and that the administration of IV fluids after the initial fluid bolus should be guided by perfusion parameters and not only by a response in hemodynamic variables.

VENTILATION

Oxygen Targets

Recommendation

46. There is insufficient evidence to make a recommendation on the use of conservative oxygen targets in adults with sepsis-induced hypoxemic respiratory failure.

Rationale

Patients who are undergoing mechanical ventilation in the ICU often receive a high fraction of inspired oxygen and have a high arterial oxygen tension. The conservative use of oxygen may reduce oxygen exposure and diminish lung and systemic oxidative injury. The evidence for the use of conservative oxygen targets (generally defined as PaO₂ 55 to 70 mmHg; SpO₂ 88 to 92%) and therapy in patients with sepsis is limited, with three randomized trials in the critically ill population (404–406). In the 1,000-participant ICU-ROX trial (405), conservative oxygen therapy did not significantly affect the primary outcome, which was the

number of ventilator-free days, compared with liberal oxygen therapy for ventilated adults in ICU. Mortality at 90 and 180 days did not differ. These findings are at variance with the results of a previous single-centre trial, which was stopped early after an unplanned interim analysis. In that trial, conservative oxygen therapy in the ICU was associated with a markedly lower rate of death than usual oxygen therapy (404). In a recent systematic review and meta-analysis of multiple clinical syndromes, investigators found that a conservative oxygen strategy was associated with a lower rate of death in acutely ill adults than a liberal oxygen strategy (407). However, in a post hoc analysis of the ICU-ROX trial including adults with sepsis, point estimates for the treatment effect of conservative oxygen therapy on 90-day mortality raise the possibility of clinically important harm (408). The LOCO-2 study was terminated early by the data safety and monitoring board and reported no difference in 28-day survival in ARDS patients managed with a conservative oxygenation strategy (409). There are several ongoing trials of conservative oxygen targets that will inform clinical practice in the future. At this point in time, there is insufficient evidence to make an evidence-based recommendation.

High-Flow Nasal Oxygen Therapy

Recommendation

47. For adults with sepsis-induced hypoxemic respiratory failure, we **suggest** the use of high flow nasal oxygen over noninvasive ventilation.
Weak recommendation, low quality of evidence.

Rationale

Acute hypoxemic respiratory failure can result from causes of sepsis such as pneumonia or non-pulmonary infections resulting in ARDS. Patients presenting with hypoxia without hypercapnia are treated with high concentrations of inhaled oxygen which may be delivered conventionally with interfaces including nasal prongs, facemask with reservoir or Venturi mask.

Advanced interventions for patients with severe hypoxia requiring escalation of support include non-invasive ventilation (NIV) or high flow oxygen. Both therapies avoid the complications of intubation and invasive mechanical ventilation and promote patient interaction. In addition to improving gas exchange, NIV

may help to reduce work of breathing in select patients. However, NIV use can be associated with development of complications including increased risk of gastric insufflation and aspiration, facial skin breakdown, excessively high tidal volumes as well as patient discomfort related to inability to eat or effectively phonate during therapy.

High flow nasal cannula (HFNC) is a noninvasive, high concentration oxygen delivery interface that confers warming and humidification of secretions, high flow rates to better match patient demand, washout of nasopharyngeal dead space, and modest positive airway pressure effect. The single inspiratory limb of HFNC allows for airflows as high as 60 liters per minute to achieve inspired oxygen fractions (FiO_2) as high as 95–100%. However, HFNC is less effective at reducing work of breathing and supplying a moderate or higher level of PEEP (410). Complications with HFNC are possible; however, they are usually self-limited and do not require discontinuing therapy.

When comparing the strategies of NIV versus HFNC for acute hypoxemic respiratory failure *despite conventional oxygen*, a single, large, randomized trial has been conducted for direct comparison (411). Although the primary outcome of intubation rate at 28 days was not different, this study demonstrated improved 90-day survival with HFNC compared with NIV (OR, 0.42; 95% CI, 0.21 to 0.85) and HFNC patients experienced significantly more days free of mechanical ventilation during a 28-day study period (411). In a post hoc analysis of patients with severe hypoxemia ($PaO_2/FiO_2 \leq 200$ mm Hg) from the above trial, HFNC resulted in lower intubation rates compared with NIV (35% versus 58%, respectively). A systematic review and meta-analysis of nine RCTs (2,093 patients) showed that HFNC reduces intubation compared with conventional oxygen (RR, 0.85; 95% CI, 0.74 to 0.99) but does not affect the risk of death or ICU length of stay (412–414). However, the NIV technique was not standardized, and the experience of the centers varied.

Although the quality of evidence is low, the benefits of a trial of HFNC for the sepsis patient with non-hypercapnic progressive hypoxia over NIV seems justified. Patients requiring HFNC for acute hypoxemic respiratory failure are at high risk of requiring intubation; therefore, such trials must be accompanied by careful surveillance for ventilatory failure.

Noninvasive Ventilation

Recommendation

48. There is insufficient evidence to make a recommendation on the use of noninvasive ventilation in comparison to invasive ventilation for adults with sepsis-induced hypoxemic respiratory failure.

Rationale

When directly compared with invasive positive pressure ventilation, NIV may be able to achieve similar physiologic benefits including improved gas exchange and reduced work of breathing in select patients, while avoiding complications associated with intubation, invasive ventilation, and accompanying sedation. In contrast, NIV can cause mask-related discomfort, unrecognized patient-ventilator asynchrony due to leaks, and gastric insufflation. The main risk of NIV for the indication of acute respiratory failure is the potential for delaying needed intubation and increasing the risk of an interval aspiration events. Studies have suggested that NIV failure is an independent risk factor for mortality specifically in this population, although careful patient selection may reduce this risk (415, 416).

Patients with sepsis-induced hypoxemic respiratory failure may or may not have a competing chronic respiratory disease (COPD, obesity) and the use of NIV for the rescue of patients with exclusively acute hypoxic respiratory failure (“de novo respiratory failure”) is less well studied, but not uncommon. For example, the LUNG SAFE trial demonstrated that NIV was used in 15% of patients with ARDS with varying failure and mortality rates, depending on ARDS severity (417).

A few small RCTs have shown benefit with NIV for early or mild ARDS or de novo hypoxic respiratory failure (418, 419). Since the last guideline distribution, only one additional study was added for analysis (420). Due to a small number of patients studied, low quality of evidence, uncertainty regarding whether clinicians can identify hypoxic patients in respiratory failure in whom NIV might be beneficial, and observational data that suggest the potential for harm with NIV in this setting, no clear recommendation can be made. If NIV is used for patients with sepsis-associated hypoxic respiratory failure, we suggest monitoring for an early reduction in work of breathing and close monitoring of tidal volumes (421).

Protective Ventilation in Acute Respiratory Distress Syndrome (ARDS)

Recommendation

49. For adults with sepsis-induced ARDS, we **recommend** using a low tidal volume ventilation strategy (6 mL/kg), over a high tidal volume strategy (> 10 mL/kg).
Strong recommendation, high quality of evidence.

Rationale

This recommendation is the same as that of the previous guidelines. Of note, the studies that guide the recommendations in this section enrolled patients using criteria from the American-European Consensus Criteria Definition for Acute Lung Injury and ARDS (422). For the current document, we used the 2012 Berlin definition and the terms mild, moderate, and severe ARDS ($\text{PaO}_2/\text{FiO}_2 \leq 300$, ≤ 200 , and ≤ 100 mm Hg, respectively) (423). Several multicenter RCTs have been performed in patients with established ARDS to evaluate the effects of limiting inspiratory pressure through moderation of tidal volume (424–427). These studies showed differing results, which may have been caused by differences in airway pressures in the treatment and control groups (423, 424, 428).

Several meta-analyses suggest decreased mortality in patients with a pressure- and volume-limited strategy for established ARDS (353, 354). The largest trial of a volume- and pressure-limited strategy showed 9% absolute decrease in mortality in ARDS patients ventilated with tidal volumes of 6 mL/kg compared with 12 mL/kg predicted body weight (PBW), and aiming for plateau pressure ≤ 30 cm H₂O (424).

The use of lung-protective strategies for patients with ARDS is supported by clinical trials and has been widely accepted; however, the precise tidal volume for an individual ARDS patient requires adjustment for factors such as the plateau pressure, the selected positive end-expiratory pressure (PEEP), thoracoabdominal compliance, and the patient's breathing effort. Patients with profound metabolic acidosis, high minute ventilation, or short stature may require additional manipulation of tidal volumes. Some clinicians believe it may be safe to ventilate with tidal volumes > 6 mL/kg PBW, as long as plateau pressure can be maintained ≤ 30 cm H₂O (429, 430). The plateau pressure is only truly valuable if the patient is passive

during the inspiratory hold. Conversely, patients with very stiff chest/abdominal walls and high pleural pressures may tolerate plateau pressures > 30 cm H₂O because transpulmonary pressures will be lower. A retrospective study suggested that tidal volumes should be lowered even with plateau pressures ≤ 30 cm H₂O (431) because lower plateau pressures were associated with reduced hospital mortality (432). A recent patient-level mediation analysis suggested that a tidal volume that results in a driving pressure (plateau pressure minus set PEEP) below 12–15 cm H₂O may be advantageous in patients without spontaneous breathing efforts (433). Prospective validation of tidal volume titration by driving pressure is needed before this approach can be recommended. Tidal volumes > 6 cc/kg coupled with plateau pressures > 30 cm H₂O should be avoided in ARDS. Clinicians should use as a starting point the objective of reducing tidal volume over 1 to 2 hours from its initial value toward the goal of a “low” tidal volume (≈ 6 mL/kg PBW) achieved in conjunction with an end-inspiratory plateau pressure ≤ 30 cm H₂O. If plateau pressure remains > 30 cm H₂O after reduction of tidal volume to 6 mL/kg PBW, tidal volume may be further reduced to as low as 4 mL/kg PBW. The clinician should keep in mind that very low tidal volumes may result in significant patient-ventilatory dyssynchrony and patient discomfort. Respiratory rate should be increased to a maximum of 35 breaths/min during tidal volume reduction to maintain minute ventilation. Volume- and pressure-limited ventilation may lead to hypercapnia even with these maximum tolerated set respiratory rates; this appears to be tolerated and safe in the absence of contraindications (e.g., high intracranial pressure, sickle cell crisis). No single mode of ventilation (pressure control, volume control) has consistently been shown to be advantageous when compared with any other that respects the same principles of lung protection.

Recommendation

50. For adults with sepsis-induced severe ARDS, we **recommend** using an upper limit goal for plateau pressures of 30 cm H₂O, over higher plateau pressures.
Strong recommendation, moderate quality of evidence.

Rationale

This recommendation is unchanged from the previous guidelines, as no new trials evaluating plateau

pressure have been published since then. Of note, the three RCTs that guide this recommendation (424, 426, 427) enrolled patients using the criteria from the American-European Consensus Criteria Definition for Acute Lung Injury and ARDS (422) whereas the current document use the 2012 Berlin definition and the terms mild, moderate, and severe ARDS ($\text{PaO}_2/\text{FiO}_2 \leq 300$, ≤ 200 , and ≤ 100 mm Hg, respectively) (423). These three RCTs compared a strategy of low tidal volume and limited plateau pressure with a strategy using higher tidal volume and plateau pressure; pooled data suggest reduced mortality (RR, 0.83; 95% CI, 0.70 to 0.97) and more ventilator-free days (MD 1.8 days; 95% CI, 0.35 to 3.25) in patients managed with low plateau pressures.

A recent systematic review which included five RCTs also identified a strong relationship between plateau pressure and mortality (434). The recommendation is also supported by observational data. LUNGSAFE, a large international observational study, which reported that plateau pressure correlated with mortality; however, the relationship between the two was not evident when plateau pressure was below 20 cm H₂O (435). A secondary analysis of five observational studies identified a plateau pressure cut-off value of 29 cm H₂O, above which an ordinal increment was accompanied by an increment of risk of death (436). We therefore recommend that the upper limit goal for plateau pressure should be less than 30 cm H₂O.

Recommendation

51. For adults with moderate to severe sepsis-induced ARDS, we **suggest** using higher PEEP over lower PEEP.

Weak recommendation, moderate quality of evidence.

Rationale

The recommendation is unchanged from 2016. Two RCTs (437, 438) were published since the 2016 Guidelines (12, 13), but we did not include these trials in the meta-analyses because both studies applied recruitment maneuvers to titrate PEEP levels. Our conclusions did not change in a sensitivity analysis which includes these two trials.

Applying higher PEEP in patients with ARDS may open lung units to participate in gas exchange and may increase PaO_2 . We included three multicenter RCTs (439–441) and one pilot RCT (442), investigating use of higher PEEP versus lower PEEP strategies *in conjunction with low tidal volumes* for the management of patients with ARDS. Among patients with ARDS receiving lower VTs, we did not identify a significant benefit for use of a higher PEEP versus lower PEEP strategy for improving mortality (RR, 0.93; 95% CI, 0.83–1.03), days on mechanical ventilation (RR, 0.00; 95% CI, -1.02–1.02), or ventilator-free days (RR, 1.48; 95% CI, 0.19–2.76); and there was no increase in the risk of barotrauma (RR, 1.49; 95% CI, 0.99–2.23).

A patient-level meta-analysis showed no benefit of higher PEEP in *all patients* with ARDS; however, patients with moderate or severe ARDS ($\text{PaO}_2/\text{FiO}_2 \leq 200$ mm Hg) had decreased mortality with the use of higher PEEP, whereas those with mild ARDS did not (443). A patient-level analysis of two of the randomized PEEP trials (440, 441) suggested that patients with ARDS who respond to increased PEEP with improved oxygenation have a lower risk of death; this association was stronger in patients with more severe ARDS ($\text{PaO}_2/\text{FiO}_2 < 150$ mm Hg) compared with patients with less severe ARDS (444).

The optimal method of selecting a higher PEEP level is not clear. One option is to titrate PEEP according to bedside measurements of thoracopulmonary compliance with the objective of obtaining the best compliance or lowest driving pressure, reflecting a favorable balance of lung recruitment and overdistension (445). The second option is to titrate PEEP upward while the patient is receiving a tidal volume of 6 mL/kg PBW, until the plateau airway pressure is 28 cm H₂O (441). A third option is to use a PEEP/ FiO_2 titration table that titrates PEEP based on the combination of FiO_2 and PEEP required to maintain adequate oxygenation (439–441). A PEEP >5 cm H₂O is usually required to avoid lung collapse (446). Esophageal pressure guided PEEP titration has been evaluated in two trials (447, 448). While the pilot study suggested benefit (448), the subsequent 200 patient multicenter RCT that compared PEEP titration guided by esophageal (P_{ES}) measurement versus empirical high PEEP- FiO_2 titration, showed no significant difference in a composite outcome

of death and days free from mechanical ventilation through day 28 (449).

Low Tidal Volume in non-ARDS Respiratory Failure

Recommendation

52. For adults with sepsis-induced respiratory failure (without ARDS), we **suggest** using low tidal volume as compared to high tidal volume ventilation.

Weak recommendation, low quality of evidence.

Rationale

Previous versions of SSC guidelines issued a strong recommendation with a moderate-quality evidence for using low tidal volume (V_t) ventilation (V_t 4–8 mL/kg of predicted body weight), over higher tidal volumes (V_t > 8 mL/kg) in the management of patients with ARDS (12, 13, 226). There is not as strong an evidence base, however, for the patients presenting with acute respiratory failure requiring mechanical ventilation who do not fulfil the criteria for ARDS. A 2015 systematic review and meta-analysis found a reduction in the risk of a composite endpoint of ARDS or pneumonia during the hospital stay in the low tidal volume ventilation group compared to the high tidal volume ventilation group (RR, 0.72; 95% CI, 0.52 to 0.98) (450). Our analysis of three RCTs (1,129 patients) showed no difference in mortality with low V_t ventilation (RR, 1.07; 95% CI, 0.91 to 1.26), with a trend toward lower risk of developing ARDs (RR, 0.59; 95% CI, 0.34 to 1.02) (Supplemental Digital Content: Appendix 4).

There are limited data on ventilation strategies for patients with sepsis-induced respiratory failure who do not meet criteria for ARDS. However, sepsis is an independent risk factor for the development of ARDS, and delays in diagnosing ARDS may result in delayed use of low tidal volumes. We therefore suggest that low tidal volume ventilation be used in all patients with sepsis who are receiving mechanical ventilation to avoid underuse or delayed use of this intervention. Furthermore, the use of low tidal volume ventilation avoids the risk of promoting ventilator induced lung injury in septic patients in whom the diagnosis of ARDS has been missed.

Recruitment Maneuvers

Recommendations

53. For adults with sepsis-induced moderate-severe ARDS, we **suggest** using traditional recruitment maneuvers.
Weak recommendation, moderate quality of evidence.

54. When using recruitment maneuvers, we **recommend against** using incremental PEEP titration/strategy.
Strong recommendation, moderate quality of evidence.

Rationale

Many strategies exist for treating refractory hypoxemia in patients with severe ARDS (451). Temporarily raising transpulmonary pressure may facilitate opening atelectatic alveoli to permit gas exchange (446), but could also over distend aerated lung units leading to ventilator-induced lung injury and transient hypotension. Since the publication of the previous SSC Guidelines, two important RCTs were published both of which utilized a “non-traditional” approach to recruitment maneuvers. Instead of the “traditional” recruitment maneuver which consists of the application of sustained continuous positive airway pressure (e.g., 30–40 cm H₂O for 30–40 seconds), both trials conducted lung recruitment with incremental PEEP levels, followed by a decremental PEEP titration according to either best respiratory-system static compliance (452) or oxygen saturation (437). When the incremental PEEP recruitment studies are analyzed separately from studies utilizing traditional recruitment maneuvers, recruitment with incremental PEEP is associated with increased 28-day mortality RR, 1.12; 95% CI, 1.00–1.25), which justifies the strong recommendation against using incremental PEEP titration for recruitment. Traditional recruitment maneuvers appear to improve 28-day mortality (RR, 0.79; 95% CI, 0.64–0.96) in patients with ARDS (Supplemental Digital Content: Appendix 4). Although the effects of recruitment maneuvers improve oxygenation initially, the effects can be transient (453). Selected patients with severe hypoxemia may benefit from recruitment maneuvers in conjunction with higher levels of PEEP, but little evidence supports the routine use in all ARDS patients, so we have focused our recommendations to patients with moderate-to-severe ARDS (453). Any patient receiving recruitment maneuvers should be monitored closely and recruitment maneuvers should be discontinued if deterioration in clinical status is observed.

Prone Ventilation

Recommendation

55. For adults with sepsis-induced moderate-severe ARDS, we **recommend** using prone ventilation for more than 12 hours daily.
Strong recommendation, moderate quality of evidence.

Rationale

There were no new randomized, controlled trials evaluating the use of prone ventilation in sepsis induced severe ARDS published since the 2016 guidelines. Therefore, no change in the recommendation was made. In 2017, a meta-analysis was published (454) that was updated from a previous meta-analysis published in 2010 (455), to which only one study, the PROSEVA trial published in 2013 (456), was added. This repeated meta-analysis confirmed the results from the previous published work: In patients with ARDS and a PaO₂/FiO₂ ratio < 200, the use of prone compared with supine position within the first 36 hours of intubation, when performed for > 12 hours a day, showed improved survival. Meta-analysis including this study demonstrated reduced mortality in severe ARDS patients treated with prone compared with supine position (RR, 0.74; 95%CI 0.56–.99) as well as improved oxygenation as measured by change in PaO₂/FiO₂ ratio (median 23.5 higher; 95% CI, 12.4–34.5 higher) (454). Most patients respond to the prone position with improved oxygenation and may also have improved lung compliance (457–459). While prone position may be associated with potentially life-threatening complications including accidental removal of the endotracheal tube, this was not evident in pooled analysis (RR, 1.09; 95% CI, 0.85–1.39). However, prone position was associated with an increase in pressure sores (RR, 1.22; 95% CI, 1.05–1.41) (460, 461), and some patients have contraindications to the prone position (460, 461).

Neuromuscular Blocking Agents

Recommendation

56. For adults with sepsis induced moderate-severe ARDS, we **suggest** using intermittent NMBA boluses, over NMBA continuous infusion.
Weak recommendation, moderate quality of evidence.

Rationale

The most common indication for neuromuscular blocking agents (NMBAs) use in the ICU is to facilitate mechanical ventilation (462). These drugs may improve chest wall compliance, prevent respiratory dyssynchrony, and reduce peak airway pressures (463). In addition, use of NMBA may reduce oxygen consumption by decreasing the work of breathing (464). In the 2016 SSC guidelines we issued a weak recommendation for using NMBA infusion for 48 hours in sepsis-induced moderate to severe ARDS (12, 13). This recommendation was based on a meta-analysis of three trials that examined the role of NMBAs in ARDS (465–467), showing reduced risks of death (RR, 0.72; 95% CI, 0.58–0.91) and barotrauma (RR, 0.43; 95% CI, 0.20–0.90) with the use of cisatracurium infusion (468).

Since then, several RCTs have been published (469–471), the largest of which is the ROSE Trial (471). Because of the presence of significant statistical and clinical heterogeneity, a meta-analysis of all seven trials was not appropriate. A continuous NMBA infusion did not improve mortality when compared with a light sedation strategy with as needed NMBA boluses but no continuous infusion (RR, 0.99; 95% CI, 0.86–1.15). On the other hand, continuous NMBA infusion reduced mortality when compared to deep sedation with as needed NMBA boluses (RR, 0.71; 95% CI, 0.57–0.89). Overall, continuous NMBA infusion reduced the risk of barotrauma (RR, 0.55; 95% CI, 0.35–0.85), but the effect on ventilator-free days, duration of mechanical ventilation, and ICU-acquired weakness was unclear (472, 473).

Given the uncertainty that still exists pertaining to these important outcomes and the balance between benefits and potential harms, the panel issued a weak recommendation favoring intermittent NMBA boluses over a continuous infusion. Importantly, if NMBAs are used, clinicians must ensure adequate patient sedation and analgesia (191, 474). Recently updated clinical practice guidelines are also available for specific guidance (472).

Extracorporeal Membrane Oxygenation

Recommendation

57. For adults with sepsis-induced severe ARDS, we **suggest** using venovenous (VV) ECMO when conventional mechanical ventilation fails in experienced centers with the infrastructure in place to support its use.
Weak recommendation, low quality of evidence.

Rationale

Venovenous (VV) extracorporeal membrane oxygenation (ECMO) is used in patients with severe acute respiratory failure to facilitate gas exchange in the setting of refractory hypoxemia or hypercapnic respiratory acidosis (475). It may also be used to facilitate a reduction in the intensity of mechanical ventilation. The evidence for the use of VV-ECMO in sepsis-induced ARDS is limited, with two RCTs completed in the last 10 years to assess the potential efficacy of VV-ECMO for severe ARDS (476, 477). The inclusion criteria of the trials were strict and focused on a very sick population of patients with severe ARDS refractory to conventional ventilation strategies and other rescue therapies such as prone position. The evidence in this guideline was downgraded to very low quality due to indirectness.

There were methodological limitations of the included studies. In one trial, all intervention participants were treated at one center, which may have inflated the effect size because the center specialized in ECMO management (477). Additionally, some of the participants in this trial did not receive the intervention (477). However, one recent systematic review found that VV-ECMO delivered at expert centers reduced mortality for patients with severe ARDS (475). In clinical practice, patient selection is important and usually discussed prior to initiation of ECMO at an ECMO center. Cost and equity are substantial issues; and registry data will be very important to document longer term outcomes in these patients outside of the clinical trial context.

ADDITIONAL THERAPIES

Corticosteroids

Recommendation

58. For adults with septic shock and an ongoing requirement for vasopressor therapy we **suggest** using IV corticosteroids.

Weak recommendation; moderate quality of evidence.

Remarks:

The typical corticosteroid used in adults with septic shock is IV hydrocortisone at a dose of 200 mg/d given as 50 mg intravenously every 6 hours or as a continuous infusion. It is suggested that this is commenced at a dose of norepinephrine or epinephrine ≥ 0.25 mcg/kg/min at least 4 hours after initiation.

Rationale

In the 2016 guidance, the accumulated evidence did not support a recommendation for their use if adequate fluid resuscitation and vasopressor therapy were able to restore hemodynamic stability (12, 13). Since then, three large RCTs have been published (354, 478, 479). An updated meta-analysis (480) found systemic corticosteroid to accelerate resolution of shock (MD, 1.52 days; 95% CI, 1.71 to 1.32). A meta-analysis conducted for this guideline revision (Supplemental Digital Content: Appendix 5) found an increase vasopressor-free days (MD, 1.5 days; 95% CI, 0.8 to 3.11 days); however, corticosteroid use increased neuromuscular weakness (RR, 1.21; 95% CI, 1.01 to 1.45), without a clear effect on short- or long-term mortality.

The overall quality of evidence was moderate. The panel judged the desirable effects (shock resolution, vasopressor free days) to outweigh the undesirable effects of low dose corticosteroid. This observation, when taken into consideration with the resources required, cost of the intervention, and feasibility supported a weak recommendation in favor of using low dose corticosteroid therapy in septic shock.

The optimal dose, timing of initiation, and duration of corticosteroids remain uncertain; recent RCTs used 200 mg per day of IV hydrocortisone in divided doses (354, 479, 480). The three trials (354, 478, 479) also used different inclusion criteria: in ADRENAL (479) eligible patients were those on any dose of vasopressor or inotrope for ≥ 4 hours to maintain a MAP > 60 mm Hg, and present at the time of randomization. In APROCCHSS (478) the dose of vasopressor was ≥ 0.25 $\mu\text{g}/\text{kg}/\text{min}$ or ≥ 1 mg/hr of norepinephrine or epinephrine, or any other vasopressor for at least 6 hours to maintain a MAP ≥ 65 mmHg. In the ADRENAL (479) study, hydrocortisone was administered for a maximum of seven days or until ICU discharge or death; in APROCCHSS (478) hydrocortisone was administered for seven days; in VANISH (354) 200 mg of hydrocortisone was administered daily for 5 days and then tapered over further 6 days.

Our recommendation focuses on adults with septic shock and ongoing requirement for vasopressor therapy. We defined ongoing requirement as a dose of norepinephrine or epinephrine ≥ 0.25 mcg/kg/min for at least 4 hours after initiation to maintain the target MAP. The dose of hydrocortisone is typically 200 mg/d. No dose response benefit was seen in a prior systematic review and meta-analysis (480).

Blood Purification

Recommendations

59. For adults with sepsis or septic shock, we **suggest against** using polymyxin B hemoperfusion.

Weak recommendation; low quality of evidence.

60. There is insufficient evidence to make a recommendation on the use of other blood purification techniques.

Rationale

Hemoperfusion refers to the circulation of blood through an extracorporeal circuit that contains an adsorbent containing cartridge. The previous guidelines made no recommendation regarding the use of blood purification techniques (12, 13). The updated literature search for guideline identified one new relevant RCT (481).

The most widely investigated technique involves the use of polymyxin B-immobilized polystyrene-derived fibers. Randomized trials of this technique have been previously summarized in a systematic review and meta-analysis (482). An updated meta-analysis of all available RCTs (Supplemental Digital Content: Appendix 5) demonstrated a possible reduction in mortality (RR, 0.87; 95% CI, 0.77–0.98, low quality), however this finding was challenged by sensitivity analyses: after excluding high risk of bias trials the risk ratio is 1.14 (95% CI, 0.96–1.36); and after excluding trials published prior to 2010 we observed higher mortality with hemoperfusion (RR, 1.23; 95% CI, 1.04–1.46). Overall, the quality of evidence is judged as low (Supplemental Digital Content: Appendix 5).

Substantial uncertainty as to any beneficial effect exists and the frequency of undesirable effects is reported in few trials. Polymyxin B hemoperfusion is expensive, resource intensive, potentially reduces health equity, and is infeasible in low-income economies. All considered, the panel issued a weak recommendation against the use of polymyxin B hemoperfusion therapy.

We did not identify new evidence on other modalities such as hemofiltration, combined hemoperfusion and hemofiltration or plasma exchange. Accordingly, no recommendation regarding the use of these modalities is made and this is unchanged from the 2016 guidelines. Since the analysis, new data has emerged, but at this stage was not sufficient for us to reconsider the recommendation (483).

Further research is needed to determine the effect of various blood purification techniques on patient outcomes.

Red Blood Cell (RBC) Transfusion Targets

Recommendation

61. For adults with sepsis or septic shock, we **recommend** using a restrictive (over liberal) transfusion strategy.

Strong recommendation; moderate quality of evidence.

Remarks:

A restrictive transfusion strategy typically includes a hemoglobin concentration transfusion trigger of 70 g/L; however, RBC transfusion should not be guided by hemoglobin concentration alone. Assessment of a patient's overall clinical status and consideration of extenuating circumstances such as acute myocardial ischemia, severe hypoxemia or acute hemorrhage is required.

Rationale

The previous guidance was informed by two RCTs (484, 485). The Transfusion Requirements in Septic Shock (TRISS) trial addressed a transfusion threshold of 70 g/L versus 90 g/L in 1,000 septic shock patients after admission to the ICU. The results showed similar 90-day mortality, ischemic events, and use of life support in the two treatment groups with fewer transfusions in the lower-threshold group. The Transfusion requirements in Critical Care trial (TRICC), which compared a restrictive transfusion threshold of 70 g/L versus 100 g/L in 838 euvolemic ICU patients, demonstrated no difference in the primary outcome (30-day mortality). In the subgroup of 218 patients with sepsis or septic shock 30-day mortality was similar in the two groups (22.8% in the restrictive group vs. 29.7% in the liberal group, $p = 0.36$).

Our literature search identified a recent systematic review and meta-analysis of RCTs (486) and one new RCT: The Transfusion Requirements in Critically Ill Oncologic Patients (TRICOP) trial (487). This trial randomized 300 adult cancer patients with septic shock to either a liberal (hemoglobin threshold, < 90 g/L) or restrictive strategy (hemoglobin threshold, < 70 g/L) of RBC transfusion. At 28 days after randomization, the mortality rate in the liberal group was 45% (67 patients) versus 56% (84 patients) in the restrictive group (HR 0.74; 95% CI, 0.53–1.04; $p = 0.08$) with no

differences in ICU and hospital length of stay. At 90 days after randomization, mortality rate in the liberal group was lower (59% vs 70%) than in the restrictive group (hazard ratio, 0.72; 95% CI, 0.53–0.97).

Our update of the meta-analysis showed no difference in 28-day mortality (OR, 0.99 95% CI, 0.67–1.46, moderate quality). This is due to the inclusion of the TRICOP study where lower 28 mortality was observed with a liberal strategy. Overall, the quality of evidence was judged moderate.

The overall balance of effects is uncertain and does not favor either the intervention or comparator. However, a restrictive strategy was determined likely beneficial with regards to resources required, cost effectiveness, and health equity considerations. A restrictive strategy is feasible in low- and middle-income countries. The 2016 strong recommendation favoring a restrictive strategy is unchanged; however, the overall quality of evidence changed from strong to moderate.

Immunoglobulins

Recommendation

62. For adults with sepsis or septic shock, we **suggest against** using intravenous immunoglobulins
Weak recommendation, low quality of evidence.

Rationale

Patients with sepsis and septic shock may have evidence of hyper-inflammation and immunosuppression (488). There are no high-quality studies examining the effect of intravenous (IV) immunoglobulins on the outcomes of patients with sepsis or septic shock. The previous guidance was a weak recommendation against their use (12, 13).

Our literature search identified two new RCTs (489, 490) and three meta-analyses (350, 491, 492) evaluating the effects of polyclonal IV immunoglobulins (IVIG) and immunoglobulin M-enriched polyclonal Ig (IVIGM) in patients with sepsis. The updated meta-analyses demonstrated reduced mortality with IVIG (RR, 0.73; 95% CI, 0.51–0.91) and IVIGM (RR, 0.69; 95% CI, 0.55–0.85), however the quality of evidence is low with many of the included studies at high risks of bias including single-center trials with small sample size, undefined randomization, allocation and blinding procedures, different

dosing regimens and durations of treatment, different controls and few studies reported adverse events. Furthermore, after excluding high risk of bias studies, the significant reduction in mortality is no longer apparent.

Overall, the balance of effects (beneficial and undesirable) remains uncertain. Intravenous immunoglobulin is also relatively expensive, possibly not cost-effective and may reduce health equity. Its cost also limits its feasibility in countries with low- and middle-income economies. Based on these judgments, clinicians may consider avoiding the routine use of IV immunoglobulins in patients with sepsis and septic shock. Large, multicenter, well designed, RCTs are needed to resolve the uncertainty regarding the role of immunoglobulin therapies in this patient population.

Stress Ulcer Prophylaxis

Recommendation

63. For adults with sepsis or septic shock, and who have risk factors for gastrointestinal (GI) bleeding, we **suggest** using stress ulcer prophylaxis.
Weak recommendation, moderate quality of evidence.

Rationale

Stress ulcers develop in the gastrointestinal (GI) tract of critically ill patients and can be associated with significant morbidity and mortality (493). In 2016, this guideline recommended stress ulcer prophylaxis for patients with risk factors (12, 13).

Our literature search identified one new RCT (494) and the meta-analysis from the previous guideline was updated. This demonstrated no effect on mortality (RR, 1.01 95% CI, 0.93–1.10) and a reduction in GI hemorrhage (RR, 0.52 95% CI, 0.45–0.61). A sensitivity analysis including only trials at low risk of bias provided similar results. No increase in *Clostridioides difficile* colitis or pneumonia was observed. However, it was noted that the most recent (and largest) RCT did not demonstrate any effect of pantoprazole versus placebo on 90-day mortality and a composite outcome of clinically important events (494). A recent meta-analysis published since the finalization of the literature searches has suggested that there is a higher risk of recurrent *Clostridioides difficile* infections with proton pump inhibitors (495).

Overall, it was judged that the evidence probably favored the administration of stress ulcer prophylaxis. This is driven by a modest reduction in gastrointestinal hemorrhage for which there is moderate quality of evidence (Supplemental Digital Content: Appendix 5). While no adverse effects were observed, the quality of evidence for these outcomes was low. Stress ulcer prophylaxis is relatively inexpensive, requires limited resources and is applicable to countries with low-income economies. These judgements support a weak recommendation for the use of stress ulcer prophylaxis in at-risk patients. This represents a downgrading of the strong recommendation based on low-quality evidence made in 2016.

A recent systematic review evaluated risk factors for clinically important GI bleeding (496). After excluding high risk of bias studies, risk factors included: coagulopathy (relative effect (RE) 4.76; 95% CI, 2.62-8.63), shock (RE 2.60; 95% CI, 1.25-5.42), and chronic liver disease (RE 7.64; 95% CI, 3.32-17.58). The effect of mechanical ventilation on clinically important bleeding was unclear (RE 1.93, 0.57-6.50, very low certainty).

Venous Thromboembolism (VTE) Prophylaxis

Recommendations

- | | |
|-----|--|
| 64. | For adults with sepsis or septic shock, we recommend using pharmacologic VTE prophylaxis unless a contraindication to such therapy exists.
<i>Strong recommendation, moderate quality of evidence.</i> |
| 65. | For adults with sepsis or septic shock, we recommend using low molecular weight heparin (LMWH) over unfractionated heparin (UFH) for VTE prophylaxis.
<i>Strong recommendation, moderate quality of evidence.</i> |
| 66. | For adults with sepsis or septic shock, we suggest against using mechanical VTE prophylaxis in addition to pharmacological prophylaxis, over pharmacologic prophylaxis alone.
<i>Weak recommendation, low quality of evidence.</i> |

Rationale

Critically ill patients are at risk for deep vein thrombosis (DVT) as well as pulmonary embolism (PE). The incidence of DVT acquired in the ICU may be as high as 10% (497), the incidence of acquired PE may be 2%–4% (498, 499).

No new RCT evidence was identified. Our previous meta-analysis demonstrated a significant reduction in both DVT and PE and no increase in bleeding complications.

On balance, the effect favors the intervention with a moderate quality of evidence. The cost of intervention is not large, and it is likely feasible in countries with low- and middle-income economies. These judgements support a recommendation for the use of pharmacologic venous thromboembolism (VTE) prophylaxis unless a contraindication exists. The recommendation is unchanged from the 2016 guidelines.

Our literature review found no new RCT evidence comparing the administration of low molecular weight heparin (LMWH) to unfractionated heparin (UFH). The prior meta-analysis demonstrated significantly lower rates of DVT following the administration of LMWH compared to UFH (RR, 0.84; 95% CI, 0.71–0.98). No difference in the rates of clinically significant bleeding, mortality or PE were observed. The overall quality of evidence was rated as moderate: it was downgraded for imprecision. It was determined that the balance of overall effects favored LMWH over UFH. Any difference in resources required between the two interventions was considered negligible, and LMWH administration was feasible and applicable in countries with low- and middle-income economies. Further, LMWH may have greater consumer acceptance as it requires only one subcutaneous injection daily. These judgements support a recommendation for the use of LMWH over UFH for VTE prophylaxis in patients with sepsis or septic shock. This recommendation is unchanged from the 2016 guidelines.

Combined pharmacologic prophylaxis and mechanical prophylaxis with intermittent pneumatic compression (IPC) and/or graduated stockings may offer another option for patients with sepsis and septic shock. In the 2016 guidelines, a suggestion to use combination therapy whenever possible, was based on indirect and imprecise data (12, 13). Our literature search identified one new RCT that compared the combination of mechanical and pharmacological prophylaxis to pharmacological prophylaxis alone (500).

The PREVENT study randomized 2003 critically ill patients to intermittent pneumatic calf compression alone or in combination with pharmacological prophylaxis (500). No difference in mortality (RR, 0.98; 95% CI, 0.84–1.13), or the rates of DVT and PE were observed. No difference in lower extremity ischemia was demonstrated. The study was downgraded during the quality assessment for imprecision. For the outcome of mortality, the quality was assessed as moderate; for other outcomes it was further downgraded for risk of bias.

It was judged that any effects of the intervention (mechanical prophylaxis in addition to pharmacologic), either beneficial or undesirable, were likely trivial (Supplemental Digital Content: Appendix 5). However, there are resource implications and costs associated with the use of mechanical VTE prophylaxis. These, together with the lack of any effect on a patient centered outcome support a weak recommendation against the use of the combination of mechanical and pharmacologic prophylaxis.

It is acknowledged that in some patients with sepsis and septic shock pharmacologic prophylaxis may be contraindicated. These patients may benefit from mechanical VTE prophylaxis. No data for this population exist. Further research is indicated.

Renal Replacement Therapy

Recommendations

67. In adults with sepsis or septic shock and AKI who require renal replacement therapy, we **suggest** using either continuous or intermittent renal replacement therapy.
Weak recommendation, low quality of evidence.

68. In adults with sepsis or septic shock and AKI, with no definitive indications for renal replacement therapy, we **suggest against** using renal replacement therapy.
Weak recommendation, moderate quality of evidence.

Rationale

Two systematic reviews and meta-analyses (501, 502) summarized the total body of evidence: they do not show a difference in mortality between patients who receive continuous (CRRT) versus intermittent hemodialysis (IHD). The results remained the same when the analysis is restricted to RCTs (502).

Our updated literature search identified no new RCTs but two meta-analysis comparing continuous and intermittent renal replacement therapies (503, 504). The quality of evidence was judged as low. The balance of effects favored neither (IHD) nor CRRT. It was acknowledged that the resources required for the interventions vary. In low- and middle-income economies, the specialized equipment, expertise and personal required for continuous modalities may not be available. The recommendation, for either intervention, is unchanged from the 2016 guidelines.

Timing of renal replacement therapy initiation is of importance. Prior research has suggested benefit (505) or harm (506) for “early” versus “delayed” initiation of RRT.

Our search identified a new RCT comparing early versus delayed RRT (507). This trial included 488 patients with AKI and septic shock. It was stopped early, after the second planned interim analysis, for futility. Eligible patients were those with septic shock (within 48 hours of the onset of vasopressor therapy and AKI defined as oliguria (< 0.3 mL/kg/hr for \geq 24 hours), anuria for 12 hours or more, or a serum creatinine level 3 times baseline accompanied by a rapid increase of \geq 0.5 mg/dL. Subsequent to the censor date for our literature search, the results of the STARRT-AKI trial were published. The trial, which randomized 3,000 participants, demonstrated no difference in mortality in those allocated to an accelerated strategy of RRT compared with those allocated to a “standard” strategy. No differential effect was observed in the a priori sepsis subgroup of 1,689 patients (508).

The results of this trial were included in an updated metaanalysis (Supplemental Digital Content: Appendix 5). No effect of the timing of initiation of renal replacement therapy on mortality and renal recovery was observed. The IDEAL-ICU trial (507) did not report central venous access device (CVAD) infections: the results for this outcome are unchanged from 2016. The certainty of evidence for the key outcomes of mortality, renal recovery and CVAD infection was a least moderate and was only downgraded for imprecision (Supplemental Digital Content: Appendix 5). Overall, the balance of effects favored delayed rather than early initiation of RRT. This is principally driven by the higher rate of CVAD infection in the “early” initiation. Therefore, after considering of the resources required, cost and health equity issues, the panel issued a weak recommendation against the use of RRT in patients with sepsis and AKI for increases in creatinine or oliguria alone, and without other absolute indications for dialysis (uremic complications, refractory acidemia, refractory fluid overload or hyperkalemia).

Glucose Control

Recommendation

69. For adults with sepsis or septic shock, we **recommend** initiating insulin therapy at a glucose level of \geq 180 mg/dL (10 mmol/L).

Strong recommendation; moderate quality of evidence.

Remark:

Following initiation of an insulin therapy, a typical target blood glucose range is 144–180 mg/dL (8–10 mmol/L).

Rationale

Hyperglycemia (> 180mg/dL), hypoglycemia and increased glycemic variability are associated with increased mortality in critically ill patients (509–511). The American Diabetes Association, in its most recent recommendations for glycemic control of critically ill patients, recommended the initiation of insulin therapy for persistent hyperglycemia > 180 mg/dL and thereafter a target glucose range of 140–180 mg/dL (512).

In a single-center study, targeting blood glucose to 80–110 mg/dL reduced ICU mortality (513), however this finding was not reproduced in subsequent multicenter RCTs (514, 515). Meta-analyses also report a higher incidence of hypoglycemia (glucose < 40 mg/dL) in critically patients where blood glucose was targeted to 80–110 mg/dL (516, 517). The previous recommendation to commence insulin when two consecutive blood glucose levels are > 180 mg/dL derives from the NICE-SUGAR trial (518). A summary of the evidence for this trigger of > 180 mg/dL is found in Supplemental Digital Content: Appendix 5. In this version of the guideline, we asked a new question: in adults with sepsis or septic shock, what level of glucose should trigger one to start an insulin infusion (> 180 or > 150 mg/dL)?

We identified a recent network meta-analysis of 35 RCTs (519). The analysis compared four different blood glucose targets (< 110, 110–144, 144–180, and > 180 mg/dL). No significant difference in the risk of hospital mortality was observed between the four blood glucose ranges. Target concentrations of < 110 and 110–144 mg/dL were associated with a four- to nine-fold increase in the risk of hypoglycemia compared with 144–180 and > 180 mg/dL. No significant difference in the risk of hypoglycemia comparing a target of 144–180 and > 180 mg/dL was demonstrated (OR, 1.72; 95% CI, 0.79–3.7).

The overall quality of evidence was rated as moderate (Supplemental Digital Content: Appendix 5). Overall, the balance of effects favored initiation of insulin therapy at a glucose level of > 180 mg/dL. This was principally driven by the increased risk of hypoglycemia observed with lower targets. No significant differences existed between the two-insulin initiation blood glucose levels evaluated. After considering the resources required, cost, health equity issues, and applicability to low- and middle-income economies, the

panel made a strong recommendation for the initiation of insulin therapy at a glucose level of ≥ 180 mg/dL (10 mmol/L).

Further research is indicated to: (1) identify which technologies including electronic glucose management, continuous glucose monitoring, and closed loop systems, can more safely achieve better glycemic control and lower rates of hypoglycemia; and (2) determine the optimal glycemic control for different patient populations including diabetic and nondiabetic patients, medical and surgical patients.

Vitamin C

Recommendation

70. For adults with sepsis or septic shock, we **suggest against** using IV vitamin C.
Weak recommendation, low quality of evidence.

Rationale

Vitamin C is known to have anti-inflammatory properties (520). In 2017, a single center before and after study reported shorter duration of vasopressor therapy and lower mortality following the administration of combination of high dose vitamin C, hydrocortisone, and thiamine to patients with sepsis and septic shock (521). Our literature review found one systematic review and meta-analysis (522) (containing six RCTs) and one additional RCT (523).

Our updated analysis (Supplemental Digital Content: Appendix 5) included seven RCTs (416 critically ill patients). The use of vitamin C did not reduce mortality compared to usual care (RR, 0.79; 95% CI, 0.57 to 1.1, low quality). One study reported reduced vasopressor use at 168 hours (523). Of the patients alive at 7 days, 22% (16/72) administered vitamin C remained on vasopressor therapy compared to 10% (6/59) of controls.

Subsequent to the censor date for our literature search, the results of two additional RCTs of Vitamin C versus placebo were published (524, 525). In the study by Fujii et al (524), 211 adults with septic shock were randomized to the combination of vitamin C, hydrocortisone, and thiamine vs hydrocortisone alone. The authors reported no difference for the primary outcome of time alive and free of vasopressors up to 168 hours between the intervention and control group (median 122.1 hr [IQR, 76.3–145.4 hr] vs

124.6 hr [IQR, 82.1–147 hr]; $p = 0.83$). Ninety-day mortality was 28.6% (30/105) in the vitamin C group, and 24.5% (25/102) in the control group (HR, 1.18; 95% CI, 0.69 to 2.0). In the study by Moskowitz et al (525), 200 patients were randomized to a combination of vitamin C, hydrocortisone and thiamine vs placebo. No difference in the primary outcome of mean SOFA score at 72 hours post enrollment was observed. At 30 days, 34.7% (35/101) of patients randomized to combination therapy had died vs. 29.3% (29/99) randomized to placebo (HR, 1.3; 95% CI, 0.8–2.2; $p = 0.26$). When these data are added to our meta-analysis, the point estimate for mortality becomes RR, 0.9 (95% CI, 0.69–1.18; low quality).

The overall size of any desirable effect was judged as small with a low quality of evidence (Supplemental Digital Content: Appendix 5). There are limited available data of any undesirable effects: it was noted that the point estimate of the HR for 90-day mortality in the largest RCT (524) was 1.18 (95% CI, 0.69–2.00) i.e., favoring the control group. The balance of effects was accordingly judged as favoring neither the intervention nor the comparator. The intervention itself requires limited resources and is feasible in low- and middle-income economies.

The panel issued a weak recommendation against the use of vitamin C in patients with sepsis and septic shock. The results of ongoing RCTs may influence the quality of evidence and future updates of the guidelines.

Bicarbonate Therapy

Recommendations

71. For adults with septic shock and hypoperfusion-induced lactic acidemia, we **suggest against** using sodium bicarbonate therapy to improve hemodynamics or to reduce vasopressor requirements.
Weak recommendation, low quality of evidence.
72. For adults with septic shock, severe metabolic acidemia ($\text{pH} \leq 7.2$) and AKI (AKIN score 2 or 3), we **suggest** using sodium bicarbonate therapy.
Weak recommendation, low quality of evidence.

Rationale

The previous guidance was based on two small, blinded crossover RCTs that compared equimolar saline vs sodium bicarbonate in patients with lactic acidosis and failed to reveal any difference in

hemodynamic variables or vasopressor requirements (526, 527). A weak recommendation was made against the use of bicarbonate therapy to improve hemodynamics or to reduce vasopressor requirements in patients with hypoperfusion-induced lactic acidemia with $\text{pH} \geq 7.15$.

Our literature search identified one new RCT (528). In this multicenter trial, 400 patients with severe metabolic acidemia ($\text{pH} \leq 7.20$) were randomly allocated to receive IV 4.2% sodium bicarbonate with the aim of achieving an arterial pH of 7.3, or control (no bicarbonate). No between-group difference was observed in the primary outcome of a composite of 28-day mortality and organ failure at day 7. However, hypernatremia, hypocalcemia, and metabolic alkalosis were observed more frequently in those randomized to bicarbonate. In the subgroup of patients with AKI defined as AKI Network (AKIN) stage 2 or 3 at randomization (182/389–47%), lower mortality was observed with bicarbonate therapy: control 57/90 (63%), bicarbonate (42/92, 46%), absolute risk reduction (ARR) -17.7% (-33.0 to -2.3), $p = 0.016$. There was a significant differential effect between patients with an AKIN score of 2 or 3 compared with those with a score of 0–1 (p value for heterogeneity = 0.023).

Sepsis was present in 61% (238/389) of patients at the time of randomization. No differential effect was observed between patients with vs without sepsis. The outcomes of patients with both sepsis and AKI were not reported.

Overall, the quality of evidence is low (Supplemental Digital Content: Appendix 5). The summary of judgements supported a weak recommendation against the intervention. The 2016 recommendation is essentially unchanged. However, when considering the subset of patients with septic shock, severe metabolic acidosis and AKI, the balance of effects probably favors IV bicarbonate. A weak recommendation for the use of IV bicarbonate in this population was made.

Nutrition

Recommendation

73. For adult patients with sepsis or septic shock who can be fed enterally, we **suggest** early (within 72 hours) initiation of enteral nutrition.
Weak recommendation; very low quality of evidence.

Rationale

The early administration of enteral nutrition in patients with sepsis and septic shock has potential physiologic advantages related to the maintenance of gut integrity and prevention of intestinal permeability, dampening of the inflammatory response, and modulation of metabolic responses that may reduce insulin resistance (529, 530). Our literature search defined early enteral nutrition as enteral nutrition commenced within 72 hours of ICU admission. The comparator was enteral nutrition commenced after 72 hours.

The literature search identified one new RCT (531). This multicenter trial conducted in 44 French ICUs randomized 2,410 invasively mechanically ventilated patients with shock to early enteral nutrition vs early parenteral nutrition. Of those participants, 1,504 (62%) had sepsis. The results of this trial were included in a meta-analysis with four relevant trials from the 2016 guidelines (532–535). No significant effect favoring early enteral nutrition was observed for all outcomes evaluated. The quality of evidence was assessed low or very low: downgrades were for risk of bias, inconsistency, and imprecision.

The overall balance of effects did not favor either early enteral feeding (within 72 hours) compared with enteral feeding commenced after that time. Although the available evidence is of low quality, it does not suggest harm following the institution of early enteral feeding. Neither intervention was considered more beneficial when considering resources utilization, cost effectiveness, and equity issues. The institution of early enteral nutrition was also considered feasible in low- and middle-income economies.

Given the plausible possibility of benefit when considering the available physiological data, and the absence of any apparent harm, a weak recommendation to start feeding early in patients with sepsis and septic shock was made. Further research addressing this question in patients with sepsis and septic shock is required.

LONG-TERM OUTCOMES AND GOALS OF CARE

Patients who survive a protracted period of ICU care for sepsis typically face a long and complicated road to recovery. There will not only be physical rehabilitation challenges to overcome but also great uncertainty about the way to organize and coordinate care, both to promote

recovery/avoid complications/recurrence and to ensure care is matched to patient and family goals of care.

There is broad consensus that the current healthcare system is likely falling short of what optimal care during the recovery period might look like for this patient population. However, generating a robust evidence base upon which to make concrete recommendations about changes in the care paradigm has proven to be extraordinarily difficult. Some of the difficulties relate to:

- not all patients are the same, and understanding which patients ought to receive which interventions is very poor;
- not all healthcare delivery systems are the same—even within one system, some patients may be very well supported while others may not—really complicating what ‘control’ care looks like;
- lack of understanding about dosing and intensity of many of the proposed interventions, and when and whether they should be combined in packages is generally missing.

While these issues of patient heterogeneity, variable control care, and lack of understanding about ideal configuration of interventions are protean, they are exquisitely true in this setting: while two ICUs may be different, each ICU discharges patients into a broad and variable milieu of settings. The variation in both ICU and post-ICU management of critically ill patients increases the complexity of understanding and defining best practice.

Thus, putting all this together, there are some overarching conceptual features about ‘best practice’ that the panel endorses, recognizing, however, that the nature, timing, and combination of these broad aspects of care may vary, and strong unambiguous evidence for the ‘how to’ for these things is often going to be lacking.

Goals of Care

Recommendations

- | | |
|-----|--|
| 74. | For adults with sepsis or septic shock, we recommend discussing goals of care and prognosis with patients and families over no such discussion.
<i>Best practice statement.</i> |
| 75. | For adults with sepsis or septic shock, we suggest addressing goals of care early (within 72 hours) over late (72 hours or later).
<i>Weak recommendation, low-quality evidence.</i> |
| 76. | There is insufficient evidence to make a recommendation for any specific standardized criterion to trigger goals of care discussion. |

Rationale

Patients with sepsis or septic shock are at high risk of multi-organ failure, long-term functional sequelae, and death. Some patients may accept any and all treatments for their condition, but others may consider limitations depending on prognosis, invasiveness of interventions, and predicted quality of life (QoL). A discussion of goals of care and prognosis is essential to determine which treatments are acceptable and those interventions that are not desired (536).

There were no studies identified that compared discussions of goals of care and prognosis versus no such discussion in critically ill or septic patients. While advance care planning in patients with life-limiting illness may reduce use of life-sustaining treatments, it may also increase use of hospice and palliative care, and improve concordance between treatment and patient values (537). The relevance of advance care planning for future health needs to goals of care discussions at the time of a critical illness is unclear. Despite lack of evidence, the panel recognized that discussion of prognosis and exploration of goals of care with patients and/or family is a necessary precondition to determine patient treatment preferences and providing value-concordant care. Thus, the panel made a best practice recommendation to discuss goals of care and prognosis with patients and families.

The timing of discussions of goals of care and prognosis in the ICU was addressed in one study where 26% of patients had infection or sepsis as a primary diagnosis (538). A multicomponent family support intervention included a meeting at 48 hours after ICU admission that included discussion of goals of care and prognosis. The support intervention did not affect family psychological outcomes but did improve perceived quality of communication and perception of patient- and family-centeredness of care. A reduction in ICU length of stay was noted, yet it is unknown if the reduction is due to increased mortality. Based on this study, early (within 72 hours of ICU admission) discussion of the goals of care is suggested.

We identified several studies exploring the use of specific criteria to trigger a goals of care discussion in critically ill patients, though none report the proportion of patients with sepsis or septic shock. Conflict over values-based treatment was used to trigger ethics consultation in the intervention group in three

randomized ICU studies (539–541). Reductions in ICU and ventilator days in intervention patients who died before hospital discharge were found in two studies (539, 540), and the third study found overall shorter ICU and hospital stay in the ethics consultation group (541). Ethics consultation did not affect overall mortality in any study. Duration of mechanical ventilation and duration of ICU stay were used to trigger specific interventions in two randomized studies (542, 543). The study by Carson et al randomized patients after 7 days of mechanical ventilation to a group receiving an informational brochure, and two family meetings with palliative care specialists to address goals of care or a group receiving an informational brochure and meetings led by the ICU team (543). Palliative care meetings failed to show benefit in decreasing anxiety and depression in surrogate decision makers in the intervention group but did increase post-traumatic stress disorder (PTSD) symptoms. There was no benefit demonstrated on family satisfaction, ICU days, or hospital days. Andreck et al randomized patients after 5 days or more in a medical-surgical ICU to proactive ethics consultation versus usual care (542). Ethics consultation did not result in a reduction in ICU stay, hospital stay, or life-sustaining treatments in patients who did not survive to discharge. Neither study demonstrated an effect of interventions on mortality. One study (544) investigated the use of an automated early warning system alert in patients hospitalized on medical units (27% with infection). The early warning system did not impact hospital mortality or hospital length of stay but did reduce ICU transfers and ICU length of stay and increased documentation of advance directives and resuscitation status compared to the usual care group.

Given the variety of triggers used in these studies and the lack of superiority of any single trigger, no recommendation can be made for specific criteria to initiate a goals of care discussion. The timing of and triggers for such discussions should take into consideration the current condition of the patient, premorbid health and QoL, prognosis, response to treatment, interventions under consideration, anticipated QoL following treatment, availability of resources, and readiness and ability of the patient or family to engage in the discussion.

Public members judged it important to assess patient and family understanding of the information provided in goals of care discussion and for a member

of the care team to check with them to determine if further explanations are needed. Additional input included the recommendation that a goals of care discussion should take into consideration chronic medical conditions in addition to sepsis.

Palliative Care

Recommendations

77. For adults with sepsis or septic shock, we **recommend** integrating principles of palliative care (which may include palliative care consultation based on clinician judgement) into the treatment plan, when appropriate, to address patient and family symptoms and suffering.

Best practice statement.

78. For adults with sepsis or septic shock, we **suggest against** routine formal palliative care consultation for all patients over palliative care consultation based on clinician judgement.

Weak recommendation, low-quality evidence.

Rationale

While the goal of treating most patients with sepsis or septic shock is to improve survival, some patients have significant comorbidities that may be life limiting or significantly impair QoL. Palliative (supportive) care may be particularly helpful in patients with sepsis who are not responding to treatment or for whom sepsis is an end-stage manifestation of their underlying chronic illness. Studies have evaluated palliative care interventions in the ICU but not specifically in patients with sepsis (543, 545–548). However, indirect evidence from these studies was judged likely to apply to patients with sepsis.

Criteria for patient inclusion and the interventions in these studies demonstrate significant heterogeneity. Inclusion criteria for ICU patients consisted of mechanical ventilation for 7 days (543), high risk on a palliative care screen (548), physician determination that care should not be escalated or care should be withdrawn (545), physician belief that the patient would die in a few days (547), or death in the ICU or within 30 hours of transfer out of the ICU (546). Interventions comprised formal palliative care consultation (543, 545, 548), a complex quality improvement project to improve end-of-life care (546), and a planned end-of-life conference conducted by

intensivists according to specific guidelines along with a bereavement brochure (547).

Various outcome measures are reported but none of the studies evaluated critical patient-centered outcomes such as QoL, physical or cognitive recovery, psychological outcomes, or symptoms. Only one study with a structured palliative care intervention (547) demonstrated a beneficial effect of lower prevalence of anxiety and depression symptoms and PTSD symptoms in family members 90 days after the patient's death. In contrast, Carson et al. found an increase in PTSD symptoms in family surrogate decision makers with palliative care consultation (543). Palliative care interventions had no significant impact on family satisfaction with care, ICU length of stay (543, 545–548), hospital length of stay (543, 545, 548), or mortality (543, 545, 548).

Overall evidence for routine formal palliative care interventions in ICU patients is of low quality and provides mixed evidence of benefit. Thus, the panel suggests against routine formal palliative care consultation for all patients with sepsis or septic shock, instead using clinician judgment to determine which patients and families may benefit from a palliative care consultation.

Despite the lack of evidence for formal palliative care consultation, the panel and public members judged that the principles of palliative care, whether instituted by palliative care specialists, intensivists or other clinicians are essential to address symptoms and suffering in patients and their families. Therefore, the panel made a best practice statement recommending incorporation of palliative care principles in the care of patients with sepsis and septic shock.

Peer Support Groups

Recommendation

79. For adult survivors of sepsis or septic shock and their families, we **suggest** referral to peer support groups over no such referral.

Weak recommendation, very low quality of evidence.

Rationale

Peer support groups have been used to enhance recovery from illness when survivors have long-lasting disability but have only recently been used in critical

Downloaded from http://journals.lww.com/ccmjournal by BHDMM5ePHKav1Zecum1tQIN4a+KJLhE2g0sIHo4XM10hCj WCCX1AWNYQpIICqHD33D00dRy7TTSF4Cj3VCA#OAVpDDa8K2+YabH5t5KE= on 09/11/2024

care and sepsis (549–551). With increased recognition of post-intensive care syndrome (PICS) in survivors of critical illness and their families, peer support represents a patient-centered approach to improve long-term outcomes (552, 553). Public members suggested that referral to an individual peer support person during the sepsis hospitalization may provide a means of support and hope for recovery while referring sepsis survivors and their families to a peer support group may help them regain functional and emotional health.

Models of peer support are numerous and include community-based in person or virtual peer support; outpatient ICU follow-up clinics (with or without psychologist support); within-ICU peer support; and individual peer mentors (551). We did not identify sufficient studies to allow for meta-analysis. Four observational studies examined the impact of peer support groups on ICU patients, though they were not specific to sepsis patients. These studies evaluated the impact of peer support in ICU survivors from a surgical ICU (554), two general ICUs (555–557) and two cardiac ICUs (555, 558). Group models varied, with facilitated in-person (554, 557), group-based integrated with rehabilitation (555, 556) or a “buddy” with a former patient-to-patient program (558). In several qualitative studies, ICU survivors described peer support as a helpful aid to recovery (559–563). Three qualitative studies identified two common themes of peer support, 1) benefit of knowing that others shared similar experiences and 2) benefit of shared coping with others (564).

Overall quality of evidence was judged to be very low for the impact of peer support groups on outcomes. No studies described costs associated with support groups, which will vary given the model and resource availability. Research evaluating support groups is needed with at least two RCTs planned (564–566).

Despite the very low certainty of evidence, the panel made a weak recommendation in favor of referring patients and families to peer support, which will increase the equity of access to such services. As individuals who receive referral to peer support have the choice to participate or not (based on personal preference, timing, location, functional status, and resources required) a weak recommendation provides an opportunity to access support for sepsis survivors who otherwise may not know where to turn (552).

Transitions of Care

Recommendations

- | | |
|-----|--|
| 80. | For adults with sepsis or septic shock, we suggest using a handoff process of critically important information at transitions of care, over no such handoff process. <i>Weak recommendation, very low-quality evidence.</i> |
| 81. | There is insufficient evidence to make a recommendation for the use of any specific structured handoff tool over usual handoff processes. |

Rationale

Transitions of care are prone to communication errors, which have been identified as a barrier to the timely detection and management of sepsis (567). Improving handoff at transitions in care represents an opportunity to improve patient outcomes across the entire spectrum of sepsis care, from hospitalization to return to the community.

We did not identify any studies specifically evaluating patients with sepsis. Structured handoff interventions for critically ill patients have been evaluated at many transitions of patient care (ED/ICU, OR/ICU, ICU/ward, and hospital/home). The majority are observational pre-post studies and report process measures such as completeness and accuracy of communication rather than clinical outcomes. There were insufficient data to allow for meta-analysis.

A single RCT using a stepped-wedge design in eight ICUs evaluated the impact of a standardized handoff process, finding no effect upon duration of mechanical ventilation, ICU length of stay or duration of handover (568). Observational studies of structured handoff process have demonstrated mixed effects, with some finding reductions in unexpected clinical events (569), or ICU readmission (570, 571) and others without impact upon length of stay (572), mortality (572, 573) or hospital readmission (572, 573).

Overall quality of evidence was judged to be very low. While it is unclear whether structured handoffs impact important patient outcomes, many sepsis interventions and tests are time-dependent and communication failures may increase the chances of critical medical errors. Structured handoff processes appear to result in more complete and accurate transfer of information, without any undesirable effects. Thus, despite the low certainty of evidence, the panel made a weak

recommendation in favor of structured handoff processes at transitions of care. Of the structured handover tools studied, none specifically applies to sepsis. Given the wide variety of hospital staffing models, medical records, and discharge processes, along with the lack of evidence to recommend any one tool over another, the panel chose to make no recommendation for a specific structured handover tool.

Screening for Economic or Social Support

Recommendation

82. For adults with sepsis or septic shock and their families, we **recommend** screening for economic and social support (including housing, nutritional, financial, and spiritual support), and make referrals where available to meet these needs.

Best practice statement.

Rationale

Nonmedical social needs and potentially modifiable factors such as economic and social support largely influence health outcomes. While survival from sepsis is improving, long-term health requires survivors to have the resources to recover and thrive. Notably, critically ill patients have a decline in socio-economic status (SES) after their illness (574). Many observational studies describe the relationship between various socioeconomic supports and patient outcomes that suggest that low SES, substance abuse and poor nutritional status lead to poor outcomes, and that critical illness itself results in lower SES post-illness. Additionally, living in neighborhoods with low SES is associated with an increased risk of sepsis (575), community-acquired bacteremia (575) and death from bacteremia (576) and worse outcomes (577). Racial disparities in sepsis (578) are at least partially explained by living in medically underserved neighborhoods (579).

Screening for economic and social support may help reduce these inequities. Although socioeconomic screening is considered part of standard clinical practice, all clinical teams in many settings may not do it. This may be particularly true in the critical care setting where patients are often unable to communicate, and social determinants of health may not be addressed during management of the acute illness.

No studies were identified comparing screening versus no screening for economic and social support.

Furthermore, it is unlikely that many research studies would be conducted, since locally available social needs and supports vary. In LMIC where resources are limited, needs may be vast. Despite these variations, social and economic screening may identify challenges that sepsis survivors are experiencing, allowing clinicians to identify potential resources and referrals, which can assist to improve long-term health outcomes.

Sepsis Education for Patients and Families

Recommendation

83. For adults with sepsis or septic shock and their families, we **suggest** offering written and verbal sepsis education (diagnosis, treatment, and post-ICU/post-sepsis syndrome) prior to hospital discharge and in the follow-up setting.

Weak recommendation, very low-quality evidence.

Rationale

Almost 40% of sepsis survivors are re-hospitalized within 3 months, often for preventable conditions (580), contributing to increased healthcare costs (581). Given the risk of post-sepsis morbidity, sepsis education may have a role in the timely healthcare seeking behavior in sepsis survivors who experience complications. In an international survey of sepsis survivors from 41 countries, 45% and 63% reported dissatisfaction with sepsis education at the acute and post-acute phase, respectively (582). We identified six RCTs that evaluated educational interventions for critically ill patients and their families (583–588). Only one specifically studied patients with sepsis (588), evaluating a complex intervention, which included education along with primary care follow-up and post-discharge monitoring. Varied education methods were employed, including delivery by trained nurses (586, 588), multimedia nursing education (585), information booklets developed by nurses (584), a family information leaflet (583), and informational videos with accompanying web-based content (587).

These studies provided limited data for review. ICU education did not appear to impact patients' anxiety and depression (584, 586, 588), but did improve families' satisfaction with care (583). The panel judged that education would likely have variable acceptability, as a qualitative study showed that patients who survived sepsis had diverse viewpoints ranging from

appreciating the education about sepsis to not being able to recall the education session, to even disliking it as a reminder of the severity of their condition (587). Based on these data and feedback from the public panel, we suggest that multiple opportunities for education be offered prior to hospital discharge and in the follow-up setting, taking into account the patients' and/or families' readiness to process information. Sepsis education is regarded as a low cost intervention and feasible, even in low-resource settings, as a number of online and published sepsis education resources exist (589). Future studies are needed to better understand the effects, the cost-effectiveness, and the optimal approach for educating patients and families after sepsis.

Shared Decision Making

Recommendation

84. For adults with sepsis or septic shock and their families, we **recommend** the clinical team provide the opportunity to participate in shared decision making in post-ICU and hospital discharge planning to ensure discharge plans are acceptable and feasible.

Best practice statement.

Rationale

Shared decision making (SDM) is a process in which health professionals, patients and their caregivers collaborate in making decisions about a patient's care options (590). This patient-centered approach may be less routinely used in post-ICU and hospital discharge planning than in other aspects of acute patient care. No studies were identified that compared SDM with other types of ICU or hospital discharge planning. Despite the lack of evidence, SDM in discharge planning as in other care decisions is more likely to result in decisions consistent with the values and preferences of the patient and family. Patient and family involvement in discharge planning may also increase family satisfaction. A small study of ICU relatives found that anxiety and depression rates were lower in those who preferred an active role or shared responsibility in decision-making compared to those who preferred a passive role (591). A family care conference with nursing staff at the time of discharge from the ICU resulted in lower anxiety scores for family members compared to a control group although it is not clear that families participated in SDM (592). Family caregivers of

critically ill patients discharged home felt overwhelmed and unprepared and had difficulty managing expectations (593). Communication through SDM at the time of ICU or hospital discharge may improve support for family caregivers as communication was found to be important to decision-making for family surrogates of chronic critically ill patients (594). Studies of tools employed to promote SDM in patients with other serious illnesses show improved patient knowledge and awareness of treatment options (595). Due to the potential benefits of SDM and the current emphasis on patient-centered care, the opportunity for patients and/or family to participate in SDM for ICU and hospital discharge planning is recommended as a best practice statement.

Discharge Planning

Recommendations

85. For adults with sepsis and septic shock and their families, we **suggest** using a critical care transition program, compared to usual care, upon transfer to the floor.
Weak recommendation, very low-quality evidence.

86. For adults with sepsis and septic shock, we **recommend** reconciling medications at both ICU and hospital discharge.
Best practice statement.

87. For adult survivors of sepsis and septic shock and their families, we **recommend** including information about the ICU stay, sepsis and related diagnoses, treatments, and common impairments after sepsis in the written and verbal hospital discharge summary.
Best practice statement.

Rationale

Transfer from ICU to general floor and discharge from the hospital are both vulnerable periods for patients, with high frequency of medication errors and information loss (596–602). Sepsis patients, with longer than average hospitalizations and higher comorbidity burden, may be at particular risk for poor outcomes with transitions. Several studies, mostly before-and-after design, have examined the impact of critical care transition programs on reducing ICU readmission or death among patients transferred from ICU to the ward (597, 601, 603–611). These programs have used varied models, but generally involve ICU clinicians (e.g., nurse, respiratory therapist, and/or physician) following patients daily on the wards after transferring out of the ICU for a

few days or until clinically stable. Meta-analysis of these studies suggests that critical care transition programs reduce risk of in-hospital mortality and potentially reduce risk of ICU readmission. Effects on ICU workload and workflow have not been systematically examined. Public panel members were supportive of such programs, as they may provide reassurance and a sense of protection to patients after they leave the ICU.

Medication reconciliation is broadly recognized to be important during patient transitions. Hospitalization and ICU admission are high-risk periods for unintentional medication error—both continuations of medications for temporary indications and unintentional discontinuations of chronic medications (596, 599, 600, 602). Medication reconciliation has been associated with fewer medication errors (598, 612) and may help reduce hospital readmission (613, 614). Given the frequency of medication changes during an ICU stay, we recommend reconciling medications at both ICU and hospital discharge. Medication reconciliation surrounding sepsis hospitalization involves getting the correct list of medications and adjusting medication dosing regularly in response to dynamic physiologic changes during and after critical illness (580).

Key information from hospitalization is often missing on hospital discharge documentation (615–618). Information on post-intensive care syndrome (PICS) may be provided to only one in three ICU survivors (550, 618). We recommend providing information about the ICU stay, sepsis diagnosis, key treatments (e.g., mechanical ventilation, dialysis), and post-ICU/post-sepsis syndrome. Public panel members stressed the importance of providing information in both verbal and written form and assessing that the information was understood. There are a growing number of online resources and informational brochures regarding “post intensive care”/“post-sepsis syndrome” (580), but more research is needed to determine the optimal approaches to providing anticipatory guidance to patients and families after critical illness (582, 619).

Recommendations	
88.	For adults with sepsis or septic shock who developed new impairments, we recommend hospital discharge plans include follow-up with clinicians able to support and manage new and long-term sequelae. <i>Best practice statement.</i>
89.	There is insufficient evidence to make a recommendation on early post-hospital discharge follow-up compared to routine post-hospital discharge follow-up.

Rationale

Many sepsis survivors experience short and/or long-term sequela such as cognitive and/or physical disability, with ongoing recovery persisting for months to years (620). Public panelists rated cognitive and physical recovery, psychologic symptoms in survivors and their families, QoL and readmission to the hospital and/or ICU as critically important outcomes. These outcomes were consistent with a 2019 qualitative analysis of health related QoL domains identified by sepsis survivors (621). Follow-up with a provider after hospital discharge is one-step in the recovery process.

Sepsis survivors are at risk for hospital readmission, which has been associated with increased mortality or discharge to hospice (622, 623). Hospital readmission within 90 days of discharge occurs in approximately 40% of sepsis survivors and is associated with high costs (624). Additionally, sepsis survivors are at increased risk for recurrent infection, AKI and new cardiovascular events compared to patients hospitalized for other diagnoses (580). Observational studies in patients with congestive heart failure have associated early (within 7–14 days) post-discharge follow-up with reduced hospital readmissions (625). Among older adults, early post discharge follow-up (within 7 days) with a primary care physician was associated with lower risk of 30-day readmission (626, 627).

Three studies, one RCT (628) and two observational studies (629, 630) evaluated early post-hospital follow-up in patients with critical illness. None of the three studies specifically evaluated a sepsis population or reported the proportion of sepsis patients. The interventions and QoL measures varied among the three studies each with severe limitations. In an analysis of older adults with severe sepsis, one study found that the combination of early home health care and a visit with a medical provider was associated with a reduced readmission risk (631). There were insufficient studies to allow meta-analysis and the limited evidence is of very low quality.

Despite these limitations, the panel recommends follow-up with a provider after hospital discharge to manage new impairments associated with sepsis. Due to the low quality and lack of evidence specific to sepsis, we are unable to make a recommendation for early (7–14 days) provider follow-up versus routine follow-up upon hospital discharge. Timely, coordinated resources and provider follow-up may lead to

Downloaded from http://journals.lww.com/ccmjournal by BHDMSepHKav/zEumt1QIN4akLhEz9sIH04XM0hCj wCX1AWN7Qp/ID333D00dRy7TTSF4C3VCA#OAVpDDa8K2+YabH515KE on 09/11/2024

improved QoL for sepsis survivors, however further research on the impact of post-discharge follow-up is needed.

Cognitive Therapy

Recommendation

90. There is insufficient evidence to make a recommendation on early cognitive therapy for adult survivors of sepsis or septic shock.

Rationale

Sepsis is associated with newly acquired cognitive impairment and functional disability amongst survivors (620). Long-term impairments in memory, attention, verbal fluency, decision-making and executive functioning may be linked to a variety of mechanisms such as metabolic derangements, cerebral ischemia, overwhelming inflammation, disrupted blood-brain barrier, oxidative stress, and severe microglial activation, particularly within the limbic system (632). A feasibility, pilot, randomized trial in general medical/surgical ICU survivors comparing usual care to an intervention of combined in-home cognitive, physical, and functional rehabilitation following discharge showed improved executive functioning at three months (633). Some small single center studies tested specific early cognitive therapies to enhance cognitive and overall functional recovery after critical illness (634, 635).

A proof-of-concept single-center pilot study aimed to evaluate the efficacy and safety of the use of a multifaceted early intervention (cognitive therapy within ICU) in patients with respiratory failure and/or shock (634). ICU patients were randomized to receive either combined cognitive and physical therapy or physical therapy alone. The results demonstrated that the intervention was feasible and safe, but the study was underpowered and therefore inconclusive regarding its clinical effects on cognitive function and health-related QoL outcomes at 3-month follow-up. In addition, a prospective cohort study testing a series of cognitive training sessions starting in the ICU and continued for up to two months, found overall minimal clinical relevance as Minimum Clinically Important Difference (MID) of Montreal Cognitive Assessment (MOCA) was small, with some meaningful results in younger

patients, but not in the middle-aged or older population (635, 636).

In view of these findings, the panel judged there to be insufficient evidence to make a recommendation. In centers where cognitive therapy is used, it could reasonably be continued as it is likely acceptable and feasible, but there is insufficient evidence to change practice in centers without such therapy. Further larger studies in patients with sepsis are required to determine the impact of early cognitive therapy, as well as costs and type of intervention.

Post-Discharge Follow-Up

Recommendations

91. For adult survivors of sepsis or septic shock, we **recommend** assessment and follow-up for physical, cognitive, and emotional problems after hospital discharge.
Best practice statement.
92. For adult survivors of sepsis or septic shock, we **suggest** referral to a post-critical illness follow-up program if available.
Weak recommendation, very low-quality evidence.
93. For adult survivors of sepsis or septic shock receiving mechanical ventilation for > 48 hours or an ICU stay of > 72 hours, we **suggest** referral to a post-hospital rehabilitation program.
Weak recommendation, very low-quality evidence.

Rationale

Given the prevalence of new or worsening physical, cognitive, and emotional problems experienced by sepsis survivors (580, 620), we recommend assessment and follow-up for these problems after hospital discharge. There are insufficient data to suggest any specific tool to assess for these problems, and the optimal approach will vary by patient and setting. At a minimum, physicians should ask patients and families about new problems in these domains.

Post-critical illness programs have been developed as a means of screening for and addressing the multifaceted issues faced by ICU survivors. These programs vary in their structure, and are not consistently available worldwide (637). Few randomized studies have assessed post-critical illness clinics (588, 628, 638, 639), and—consistent with a recent Cochrane review (640)—our meta-analysis found no differences from usual care in terms of mortality, QoL, physical function, or

cognition, with possible small improvements in psychological symptoms (anxiety, depression, PTSD). More studies of post-sepsis follow-up programs are in process (641, 642). We suggest offering referral to post-critical illness clinics where available. While efficacy data are equivocal, these programs are consistently well-liked by patients and offer an environment to learn about challenges sepsis survivors face, as well as to pilot and test interventions for enhancing recovery (637, 643). Lessons learned in post-critical care clinics could be adapted to other, more-scalable interventions such as telehealth.

Several randomized studies have assessed physical rehabilitation programs for survivors of critical illness (581, 606, 644–651). These studies focused on critically ill patients, generally defined by days in ICU or days with mechanical ventilation and begin on the floor or post-hospital setting. Meta-analysis suggests possible small improvements in QoL and depressive symptoms, but no difference in mortality, physical function, or anxiety. Nonetheless, based on their strong rationale, and benefit in related populations (580) (e.g., older patients with cognitive impairment, patients following stroke or traumatic brain injury), we suggest referral to rehabilitation programs in survivors of sepsis. This suggestion is consistent with the guidance of several expert panels (646, 652, 653). Future research is needed to determine an optimal approach to functional rehabilitation (timing, dosing, intensity, duration) and patient selection (643).

ACKNOWLEDGEMENTS

It is with great appreciation that we acknowledge the public panel members who shared their insights and experiences as patients/relatives and provided advice which was invaluable to informing the updated guideline. Specifically, we thank Dana Mirman, sepsis survivor and member of the Board of Directors of Sepsis Alliance, Idelette Nutma and Marie Mach, and three additional public panel members.

GOVERNANCE OF SURVIVING SEPSIS CAMPAIGN

SSC Guidelines Committee Co-chairs: Andrew Rhodes, Laura Evans.

SSC Guidelines Committee Co-vice-chairs: Hallie Prescott, Marlies Ostermann.

SSC Guidelines Committee Oversight Group: Andrew Rhodes, Laura Evans, Waleed Alhazzani.

SSC Guidelines Committee Group-Heads: Craig French, Flavia Machado, Mitchell Levy, Lauralyn McIntyre, Christa Schorr, Steven Simpson, Joost Wiersinga.

SSC Conflicts of Interest Co-chairs: Massimo Antonelli, Craig Coopersmith.

GUIDE Methodology Group: Waleed Alhazzani (chair), Emilie Belley-Cote, Fayez Alshamsi, John Centofanti, Mark Nunnally, Morten Hylander-Moller, Simon Oczkowski.

ENDORSEMENTS

This manuscript has been endorsed by the following societies:

- Society of Critical Care Medicine
- European Society of Intensive Care Medicine
- American Association of Critical Care Nurses
- American College of Chest Physicians
- American College of Emergency Physicians
- American Thoracic Society
- African Sepsis Alliance
- Asia and Pacific Sepsis Alliance
- Association De Medicina Intensiva Brasileira
- Australian and New Zealand Intensive Care Society
- Canadian Critical Care Society
- Chinese Society of Critical Care Medicine
- European Respiratory Society
- European Society of Clinical Microbiology and Infectious Diseases
- Indian Society of Critical Care Medicine
- Infectious Diseases Society of North America
- Japanese Society of Intensive Care Medicine
- Latin American Sepsis Institute
- Society for Academic Emergency Medicine
- Scandinavian Critical Care Trials Group
- Surgical Infection Society
- World Federation of Critical Care Nurses
- World Federation of Societies of Intensive and Critical Care Medicine

SUPPLEMENTAL DIGITAL CONTENT

Supplemental digital content is available for these guidelines and can be accessed through the following links through the HTML and PDF versions of this article on the journal's website <http://journals.lww.com/ccmjjournal>.

They are as follows:

Supplemental Digital Content: Methodology (<http://links.lww.com/CCM/G890>)

Supplemental Digital Content: Appendix 1 Screening and Early Treatment (<http://links.lww.com/CCM/G891>)

Supplemental Digital Content: Appendix 2 Infection (<http://links.lww.com/CCM/G892>)

Supplemental Digital Content: Appendix 3 Hemodynamic Management (<http://links.lww.com/CCM/G893>)

Supplemental Digital Content: Appendix 4 Ventilation (<http://links.lww.com/CCM/G894>)

Supplemental Digital Content: Appendix 5 Additional Therapies (<http://links.lww.com/CCM/G895>)

Supplemental Digital Content: Appendix 6 Goals and Long-Term Outcomes (<http://links.lww.com/CCM/G896>)

Supplemental Digital Content: Appendix 7 Search Strategies (<http://links.lww.com/CCM/G901>)

- 1 Division of Pulmonary, Critical Care and Sleep Medicine, University of Washington, Seattle, Washington, USA.
- 2 Adult Critical Care, St. George's University Hospitals NHS Foundation Trust & St. George's University of London, London, UK.
- 3 Department of Medicine, McMaster University, Canada & Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
- 4 Dipartimento di Scienze dell' Emergenza Anestesiologiche e della Rianimazione, Policlinico Universitario A. Gemelli IRCCS Rome, Italy.
- 5 Emory University School of Medicine, Atlanta, Georgia, USA
- 6 Western Health, Melbourne, Australia.
- 7 Anesthesiology, Pain and Intensive Care Department, Federal University of São Paulo, São Paulo, Brazil.
- 8 Ottawa Hospital, Ottawa, Ontario, Canada.
- 9 Guy's & St Thomas' Hospital, London, England, UK.
- 10 University of Michigan and VA Center for Clinical Management Research, Ann Arbor, Michigan, USA.
- 11 Cooper Health System, Camden, New Jersey, USA.
- 12 University of Kansas Medical Center, Kansas City, Kansas, USA.
- 13 ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis, Division of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
- 14 Department of Internal Medicine, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.
- 15 University of Pittsburgh Critical Care Medicine CRISMA Laboratory, Pittsburgh, Pennsylvania, USA.
- 16 Intensive Care Department, Ministry of National Guard Health Affairs, King Saud Bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia.
- 17 University of São Paulo, School of Medicine, São Paulo, Brazil.
- 18 Guy's & St Thomas' Hospital, London, UK.
- 19 University of Minnesota, Minneapolis, Minnesota, USA.
- 20 Population Health Research Institute, Hamilton, Ontario, Canada.
- 21 Mount Sinai Hospital & University of Toronto (Leslie Dan Faculty of Pharmacy), Toronto, Ontario, Canada.
- 22 Department of Biomedical Sciences, Humanitas University Pieve Emanuele, Milan, Italy; Department of Anaesthesia and Intensive Care, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
- 23 Department of Anesthesia, McMaster University, Hamilton, Ontario, Canada.
- 24 Lexington Veterans Affairs Medical Center/University of Kentucky College of Medicine, Lexington, Kentucky, USA.
- 25 Ghent University Hospital, Ghent, Belgium.
- 26 Cooper Health System, Camden, New Jersey, USA.
- 27 The University of Tokyo, Tokyo, Japan.
- 28 Medical ICU, Peking Union Medical College Hospital, Beijing, China.
- 29 Hospital Interzonal de Agudos San Martin de La Plata, Buenos Aires, Argentina.
- 30 Intensive Care Department, Vall d'Hebron University Hospital, Vall d'Hebron Institut de Recerca, Barcelona, Spain.
- 31 Prince of Wales Hospital, Hong Kong, China.
- 32 Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, Victoria, Australia.
- 33 Copenhagen University Hospital Rigshospitalet, Department of Intensive Care, Copenhagen, Denmark.
- 34 University of Michigan Health System, Ann Arbor, Michigan, USA.
- 35 Liverpool School of Tropical Medicine, Liverpool, UK.
- 36 Vanderbilt University, Nashville, Tennessee, USA.
- 37 Department of Medicine, Brigham and Women's Hospital, Boston MA; Department of Population Medicine, Harvard Medical School, and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
- 38 ASAN Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
- 39 University of Manitoba, Winnipeg, MB, Canada.
- 40 Makerere University College of Health Sciences, Kampala, Uganda.
- 41 Intensive Care Division. Faculdade de Medicina de São José do Rio Preto, São Paulo, Brazil.
- 42 Critical Care Medicine Department, NIH Clinical Center, Bethesda, Maryland, USA.
- 43 Alfred Health, Melbourne, Australia.
- 44 Mount Sinai Hospital, Toronto, Ontario, Canada.
- 45 Medanta The Medicity, Gurugram, Haryana, India.
- 46 Charlotte Maxeke Johannesburg Academic Hospital and Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
- 47 New York University School of Medicine, New York, New York, USA.
- 48 Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

- 49 Washington University School of Medicine, St. Louis, Missouri, USA.
- 50 Faculty of Nursing, University of Alberta, Edmonton, Alberta, Canada.
- 51 Rigshospitalet, Copenhagen, Denmark.
- 52 University of Minnesota/Hennepin County Medical Center, Minneapolis, Minnesota, USA.
- 53 University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Australia, Departments of Pharmacy and Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, Australia, Division of Anaesthesiology Critical Care Emergency and Pain Medicine, Nîmes University Hospital, University of Montpellier, Nîmes, France.
- 54 University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- 55 ChristianaCare, Newark, Delaware, USA.
- 56 Emory University School of Medicine, Atlanta, Georgia, USA.
- 57 Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel; Department of Anesthesiology, Critical Care and Pain Medicine, Hadassah Medical Center, Jerusalem, Israel.
- 58 Medizinische Hochschule Hannover and German Center of Lung Research (DZL), Hannover, Germany.
- 59 World Federation of Intensive and Critical Care, Brussels, Belgium.
- 60 Warren Alpert School of Medicine at Brown University, Providence, Rhode Island & Rhode Island Hospital, Providence, Rhode Island, USA.

Dr. Alhazzani is the Chair of the Guidelines Chapter for the Saudi Critical Care Society and is the chair of the guidelines in intensive care, development and evaluation (GUIDE) Group, McMaster University Canada. Dr. Antonelli received funding from GE, Toray-Estor, Baxter, Pfizer, Orion, Maquet, and Fisher and Paykel; he was on the board of Baxter and Pfizer, and is a member of the executive committee and past president of Società Italiana di Anestesia Rianimazione e Terapia Intensiva (SIAARTI). Dr. French contributed to the ANZICS Guidelines and the National COVID-19 Guidelines. Dr. Machado is a member of the Executive Committee for the Basics Study (for which Baxter provided the drugs and logistics) and AMIB. Dr. McIntyre is a member of the Canadian Critical Care Society and serves on the Surviving Sepsis Campaign Steering Committee. Dr. Ostermann is a council member of the Intensive Care Society UK and member of the Renal Association UK and World Sepsis Alliance. Dr. Prescott is a member of the ATS Critical Care Program Committee. Dr. Simpson is the president-elect and Chair of CHEST, is a member of the board of directors and medical director of Sepsis Alliance, and Chair of the Sepsis Institute Advisory Board. Dr. Wiersinga is a member of ISF, ESCIMID, and SWAB. Dr. Angus received funding from Ferring Pharmaceuticals, Inc and ALung Technologies, Inc. Dr. Beale provides consultancy services for Philips Healthcare with his time billed by his institution. Dr. Beilman is the president of the Surgical Infection Society. Dr. Belley-Cote received grants from Roche and Bayer and is a panel member on the Saudi Critical Care Society COVID-19 Thrombosis Guidelines. Dr. Cecconi is

a consultant for Edwards Lifesciences, Cheetah Medical, and Directed Systems and is President of the European Society of Intensive Care Medicine. Dr. Coz is a board member of the American College of Chest Physicians. Dr. De Waele consulted for Accelerate, Bayer, Grifols, Pfizer, and MSD with all honoraria paid to Ghent University; he is a Senior Clinical Investigator with the Research Foundation Flanders. Dr. Dellinger serves as an expert witness on occasional medical legal case reviews. Dr. Doi is a member of the Japanese Society of Intensive Care Medicine. Dr. Du is a member of the Chinese Society of Critical Care Medicine and the Chinese College of Intensive Care Medicine. Dr. Ferrer received funding from Grifols, MSD, Pfizer, Shionogi, Toray, Jafron, and Cytosorbents; he is a member of SEMICYUC. Dr. Gomersall is a member of an educational subgroup of the International Forum of Acute Care Trialists. Dr. Hodgson is a member of the Australian National Health and Medical Research Council guidelines (COVID-19) and leading funded trials in early rehabilitation and ECMO. Dr. Møller contributed to guideline work for DASAIM, SSAI, GUIDE, and ESA. Dr. Iwashyna is a member of the ATS, the NIH, and an informal (unincorporated) organization called the Critical and Acute Illness Recovery Organization. Dr. Jacob co-directs the African Research Collaboration on Sepsis (ARCS, funded by UK National Institute for Health Research, sponsored by Liverpool School of Tropical Medicine), he is Secretary General for the African Sepsis Alliance, and is a technical expert for the World Health Organization panels. Dr. Kleinpell is a board member of the World Federation of Intensive and Critical Care, American Nurses Credentialing Center, and the Tennessee Nurses Association Political Action Committee. Dr. Klompas received funding from Up-to-Date; he is a member of the guidelines committees of the Infectious Disease Society of America (IDSA) and Society of Healthcare Epidemiologists of America (SHEA). Dr. Koh is a member of The Korean Society of Critical Care Medicine, The Korean Academy of Tuberculosis and Respiratory Diseases, The Korean Society of Medical Ethics, and the Asia Ventilation Forum. Dr. Kumar served as an expert witness regarding a lethal dose of narcotics. Dr. Kwizera is president of the Intensive Care Society of Uganda and PRO for the Association of Anesthesiologists of Uganda. Dr. Lobo received funding from Pfizer, MSD, Edwards, and Nestle; she is the principal investigator in new antibiotics research led by CROs/industry; she is a member of the AMIB Executive Board and was elected president for 2020-2021. Dr. McGloughlin is a member of ANZICS (Australian New Zealand Intensive Care Society). Dr. Mehta participated in two non-interventional studies by ISCCM-Hermes and Indicaps. Dr. Mer has been an invited speaker for educational talks in industry-sponsored symposia for which honoraria was received; he is the current Vice President of the Southern African Society of Thrombosis and Haemostasis (SASTH), and is involved in annual congress organization; he is an invited author of the Global guidelines for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Dr. Nunnally is the treasurer of SOCCA, committee member of ASA, NYSSA, IARS, AUA, and SAAAPM and serves on the American College of Critical Care Medicine Board of Regents. Dr. Oczkowski is a member of the European Respiratory Society, and contributed to the High Flow Nasal Cannula Guidelines, the Non-Invasive

Ventilation in COPD Guidelines. Dr. Osborn received funding from Viven Inc, Inflammatrix, Beckman, and the Foundation for Barnes Jewish Hospital; she is on the advisory board for Beckman, Inflammatrix, and Viven; she is a member of the American College of Emergency Physicians, American College of Chest Physicians, American Medical Association, Society of Academic Emergency Medicine, and American Academy of Emergency Physicians; she served as an expert witness in a case related to viral as compared to bacterial sepsis. Dr. Papatheanassoglou is a member of the World Federation of Critical Care Nurses (Editor of Journal) and the Canadian Association of Critical Care Nurses. Dr. Perner received a research grant from Pfizer Denmark. Dr. Puskarich is the co-inventor of a patent to assess L0carnitine drug responsiveness in sepsis (USPO 10330685); he is a member of the Society for Academic Emergency Medicine, American College of Emergency Physicians (ACEP); he was invited to a recently gathered ACEP early sepsis treatment policy task force asked to develop specialty recommendations for early sepsis treatment. Dr. Roberts received funding from MSD, The Medicines Company, Cardeas Pharma, Biomerieux, QPEX, Cipla, and Pfizer; he consulted for MSD, QPEX, Discuva Ltd, Accelerate Diagnostics, Bayer, Biomerieux, UptoDate, and Australian Therapeutic Guidelines; he is a member of the Society of Hospital Pharmacists of Australia Leadership Committees for Critical Care and Infectious Diseases and the Lead of Sepsis Working group for the International Society of Anti-infective Chemotherapy. Dr. Schweickert is a paid consultant to the American College of Physicians (last performed in Spring, 2019). Dr. Seckel volunteers for AACN and is a paid consultant to revise online Critical Care Orientation. Dr. Sevransky received funding from the Marcus Foundation- PI VICTAS Trial and serves on the American College of Critical Care Medicine Board of Regents. Dr. Welte received funding from Astellas, AstraZeneca, Boehringer, Basilea, Bayer, Berlin-Chemie, Grifols, Infectopharm, Mundipharma, MSD, Novartis, Pfizer, DFG, EU, BMBF, and Insmmed; he is on the advisory board for AstraZeneca, Boehringer, Bayer, Gilead, GSK, Insmmed, Novartis, Pfizer, Roche; he is a member of the European Respiratory Society, German Society of Pneumology, and Paul Ehrlich Gesellschaft. Dr. Zimmerman is a member of the ACP, AACP, and WFPICCS. Dr. Levy is a legal consultant for a few cases involving sepsis and serves as co-chair of the Surviving Sepsis Campaign Steering Committee. The remaining authors have disclosed that they do not have any potential conflicts of interest.

For information regarding this article, Email: leevans@uw.edu

REFERENCES

- Singer M, Deutschman CS, Seymour CW, et al: The third international consensus definitions for sepsis and septic shock (Sepsis-3). *JAMA* 2016; 315:801–810
- Fleischmann C, Scherag A, Adhikari NK, et al: International Forum of Acute Care Trialists: Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. *Am J Respir Crit Care Med* 2016; 193:259–272
- Fleischmann-Struzek C, Mellhammar L, Rose N, et al: Incidence and mortality of hospital- and ICU-treated sepsis: Results from an updated and expanded systematic review and meta-analysis. *Intensive Care Med* 2020; 46:1552–1562
- Rhee C, Dantes R, Epstein L, et al; CDC Prevention Epicenter Program: Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009–2014. *JAMA* 2017; 318:1241–1249
- Seymour CW, Liu VX, Iwashyna TJ, et al: Assessment of clinical criteria for sepsis: For the third international consensus definitions for sepsis and septic shock (Sepsis-3). *JAMA* 2016; 315:762–774
- Levy MM, Fink MP, Marshall JC, et al; SCCM/ESICM/ACCP/ATS/SIS: 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. *Crit Care Med* 2003; 31:1250–1256
- Dellinger RP, Levy MM, Rhodes A, et al; Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup: Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock, 2012. *Intensive Care Med* 2013; 39:165–228
- Dellinger RP, Levy MM, Rhodes A, et al; Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup: Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012. *Crit Care Med* 2013; 41:580–637
- Dellinger RP, Carlet JM, Masur H, et al; Surviving Sepsis Campaign Management Guidelines Committee: Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. *Crit Care Med* 2004; 32:858–873
- Dellinger RP, Levy MM, Carlet JM: Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008 (vol 36, pg 296, 2008). *Crit Care Med* 2008; 36:1394–1396
- Dellinger RP, Levy MM, Carlet JM, et al; International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases; European Society of Intensive Care Medicine; European Respiratory Society; International Sepsis Forum; Japanese Association for Acute Medicine; Japanese Society of Intensive Care Medicine; Society of Critical Care Medicine; Society of Hospital Medicine; Surgical Infection Society; World Federation of Societies of Intensive and Critical Care Medicine: Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. *Crit Care Med* 2008; 36:296–327
- Rhodes A, Evans LE, Alhazzani W, et al: Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016. *Crit Care Med* 2017; 45:486–552
- Rhodes A, Evans LE, Alhazzani W, et al: Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016. *Intensive Care Med* 2017; 43:304–377
- Weiss SL, Peters MJ, Alhazzani W, et al: Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. *Intensive Care Med* 2020; 46(Suppl 1):10–67
- Weiss SL, Peters MJ, Alhazzani W, et al: Surviving Sepsis Campaign International guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. *Pediatr Crit Care Med* 2020; 21:e52–e106

16. Guyatt GH, Oxman AD, Kunz R, et al: GRADE guidelines: 2. Framing the question and deciding on important outcomes. *J Clin Epidemiol* 2011; 64:395–400
17. Akl EA, Johnston BC, Alonso-Coello P, et al: Addressing dichotomous data for participants excluded from trial analysis: A guide for systematic reviewers. *PLoS One* 2013; 8:e57132
18. DerSimonian R, Laird N: Meta-analysis in clinical trials. *Control Clin Trials* 1986; 7:177–188
19. Guyatt GH, Oxman AD, Vist GE, et al; GRADE Working Group: GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008; 336:924–926
20. Balshem H, Helfand M, Schünemann HJ, et al: GRADE guidelines: 3. Rating the quality of evidence. *J Clin Epidemiol* 2011; 64:401–406
21. Andrews J, Guyatt G, Oxman AD, et al: GRADE guidelines: 14. Going from evidence to recommendations: The significance and presentation of recommendations. *J Clin Epidemiol* 2013; 66:719–725
22. Guyatt GH, Oxman AD, Santesso N, et al: GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. *J Clin Epidemiol* 2013; 66:158–172
23. Schünemann HJ, Wiercioch W, Brozek J, et al: GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT. *J Clin Epidemiol* 2017; 81:101–110
24. Guyatt GH, Schünemann HJ, Djulbegovic B, et al: Guideline panels should not GRADE good practice statements. *J Clin Epidemiol* 2015; 68:597–600
25. Dellinger RP: The future of sepsis performance improvement. *Crit Care Med* 2015; 43:1787–1789
26. Schorr C, Odden A, Evans L, et al: Implementation of a multi-center performance improvement program for early detection and treatment of severe sepsis in general medical-surgical wards. *J Hosp Med* 2016; 11(Suppl 1):S32–S39
27. Damiani E, Donati A, Serafini G, et al: Effect of performance improvement programs on compliance with sepsis bundles and mortality: A systematic review and meta-analysis of observational studies. *PLoS One* 2015; 10:e0125827
28. Alberto L, Marshall AP, Walker R, et al: Screening for sepsis in general hospitalized patients: A systematic review. *J Hosp Inf* 2017; 96:305–315
29. Bhattacharjee P, Edelson DP, Churpek MM: Identifying patients with sepsis on the hospital wards. *Chest* 2017; 151:898–907
30. Makam AN, Nguyen OK, Auerbach AD: Diagnostic accuracy and effectiveness of automated electronic sepsis alert systems: A systematic review. *J Hosp Med* 2015; 10:396–402
31. Warttig S, Alderson P, Evans DJ, et al: Automated monitoring compared to standard care for the early detection of sepsis in critically ill patients. *Cochrane Database Syst Rev* 2018; 6:CD012404
32. Islam MM, Nasrin T, Walther BA, et al: Prediction of sepsis patients using machine learning approach: A meta-analysis. *Comput Methods Programs Biomed* 2019; 170:1–9
33. Downing NL, Rolnick J, Poole SF, et al: Electronic health record-based clinical decision support alert for severe sepsis: A randomised evaluation. *BMJ Qual Saf* 2019; 28:762–768
34. Hooper MH, Weavind L, Wheeler AP, et al: Randomized trial of automated, electronic monitoring to facilitate early detection of sepsis in the intensive care unit. *Crit Care Med* 2012; 40:2096–2101
35. Shimabukuro DW, Barton CW, Feldman MD, et al: Effect of a machine learning-based severe sepsis prediction algorithm on patient survival and hospital length of stay: A randomised clinical trial. *BMJ Open Respir Res* 2017; 4:e000234
36. Rao TS, Radhakrishnan R, Andrade C: Standard operating procedures for clinical practice. *Indian J Psychiatry* 2011; 53:1–3
37. Osborn TM: Severe sepsis and septic shock trials (ProCESS, ARISE, ProMISe): What is optimal resuscitation? *Crit Care Clin* 2017; 33:323–344
38. Kahn JM, Davis BS, Yabes JG, et al: Association between state-mandated protocolized sepsis care and in-hospital mortality among adults with sepsis. *JAMA* 2019; 322:240–250
39. Morton B, Stolbrink M, Kagima W, et al: The early recognition and management of sepsis in sub-saharan african adults: A systematic review and meta-analysis. *Int J Environ Res Public Health* 2018; 15:E2017
40. Fernando SM, Tran A, Taljaard M, et al: Prognostic accuracy of the quick sequential organ failure assessment for mortality in patients with suspected infection: A systematic review and meta-analysis. *Ann Intern Med* 2018; 168:266–275
41. Herwanto V, Shetty A, Nalos M, et al: Accuracy of quick sequential organ failure assessment score to predict sepsis mortality in 121 studies including 1,716,017 individuals: A systematic review and meta-analysis. *Crit Care Explor* 2019; 1:e0043
42. Serafim R, Gomes JA, Salluh J, et al: A comparison of the quick-SOFA and systemic inflammatory response syndrome criteria for the diagnosis of sepsis and prediction of mortality: A systematic review and meta-analysis. *Chest* 2018; 153:646–655
43. Cinel I, Kasapoglu US, Gul F, et al: The initial resuscitation of septic shock. *J Crit Care* 2020; 57:108–117
44. Liu VX, Lu Y, Carey KA, et al: Comparison of early warning scoring systems for hospitalized patients with and without infection at risk for in-hospital mortality and transfer to the intensive care unit. *JAMA Netw Open* 2020; 3:e205191
45. Borthwick HA, Brunt LK, Mitchem KL, et al: Does lactate measurement performed on admission predict clinical outcome on the intensive care unit? A concise systematic review. *Ann Clin Biochem* 2012; 49:391–394
46. Liu G, An Y, Yi X, et al: Early lactate levels for prediction of mortality in patients with sepsis or septic shock: A meta-analysis. *Int J Exp Med* 2017; 10:37–47
47. Levy MM, Evans LE, Rhodes A: The surviving sepsis campaign bundle: 2018 update. *Crit Care Med* 2018; 46:997–1000
48. Levy MM, Evans LE, Rhodes A: The surviving sepsis campaign bundle: 2018 update. *Intensive Care Med* 2018; 44:925–928
49. Shankar-Hari M, Phillips GS, Levy ML, et al; Sepsis Definitions Task Force: Developing a new definition and assessing new clinical criteria for septic shock: For the third international consensus definitions for sepsis and septic shock (Sepsis-3). *JAMA* 2016; 315:775–787

50. Contenti J, Corraze H, Lemoël F, et al: Effectiveness of arterial, venous, and capillary blood lactate as a sepsis triage tool in ED patients. *Am J Emerg Med* 2015; 33:167–172
51. Karon BS, Tolan NV, Wockenfus AM, et al: Evaluation of lactate, white blood cell count, neutrophil count, procalcitonin and immature granulocyte count as biomarkers for sepsis in emergency department patients. *Clin Biochem* 2017; 50: 956–958
52. Ljungström L, Pernestig AK, Jacobsson G, et al: Diagnostic accuracy of procalcitonin, neutrophil-lymphocyte count ratio, C-reactive protein, and lactate in patients with suspected bacterial sepsis. *PLoS One* 2017; 12:e0181704
53. Morris E, McCartney D, Lasserson D, et al: Point-of-care lactate testing for sepsis at presentation to health care: A systematic review of patient outcomes. *Br J Gen Pract* 2017; 67:e859–e870
54. Abdu M, Wilson A, Mhango C, et al: Resource availability for the management of maternal sepsis in Malawi, other low-income countries, and lower-middle-income countries. *Int J Gynaecol Obstet* 2018; 140:175–183
55. Baelani I, Jochberger S, Laimer T, et al: Availability of critical care resources to treat patients with severe sepsis or septic shock in Africa: A self-reported, continent-wide survey of anaesthesia providers. *Crit Care* 2011; 15:R10
56. Baelani I, Jochberger S, Laimer T, et al: Identifying resource needs for sepsis care and guideline implementation in the Democratic Republic of the Congo: A cluster survey of 66 hospitals in four eastern provinces. *Middle East J Anaesthesiol* 2012; 21:559–575
57. Bataar O, Lundeg G, Tsenddorj G, et al; Helfen Berührt Study Team: Nationwide survey on resource availability for implementing current sepsis guidelines in Mongolia. *Bull World Health Organ* 2010; 88:839–846
58. Hernández G, Ospina-Tascón GA, Damiani LP, et al; The ANDROMEDA SHOCK Investigators and the Latin America Intensive Care Network (LIVEN): Effect of a resuscitation strategy targeting peripheral perfusion status vs serum lactate levels on 28-day mortality among patients with septic shock: The ANDROMEDA-SHOCK randomized clinical trial. *JAMA* 2019; 321:654–664
59. Machado FR, Cavalcanti AB, Bozza FA, et al; SPREAD Investigators; Latin American Sepsis Institute Network: The epidemiology of sepsis in Brazilian intensive care units (the Sepsis PREvalence Assessment Database, SPREAD): An observational study. *Lancet Infect Dis* 2017; 17:1180–1189
60. Shrestha GS, Kwizera A, Lundeg G, et al: International Surviving Sepsis Campaign guidelines 2016: The perspective from low-income and middle-income countries. *Lancet Infect Dis* 2017; 17:893–895
61. Taniguchi LU, Azevedo LCP, Bozza FA, et al: Availability of resources to treat sepsis in Brazil: A random sample of Brazilian institutions. *Rev Bras Ter Intensiva* 2019; 31:193–201
62. Levy MM, Dellinger RP, Townsend SR, et al: The Surviving Sepsis Campaign: Results of an international guideline-based performance improvement program targeting severe sepsis. *Int Care Med* 2010; 36:222–231
63. Kuttub HI, Lykins JD, Hughes MD, et al: Evaluation and predictors of fluid resuscitation in patients with severe sepsis and septic shock. *Crit Care Med* 2019; 47:1582–1590
64. Yealy DM, Kellum JA, Huang DT, et al; ProCESS Investigators: A randomized trial of protocol-based care for early septic shock. *N Engl J Med* 2014; 370:1683–1693
65. Peake SL, Delaney A, Bellomo R; ARISE Investigators: Goal-directed resuscitation in septic shock. *N Engl J Med* 2015; 372:190–191
66. Mouncey PR, Osborn TM, Power GS, et al; ProMISe Trial Investigators: Trial of early, goal-directed resuscitation for septic shock. *N Engl J Med* 2015; 372:1301–1311
67. Rowan KM, Angus DC, Bailey M, et al: Early, goal-directed therapy for septic shock - A patient-level meta-analysis. *N Engl J Med* 2017; 376:2223–2234
68. Ehrman RR, Gallien JZ, Smith RK, et al: Resuscitation guided by volume responsiveness does not reduce mortality in sepsis: A meta-analysis. *Crit Care Explor* 2019; 1:e0015
69. Andrews B, Semler MW, Muchemwa L, et al: Effect of an early resuscitation protocol on in-hospital mortality among adults with sepsis and hypotension: A randomized clinical trial. *JAMA* 2017; 318:1233–1240
70. Aya HD, Rhodes A, Chis Ster I, et al: Hemodynamic effect of different doses of fluids for a fluid challenge: A quasi-randomized controlled study. *Crit Care Med* 2017; 45:e161–e168
71. Cherpanath TG, Hirsch A, Geerts BF, et al: Predicting fluid responsiveness by passive leg raising: A systematic review and meta-analysis of 23 clinical trials. *Crit Care Med* 2016; 44:981–991
72. Misango D, Pattnaik R, Baker T, et al; Global Intensive Care Working Group; of the European Society of Intensive Care Medicine (ESICM) and the Mahidol Oxford Tropical Medicine Research Unit (MORU) in Bangkok, Thailand: Haemodynamic assessment and support in sepsis and septic shock in resource-limited settings. *Trans R Soc Trop Med Hyg* 2017; 111:483–489
73. Levy B: Lactate and shock state: The metabolic view. *Curr Opin Crit Care* 2006; 12:315–321
74. Gu WJ, Zhang Z, Bakker J: Early lactate clearance-guided therapy in patients with sepsis: A meta-analysis with trial sequential analysis of randomized controlled trials. *Intensive Care Med* 2015; 41:1862–1863
75. Simpson SQ, Gaines M, Hussein Y, et al: Early goal-directed therapy for severe sepsis and septic shock: A living systematic review. *J Crit Care* 2016; 36:43–48
76. Cecconi M, Hernandez G, Dunser M, et al: Fluid administration for acute circulatory dysfunction using basic monitoring: Narrative review and expert panel recommendations from an ESICM task force. *Intensive Care Med* 2019; 45:21–32
77. Lara B, Enberg L, Ortega M, et al: Capillary refill time during fluid resuscitation in patients with sepsis-related hyperlactatemia at the emergency department is related to mortality. *PLoS One* 2017; 12:e0188548
78. Shrestha GS, Dünser M, Mer M: The forgotten value of the clinical examination to individualize and guide fluid resuscitation in patients with sepsis. *Crit Care* 2017; 21:306
79. LeDoux D, Astiz ME, Carpati CM, et al: Effects of perfusion pressure on tissue perfusion in septic shock. *Crit Care Med* 2000; 28:2729–2732
80. Asfar P, Meziani F, Hamel JF, et al; SEPSISPAM Investigators: High versus low blood-pressure target in patients with septic shock. *N Engl J Med* 2014; 370:1583–1593

81. Hylands M, Moller MH, Asfar P, et al: A systematic review of vasopressor blood pressure targets in critically ill adults with hypotension. *Can J Anaesth* 2017; 64:703–715
82. Lamontagne F, Meade MO, Hébert PC, et al; Canadian Critical Care Trials Group.: Higher versus lower blood pressure targets for vasopressor therapy in shock: A multicentre pilot randomized controlled trial. *Intensive Care Med* 2016; 42: 542–550
83. Lamontagne F, Richards-Belle A, Thomas K, et al; 65 trial investigators: Effect of reduced exposure to vasopressors on 90-day mortality in older critically ill patients with vasodilatory hypotension: A randomized clinical trial. *JAMA* 2020; 323:938–949
84. Mohr NM, Wessman BT, Bassin B, et al: Boarding of critically ill patients in the emergency department. *Crit Care Med* 2020; 48:1180–1187
85. Cardoso LT, Grion CM, Matsuo T, et al: Impact of delayed admission to intensive care units on mortality of critically ill patients: A cohort study. *Crit Care* 2011; 15:R28
86. Groenland CNL, Termorshuizen F, Rietdijk WJR, et al: Emergency department to ICU time is associated with hospital mortality: A registry analysis of 14,788 patients from Six University Hospitals in The Netherlands. *Crit Care Med* 2019; 47:1564–1571
87. Chalfin DB, Trzeciak S, Likourezos A, et al; DELAY-ED study group: Impact of delayed transfer of critically ill patients from the emergency department to the intensive care unit. *Crit Care Med* 2007; 35:1477–1483
88. Harris S, Singer M, Sanderson C, et al: Impact on mortality of prompt admission to critical care for deteriorating ward patients: An instrumental variable analysis using critical care bed strain. *Intensive Care Med* 2018; 44:606–615
89. Montgomery A, Panagopoulou E, Kehoe I, et al: Connecting organisational culture and quality of care in the hospital: Is job burnout the missing link? *J Health Organ Manag* 2011; 25:108–123
90. Klein Klouwenberg PM, Cremer OL, van Vught LA, et al: Likelihood of infection in patients with presumed sepsis at the time of intensive care unit admission: A cohort study. *Crit Care* 2015; 19:319
91. Levin PD, Idrees S, Sprung CL, et al: Antimicrobial use in the ICU: Indications and accuracy—an observational trial. *J Hosp Med* 2012; 7:672–678
92. Minderhoud TC, Spruyt C, Huisman S, et al: Microbiological outcomes and antibiotic overuse in Emergency Department patients with suspected sepsis. *Neth J Med* 2017; 75:196–203
93. Heffner AC, Horton JM, Marchick MR, et al: Etiology of illness in patients with severe sepsis admitted to the hospital from the emergency department. *Clin Infect Dis* 2010; 50:814–820
94. Tidswell R, Parker T, Brealey D, et al: Sepsis - the broken code how accurately is sepsis being diagnosed? *J Infect* 2020; 81:e31–e32
95. Deuster S, Roten I, Muehlebach S: Implementation of treatment guidelines to support judicious use of antibiotic therapy. *J Clin Pharm Ther* 2010; 35:71–78
96. Ferrer R, Artigas A, Suarez D, et al; Edusepsis Study Group: Effectiveness of treatments for severe sepsis: A prospective, multicenter, observational study. *Am J Respir Crit Care Med* 2009; 180:861–866
97. Kalil AC, Johnson DW, Lisco SJ, et al: Early goal-directed therapy for sepsis: A novel solution for discordant survival outcomes in clinical trials. *Crit Care Med* 2017; 45:607–614
98. Seymour CW, Gesten F, Prescott HC, et al: Time to treatment and mortality during mandated emergency care for sepsis. *N Engl J Med* 2017; 376:2235–2244
99. Klompas M, Calandra T, Singer M: Antibiotics for sepsis—finding the equilibrium. *JAMA* 2018; 320:1433–1434
100. Prescott HC, Iwashyna TJ: Improving sepsis treatment by embracing diagnostic uncertainty. *Ann Am Thorac Soc* 2019; 16:426–429
101. Baggs J, Jernigan JA, Halpin AL, et al: Risk of subsequent sepsis within 90 days after a hospital stay by type of antibiotic exposure. *Clin Infect Dis* 2018; 66:1004–1012
102. Branch-Elliman W, O'Brien W, Strymish J, et al: Association of duration and type of surgical prophylaxis with antimicrobial-associated adverse events. *JAMA Surg* 2019; 154: 590–598
103. Hranjec T, Rosenberger LH, Swenson B, et al: Aggressive versus conservative initiation of antimicrobial treatment in critically ill surgical patients with suspected intensive-care-unit-acquired infection: A quasi-experimental, before and after observational cohort study. *Lancet Infect Dis* 2012; 12:774–780
104. Ong DSY, Frencken JF, Klein Klouwenberg PMC, et al; MARS consortium: Short-course adjunctive gentamicin as empirical therapy in patients with severe sepsis and septic shock: A prospective observational cohort study. *Clin Infect Dis* 2017; 64:1731–1736
105. Tamma PD, Avdic E, Li DX, et al: Association of adverse events with antibiotic use in hospitalized patients. *JAMA Intern Med* 2017; 177:1308–1315
106. Teshome BF, Vouris SM, Hampton N, et al: Duration of exposure to antipseudomonal β -lactam antibiotics in the critically ill and development of new resistance. *Pharmacotherapy* 2019; 39:261–270
107. Contou D, Roux D, Jochmans S, et al: Septic shock with no diagnosis at 24 hours: A pragmatic multicenter prospective cohort study. *Crit Care* 2016; 20:360
108. Rhee C, Kadri SS, Danner RL, et al: Diagnosing sepsis is subjective and highly variable: A survey of intensivists using case vignettes. *Crit Care* 2016; 20:89
109. Kumar A, Roberts D, Wood KE, et al: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. *Crit Care Med* 2006; 34:1589–1596
110. Liu VX, Fielding-Singh V, Greene JD, et al: The timing of early antibiotics and hospital mortality in sepsis. *Am J Respir Crit Care Med* 2017; 196:856–863
111. Peltan ID, Brown SM, Bledsoe JR, et al: ED door-to-antibiotic time and long-term mortality in sepsis. *Chest* 2019; 155:938–946
112. Abe T, Kushimoto S, Tokuda Y, et al; JAAM FORECAST group: Implementation of earlier antibiotic administration in patients with severe sepsis and septic shock in Japan: A descriptive analysis of a prospective observational study. *Crit Care* 2019; 23:360
113. Gaiieski DF, Mikkelsen ME, Band RA, et al: Impact of time to antibiotics on survival in patients with severe sepsis or

- septic shock in whom early goal-directed therapy was initiated in the emergency department. *Crit Care Med* 2010; 38:1045–1053
114. Ko BS, Choi SH, Kang GH, et al; Korean Shock Society (KoSS) Investigators: Time to antibiotics and the outcome of patients with septic shock: A propensity score analysis. *Am J Med* 2020; 133:485–491.e4
 115. Puskarich MA, Trzeciak S, Shapiro NI, et al; Emergency Medicine Shock Research Network (EMSHOCKNET): Association between timing of antibiotic administration and mortality from septic shock in patients treated with a quantitative resuscitation protocol. *Crit Care Med* 2011; 39:2066–2071
 116. Rothrock SG, Cassidy DD, Barneck M, et al: Outcome of immediate versus early antibiotics in severe sepsis and septic shock: A systematic review and meta-analysis. *Ann Emerg Med* 2020; 76:427–441
 117. Ryoo SM, Kim WY, Sohn CH, et al: Prognostic value of timing of antibiotic administration in patients with septic shock treated with early quantitative resuscitation. *Am J Med Sci* 2015; 349:328–333
 118. Weinberger J, Rhee C, Klompas M: A critical analysis of the literature on time-to-antibiotics in suspected sepsis. *J Infect Dis* 2020; 222(Suppl 2):S110–S118
 119. Alam N, Oskam E, Stassen PM, et al; PHANTASi Trial Investigators and the ORCA (Onderzoeks Consortium Acute Geneeskunde) Research Consortium the Netherlands: Prehospital antibiotics in the ambulance for sepsis: A multicentre, open label, randomised trial. *Lancet Respir Med* 2018; 6:40–50
 120. Bloos F, Rüdgel H, Thomas-Rüdgel D, et al; MEDUSA study group: Effect of a multifaceted educational intervention for anti-infectious measures on sepsis mortality: A cluster randomized trial. *Intensive Care Med* 2017; 43:1602–1612
 121. Chalya PL, Mabula JB, Koy M, et al: Typhoid intestinal perforations at a University teaching hospital in Northwestern Tanzania: A surgical experience of 104 cases in a resource-limited setting. *World J Emerg Surg* 2012; 7:4
 122. Phua J, Koh Y, Du B, et al; MOSAICS Study Group: Management of severe sepsis in patients admitted to Asian intensive care units: Prospective cohort study. *BMJ* 2011; 342:d3245
 123. Thwaites CL, Lundeg G, Dondorp AM; sepsis in resource-limited settings—expert consensus recommendations group of the European Society of Intensive Care Medicine (ESICM) and the Mahidol-Oxford Research Unit (MORU) in Bangkok, Thailand: Recommendations for infection management in patients with sepsis and septic shock in resource-limited settings. *Intensive Care Med* 2016; 42:2040–2042
 124. Urayeneza O, Mujiyarugamba P, Rukemba Z, et al; Sepsis in Resource-Limited Nations Workgroup of the Surviving Sepsis Campaign: Increasing evidence-based interventions in patients with acute infections in a resource-limited setting: A before-and-after feasibility trial in Gitwe, Rwanda. *Crit Care Med* 2018; 46:1357–1366
 125. Urayeneza O, Mujiyarugamba P, Rukemba Z, et al; Sepsis in Resource-Limited Nations Workgroup of the Surviving Sepsis Campaign: Increasing evidence-based interventions in patients with acute infections in a resource-limited setting: A before-and-after feasibility trial in Gitwe, Rwanda. *Intensive Care Med* 2018; 44:1436–1446
 126. Yokota PK, Marra AR, Martino MD, et al: Impact of appropriate antimicrobial therapy for patients with severe sepsis and septic shock—a quality improvement study. *PLoS One* 2014; 9:e104475
 127. Peng F, Chang W, Xie JF, et al: Ineffectiveness of procalcitonin-guided antibiotic therapy in severely critically ill patients: A meta-analysis. *Int J Infect Dis* 2019; 85:158–166
 128. Wacker C, Prkno A, Brunkhorst FM, et al: Procalcitonin as a diagnostic marker for sepsis: A systematic review and meta-analysis. *Lancet Infect Dis* 2013; 13:426–435
 129. Jensen JU, Hein L, Lundgren B, et al; Procalcitonin And Survival Study (PASS) Group: Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: A randomized trial. *Crit Care Med* 2011; 39:2048–2058
 130. Layios N, Lambermont B, Canivet JL, et al: Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients. *Crit Care Med* 2012; 40:2304–2309
 131. Najafi A, Khodadadian A, Sanatkar M, et al: The comparison of procalcitonin guidance administer antibiotics with empiric antibiotic therapy in critically ill patients admitted in intensive care unit. *Acta Med Iran* 2015; 53:562–567
 132. Metlay JP, Waterer GW, Long AC, et al: Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. *Am J Respir Crit Care Med* 2019; 200:e45–e67
 133. Vincent JL, Sakr Y, Singer M, et al: Prevalence and outcomes of infection among patients in intensive care units in 2017. *JAMA* 2020; 323:1478–1487
 134. Jernigan JA, Hatfield KM, Wolford H, et al: Multidrug-resistant bacterial infections in U.S. hospitalized patients, 2012–2017. *N Engl J Med* 2020; 382:1309–1319
 135. Jones M, Jernigan JA, Evans ME, et al: Vital signs: Trends in staphylococcus aureus infections in Veterans Affairs Medical Centers - United States, 2005–2017. *MMWR Morb Mortal Wkly Rep* 2019; 68:220–224
 136. Aliberti S, Reyes LF, Faverio P, et al; GLIMP investigators: Global initiative for methicillin-resistant Staphylococcus aureus pneumonia (GLIMP): An international, observational cohort study. *Lancet Infect Dis* 2016; 16:1364–1376
 137. Rhee C, Kadri SS, Dekker JP, et al; CDC Prevention Epicenters Program: Prevalence of antibiotic-resistant pathogens in culture-proven sepsis and outcomes associated with inadequate and broad-spectrum empiric antibiotic use. *JAMA Netw Open* 2020; 3:e202899
 138. Callejo-Torre F, Eiros Bouza JM, Olaechea Astigarraga P, et al: Risk factors for methicillin-resistant Staphylococcus aureus colonisation or infection in intensive care units and their reliability for predicting MRSA on ICU admission. *Infez Med* 2016; 24:201–209
 139. Epstein L, Mu Y, Belflower R, et al: Risk factors for invasive methicillin-resistant Staphylococcus aureus infection after recent discharge from an acute-care hospitalization, 2011–2013. *Clin Infect Dis* 2016; 62:45–52

140. Shorr AF, Myers DE, Huang DB, et al: A risk score for identifying methicillin-resistant *Staphylococcus aureus* in patients presenting to the hospital with pneumonia. *BMC Infect Dis* 2013; 13:268
141. Torre-Cisneros J, Natera C, Mesa F, et al: Clinical predictors of methicillin-resistant *Staphylococcus aureus* in nosocomial and healthcare-associated pneumonia: A multicenter, matched case-control study. *Eur J Clin Microbiol Infect Dis* 2018; 37:51–56
142. Wooten DA, Winston LG: Risk factors for methicillin-resistant *Staphylococcus aureus* in patients with community-onset and hospital-onset pneumonia. *Respir Med* 2013; 107:1266–1270
143. Gasch O, Camoez M, Domínguez MA, et al; REIPI/GEIH Study Groups: Predictive factors for early mortality among patients with methicillin-resistant *Staphylococcus aureus* bacteraemia. *J Antimicrob Chemother* 2013; 68:1423–1430
144. Gasch O, Camoez M, Dominguez MA, et al; REIPI/GEIH Study Groups: Predictive factors for mortality in patients with methicillin-resistant *Staphylococcus aureus* bloodstream infection: Impact on outcome of host, microorganism and therapy. *Clin Microbiol Infect* 2013; 19:1049–1057
145. Lodise TP, McKinnon PS, Swiderski L, et al: Outcomes analysis of delayed antibiotic treatment for hospital-acquired *Staphylococcus aureus* bacteremia. *Clin Infect Dis* 2003; 36:1418–1423
146. Paul M, Kariv G, Goldberg E, et al: Importance of appropriate empirical antibiotic therapy for methicillin-resistant *Staphylococcus aureus* bacteraemia. *J Antimicrob Chemother* 2010; 65:2658–2665
147. Schramm GE, Johnson JA, Doherty JA, et al: Methicillin-resistant *Staphylococcus aureus* sterile-site infection: The importance of appropriate initial antimicrobial treatment. *Crit Care Med* 2006; 34:2069–2074
148. Fang CT, Shau WY, Hsueh PR, et al: Early empirical glycopeptide therapy for patients with methicillin-resistant *Staphylococcus aureus* bacteraemia: Impact on the outcome. *J Antimicrob Chemother* 2006; 57:511–519
149. Gómez J, García-Vázquez E, Baños R, et al: Predictors of mortality in patients with methicillin-resistant *Staphylococcus aureus* (MRSA) bacteraemia: The role of empiric antibiotic therapy. *Eur J Clin Microbiol Infect Dis* 2007; 26:239–245
150. Griffin AT, Peyrani P, Wiemken TL, et al: Empiric therapy directed against MRSA in patients admitted to the intensive care unit does not improve outcomes in community-acquired pneumonia. *Infection* 2013; 41:517–523
151. Kett DH, Cano E, Quartin AA, et al; Improving Medicine through Pathway Assessment of Critical Therapy of Hospital-Acquired Pneumonia (IMPACT-HAP) Investigators: Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: An observational, multicentre cohort study. *Lancet Infect Dis* 2011; 11:181–189
152. Khatib R, Saeed S, Sharma M, et al: Impact of initial antibiotic choice and delayed appropriate treatment on the outcome of *Staphylococcus aureus* bacteremia. *Eur J Clin Microbiol Infect Dis* 2006; 25:181–185
153. Kim SH, Park WB, Lee KD, et al: Outcome of inappropriate initial antimicrobial treatment in patients with methicillin-resistant *Staphylococcus aureus* bacteraemia. *J Antimicrob Chemother* 2004; 54:489–497
154. Yoon YK, Park DW, Sohn JW, et al: Effects of inappropriate empirical antibiotic therapy on mortality in patients with healthcare-associated methicillin-resistant *Staphylococcus aureus* bacteremia: A propensity-matched analysis. *BMC Infect Dis* 2016; 16:331
155. Jones BE, Ying J, Stevens V, et al: Empirical anti-MRSA vs standard antibiotic therapy and risk of 30-day mortality in patients hospitalized for pneumonia. *JAMA Intern Med* 2020; 180:552–560
156. Webb BJ, Sorensen J, Jephson A, et al: Broad-spectrum antibiotic use and poor outcomes in community-onset pneumonia: A cohort study. *Eur Respir J* 2019; 54:1900057
157. Baby N, Faust AC, Smith T, et al: Nasal methicillin-resistant *Staphylococcus aureus* (MRSA) PCR testing reduces the duration of MRSA-targeted therapy in patients with suspected MRSA pneumonia. *Antimicrob Agents Chemother* 2017; 61:e02432–e02416
158. Cowley MC, Ritchie DJ, Hampton N, et al: Outcomes associated with de-escalating therapy for methicillin-resistant *Staphylococcus aureus* in culture-negative nosocomial pneumonia. *Chest* 2019; 155:53–59
159. Paonessa JR, Shah RD, Pickens CI, et al: Rapid detection of methicillin-resistant *Staphylococcus aureus* in BAL: A pilot randomized controlled trial. *Chest* 2019; 155:999–1007
160. Sjövall F, Perner A, Hylander Møller M: Empirical monotherapy versus combination antibiotic therapy in adult intensive care patients with severe sepsis - a systematic review with meta-analysis and trial sequential analysis. *J Infect* 2017; 74:331–344
161. Brunkhorst FM, Oppert M, Marx G, et al; German Study Group Competence Network Sepsis (SepNet): Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: A randomized trial. *JAMA* 2012; 307:2390–2399
162. Alevizakos M, Karanika S, Detsis M, et al: Colonisation with extended-spectrum β -lactamase-producing Enterobacteriaceae and risk for infection among patients with solid or haematological malignancy: A systematic review and meta-analysis. *Int J Antimicrob Agents* 2016; 48:647–654
163. Rottier WC, Bamberg YR, Dorigo-Zetsma JW, et al: Predictive value of prior colonization and antibiotic use for third-generation cephalosporin-resistant enterobacteriaceae bacteremia in patients with sepsis. *Clin Infect Dis* 2015; 60:1622–1630
164. Rottier WC, van Werkhoven CH, Bamberg YRP, et al: Development of diagnostic prediction tools for bacteraemia caused by third-generation cephalosporin-resistant enterobacteria in suspected bacterial infections: A nested case-control study. *Clin Microbiol Infect* 2018; 24:1315–1321
165. Arulkumaran N, Routledge M, Schlebusch S, et al: Antimicrobial-associated harm in critical care: A narrative review. *Intensive Care Med* 2020; 46:225–235
166. Bassetti M, Righi E, Ansaldi F, et al: A multicenter study of septic shock due to candidemia: Outcomes and predictors of mortality. *Intensive Care Med* 2014; 40:839–845
167. Kollef M, Micek S, Hampton N, et al: Septic shock attributed to *Candida* infection: Importance of empiric therapy and source control. *Clin Infect Dis* 2012; 54:1739–1746

168. Magill SS, Edwards JR, Bamberg W, et al; Emerging Infections Program Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey Team: Multistate point-prevalence survey of health care-associated infections. *N Engl J Med* 2014; 370:1198–1208
169. Méan M, Marchetti O, Calandra T: Bench-to-bedside review: Candida infections in the intensive care unit. *Crit Care* 2008; 12:204
170. Pappas PG, Kauffman CA, Andes DR, et al: Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. *Clin Infect Dis* 2016; 62:e1–50
171. Garey KW, Rege M, Pai MP, et al: Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study. *Clin Infect Dis* 2006; 43:25–31
172. Marriott DJ, Playford EG, Chen S, et al; Australian Candidaemia Study: Determinants of mortality in non-neutropenic ICU patients with candidaemia. *Crit Care* 2009; 13:R115
173. Morrell M, Fraser VJ, Kollef MH: Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: A potential risk factor for hospital mortality. *Antimicrob Agents Chemother* 2005; 49:3640–3645
174. Timsit JF, Azoulay E, Schwebel C, et al; EMPIRICUS Trial Group: Empirical micafungin treatment and survival without invasive fungal infection in adults with ICU-acquired sepsis, candida colonization, and multiple organ failure: The EMPIRICUS randomized clinical trial. *JAMA* 2016; 316:1555–1564
175. Freifeld AG, Bow EJ, Sepkowitz KA, et al; Infectious Diseases Society of America: Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. *Clin Infect Dis* 2011; 52:e56–e93
176. Taplitz RA, Kennedy EB, Bow EJ, et al: Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. *J Clin Oncol* 2018; 36:1443–1453
177. Clancy CJ, Nguyen MH: Diagnosing invasive candidiasis. *J Clin Microbiol* 2018; 56:e01909–e01917
178. Kullberg BJ, Arendrup MC: Invasive candidiasis. *N Engl J Med* 2015; 373:1445–1456
179. Sandven P, Qvist H, Skovlund E, et al; NORGAS Group and the Norwegian Yeast Study Group: Significance of Candida recovered from intraoperative specimens in patients with intra-abdominal perforations. *Crit Care Med* 2002; 30:541–547
180. Hachem R, Hanna H, Kontoyiannis D, et al: The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. *Cancer* 2008; 112:2493–2499
181. Horn DL, Neofytos D, Anaissie EJ, et al: Epidemiology and outcomes of candidemia in 2019 patients: Data from the prospective antifungal therapy alliance registry. *Clin Infect Dis* 2009; 48:1695–1703
182. Andes DR, Safdar N, Baddley JW, et al; Mycoses Study Group: Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: A patient-level quantitative review of randomized trials. *Clin Infect Dis* 2012; 54:1110–1122
183. Kett DH, Azoulay E, Echeverria PM, et al; Extended Prevalence of Infection in ICU Study (EPIC II) Group of Investigators: Candida bloodstream infections in intensive care units: Analysis of the extended prevalence of infection in intensive care unit study. *Crit Care Med* 2011; 39:665–670
184. Cleveland AA, Harrison LH, Farley MM, et al: Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008–2013: Results from population-based surveillance. *PLoS One* 2015; 10:e0120452
185. Zhang AY, Shrum S, Williams S, et al: The changing epidemiology of candidemia in the United States: Injection drug use as an increasingly common risk factor—active surveillance in selected sites, United States, 2014–2017. *Clin Infect Dis* 2020; 71:1732–1737
186. Blumberg HM, Jarvis WR, Soucie JM, et al; National Epidemiology of Mycoses Survey(NEMIS) Study Group: Risk factors for candidal bloodstream infections in surgical intensive care unit patients: The NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. *Clin Infect Dis* 2001; 33:177–186
187. Fan D, Coughlin LA, Neubauer MM, et al: Activation of HIF-1 α and LL-37 by commensal bacteria inhibits Candida albicans colonization. *Nat Med* 2015; 21:808–814
188. Chow JK, Golan Y, Ruthazer R, et al: Risk factors for albicans and non-albicans candidemia in the intensive care unit. *Crit Care Med* 2008; 36:1993–1998
189. Ostrosky-Zeichner L, Pappas PG: Invasive candidiasis in the intensive care unit. *Crit Care Med* 2006; 34:857–863
190. Vergidis P, Clancy CJ, Shields RK, et al: Intra-abdominal candidiasis: The importance of early source control and antifungal treatment. *PLoS One* 2016; 11:e0153247
191. Ballard N, Robley L, Barrett D, et al: Patients' recollections of therapeutic paralysis in the intensive care unit. *Am J Crit Care* 2006; 15:86–94; quiz 95
192. Horvath EE, Murray CK, Vaughan GM, et al: Fungal wound infection (not colonization) is independently associated with mortality in burn patients. *Ann Surg* 2007; 245:978–985
193. Murray CK, Loo FL, Hospenthal DR, et al: Incidence of systemic fungal infection and related mortality following severe burns. *Burns* 2008; 34:1108–1112
194. Baughman RP, Rhodes JC, Dohn MN, et al: Detection of cryptococcal antigen in bronchoalveolar lavage fluid: A prospective study of diagnostic utility. *Am Rev Respir Dis* 1992; 145:1226–1229
195. Ford N, Shubber Z, Jarvis JN, et al: CD4 cell count threshold for cryptococcal antigen screening of HIV-infected individuals: A systematic review and meta-analysis. *Clin Infect Dis* 2018; 66:S152–S159
196. Hage CA, Ribes JA, Wengenack NL, et al: A multicenter evaluation of tests for diagnosis of histoplasmosis. *Clin Infect Dis* 2011; 53:448–454
197. Clumeck N, Sonnet J, Taelman H, et al: Acquired immunodeficiency syndrome in African patients. *N Engl J Med* 1984; 310:492–497

198. Hajjeh RA, Conn LA, Stephens DS, et al: Cryptococcosis: Population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. Cryptococcal Active Surveillance Group. *J Infect Dis* 1999; 179:449–454
199. Maziarz EK, Perfect JR: Cryptococcosis. *Infect Dis Clin North Am* 2016; 30:179–206
200. McCarthy KM, Morgan J, Wannemuehler KA, et al: Population-based surveillance for cryptococcosis in an antiretroviral-naïve South African province with a high HIV seroprevalence. *AIDS* 2006; 20:2199–2206
201. Husain S, Wagener MM, Singh N: Cryptococcus neoformans infection in organ transplant recipients: Variables influencing clinical characteristics and outcome. *Emerg Infect Dis* 2001; 7:375–381
202. Pappas PG, Alexander BD, Andes DR, et al: Invasive fungal infections among organ transplant recipients: Results of the Transplant-Associated Infection Surveillance Network (TRANSNET). *Clin Infect Dis* 2010; 50:1101–1111
203. Singh N, Gayowski T, Wagener MM, et al: Clinical spectrum of invasive cryptococcosis in liver transplant recipients receiving tacrolimus. *Clin Transplant* 1997; 11:66–70
204. Kontoyiannis DP, Marr KA, Park BJ, et al: Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. *Clin Infect Dis* 2010; 50:1091–1100
205. Nath DS, Kandaswamy R, Gruessner R, et al: Fungal infections in transplant recipients receiving alemtuzumab. *Transplant Proc* 2005; 37:934–936
206. Tsiodras S, Samonis G, Boumpas DT, et al: Fungal infections complicating tumor necrosis factor alpha blockade therapy. *Mayo Clin Proc* 2008; 83:181–194
207. Nsenga L, Kajjimu J, Olum R, et al: Cryptococcosis complicating diabetes mellitus: A scoping review. *Ther Adv Infect Dis* 2021; 8:20499361211014769
208. Wald A, Leisenring W, van Burik JA, et al: Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. *J Infect Dis* 1997; 175:1459–1466
209. Mengoli C, Cruciani M, Barnes RA, et al: Use of PCR for diagnosis of invasive aspergillosis: Systematic review and meta-analysis. *Lancet Infect Dis* 2009; 9:89–96
210. White PL, Bretagne S, Klingspor L, et al; European Aspergillus PCR Initiative: Aspergillus PCR: One step closer to standardization. *J Clin Microbiol* 2010; 48:1231–1240
211. White PL, Wingard JR, Bretagne S, et al: Aspergillus polymerase chain reaction: Systematic review of evidence for clinical use in comparison with antigen testing. *Clin Infect Dis* 2015; 61:1293–1303
212. Meersseman W, Lagrou K, Maertens J, et al: Invasive aspergillosis in the intensive care unit. *Clin Infect Dis* 2007; 45:205–216
213. Barnes PD, Marr KA: Aspergillosis: Spectrum of disease, diagnosis, and treatment. *Infect Dis Clin North Am* 2006; 20:545–61, vi
214. Gavalda J, Len O, San Juan R, et al; RESITRA (Spanish Network for Research on Infection in Transplantation): Risk factors for invasive aspergillosis in solid-organ transplant recipients: A case-control study. *Clin Infect Dis* 2005; 41:52–59
215. Fukuda T, Boeckh M, Carter RA, et al: Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. *Blood* 2003; 102:827–833
216. Pagano L, Busca A, Candoni A, et al; SEIFEM (Sorveglianza Epidemiologica Infezioni Fungine nelle Emopatie Maligne) Group; Other Authors: Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. *Blood Rev* 2017; 31:17–29
217. Baddley JW: Clinical risk factors for invasive aspergillosis. *Med Mycol* 2011; 49 Suppl 1:S7–S12
218. Ruiz-Camps I, Aguilar-Company J: Risk of infection associated with targeted therapies for solid organ and hematological malignancies. *Ther Adv Infect Dis* 2021; 8:2049936121989548
219. Cantan B, Luyt CE, Martin-Loeches I: Influenza infections and emergent viral infections in intensive care unit. *Semin Respir Crit Care Med* 2019; 40:488–497
220. Legoff J, Zucman N, Lemiale V, et al: Clinical significance of upper airway virus detection in critically ill hematology patients. *Am J Respir Crit Care Med* 2019; 199:518–528
221. Muscedere J, Ofner M, Kumar A, et al; ICU-FLU Group and the Canadian Critical Care Trials Group: The occurrence and impact of bacterial organisms complicating critical care illness associated with 2009 influenza A(H1N1) infection. *Chest* 2013; 144:39–47
222. van Someren Gréve F, Juffermans NP, Bos LDJ, et al: Respiratory viruses in invasively ventilated critically ill patients—A prospective multicenter observational study. *Crit Care Med* 2018; 46:29–36
223. Aziz S, Arabi YM, Alhazzani W, et al: Managing ICU surge during the COVID-19 crisis: Rapid guidelines. *Intensive Care Med* 2020; 46:1303–1325
224. Wiersinga WJ, Rhodes A, Cheng AC, et al: Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. *JAMA* 2020; 324:782–793
225. Muthuri SG, Venkatesan S, Myles PR, et al; PRIDE Consortium Investigators: Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: A meta-analysis of individual participant data. *Lancet Respir Med* 2014; 2:395–404
226. Alhazzani W, Møller MH, Arabi YM, et al: Surviving Sepsis Campaign: Guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). *Intensive Care Med* 2020; 46:854–887
227. Tunkel AR, Glaser CA, Bloch KC, et al; Infectious Diseases Society of America: The management of encephalitis: Clinical practice guidelines by the Infectious Diseases Society of America. *Clin Infect Dis* 2008; 47:303–327
228. Uyeki TM, Bernstein HH, Bradley JS, et al: Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis,

- and institutional outbreak management of seasonal influenza. *Clin Infect Dis* 2019; 68:895–902
229. Lin GL, McGinley JP, Drysdale SB, et al: Epidemiology and immune pathogenesis of viral sepsis. *Front Immunol* 2018; 9:2147
 230. Gonçalves-Pereira J, Póvoa P: Antibiotics in critically ill patients: A systematic review of the pharmacokinetics of β -lactams. *Crit Care* 2011; 15:R206
 231. Mohd Hafiz AA, Staatz CE, Kirkpatrick CM, et al: Continuous infusion vs. bolus dosing: Implications for beta-lactam antibiotics. *Minerva Anestesiol* 2012; 78:94–104
 232. Roberts JA, Abdul-Aziz MH, Davis JS, et al: Continuous versus intermittent β -lactam infusion in severe sepsis. A meta-analysis of individual patient data from randomized trials. *Am J Respir Crit Care Med* 2016; 194:681–691
 233. Vardakas KZ, Voulgaris GL, Maliaros A, et al: Prolonged versus short-term intravenous infusion of antipseudomonal β -lactams for patients with sepsis: A systematic review and meta-analysis of randomised trials. *Lancet Infect Dis* 2018; 18:108–120
 234. De Waele JJ, Lipman J, Carlier M, et al: Subtleties in practical application of prolonged infusion of β -lactam antibiotics. *Int J Antimicrob Agents* 2015; 45:461–463
 235. Roberts JA, Paratz J, Paratz E, et al: Continuous infusion of beta-lactam antibiotics in severe infections: A review of its role. *Int J Antimicrob Agents* 2007; 30:11–18
 236. Lipman J, Brett SJ, De Waele JJ, et al: A protocol for a phase 3 multicentre randomised controlled trial of continuous versus intermittent β -lactam antibiotic infusion in critically ill patients with sepsis: BLING III. *Crit Care Resusc* 2019; 21:63–68
 237. Roberts JA, Abdul-Aziz MH, Lipman J, et al; International Society of Anti-Infective Pharmacology and the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases: Individualised antibiotic dosing for patients who are critically ill: Challenges and potential solutions. *Lancet Infect Dis* 2014; 14:498–509
 238. Roberts JA, Paul SK, Akova M, et al; DALI Study: DALI: Defining antibiotic levels in intensive care unit patients: Are current β -lactam antibiotic doses sufficient for critically ill patients? *Clin Infect Dis* 2014; 58:1072–1083
 239. Veiga RP, Paiva JA: Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients. *Crit Care* 2018; 22:233
 240. Nelson NR, Morbitzer KA, Jordan JD, et al: The impact of capping creatinine clearance on achieving therapeutic vancomycin concentrations in neurocritically ill patients with traumatic brain injury. *Neurocrit Care* 2019; 30:126–131
 241. Grégoire N, Marchand S, Ferrandière M, et al: Population pharmacokinetics of daptomycin in critically ill patients with various degrees of renal impairment. *J Antimicrob Chemother* 2019; 74:117–125
 242. Uldemolins M, Roberts JA, Rello J, et al: The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. *Clin Pharmacokinet* 2011; 50:99–110
 243. Choi G, Gomersall CD, Tian Q, et al: Principles of antibacterial dosing in continuous renal replacement therapy. *Crit Care Med* 2009; 37:2268–2282
 244. Roberts JA, Joynt G, Lee A, et al: The effect of renal replacement therapy and antibiotic dose on antibiotic concentrations in critically ill patients: Data from the multinational SMARRT Study. *Clin Infect Dis* 2020; 72:1369–1378
 245. Bouglé A, Dujardin O, Lepère V, et al: PHARMECMO: Therapeutic drug monitoring and adequacy of current dosing regimens of antibiotics in patients on Extracorporeal Life Support. *Anaesth Crit Care Pain Med* 2019; 38:493–497
 246. Cheng V, Abdul-Aziz MH, Roberts JA, et al: Overcoming barriers to optimal drug dosing during ECMO in critically ill adult patients. *Expert Opin Drug Metab Toxicol* 2019; 15:103–112
 247. Guilhaumou R, Benaboud S, Bennis Y, et al: Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d'Anesthésie et Réanimation-SFAR). *Crit Care* 2019; 23:104
 248. Turner RB, Kojiro K, Shephard EA, et al: Review and validation of bayesian dose-optimizing software and equations for calculation of the vancomycin area under the curve in critically ill patients. *Pharmacotherapy* 2018; 38:1174–1183
 249. Rybak M, Lomaestro B, Rotschafer JC, et al: Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. *Am J Health Syst Pharm* 2009; 66:82–98
 250. McKinnon PS, Paladino JA, Schentag JJ: Evaluation of area under the inhibitory curve (AUC) and time above the minimum inhibitory concentration ($T > MIC$) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. *Int J Antimicrob Agents* 2008; 31:345–351
 251. Rayner CR, Forrest A, Meagher AK, et al: Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. *Clin Pharmacokinet* 2003; 42:1411–1423
 252. Rubino CM, Bhavnani SM, Forrest A, et al: Pharmacokinetics-pharmacodynamics of tigecycline in patients with community-acquired pneumonia. *Antimicrob Agents Chemother* 2012; 56:130–136
 253. Wong G, Taccone F, Villosio P, et al: β -Lactam pharmacodynamics in Gram-negative bloodstream infections in the critically ill. *J Antimicrob Chemother* 2020; 75:429–433
 254. Fleuren LM, Roggeveen LF, Guo T, et al: Clinically relevant pharmacokinetic knowledge on antibiotic dosing among intensive care professionals is insufficient: A cross-sectional study. *Crit Care* 2019; 23:185
 255. Ehmann L, Zoller M, Minichmayr IK, et al: Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic/pharmacodynamic analysis. *Int J Antimicrob Agents* 2019; 54:309–317
 256. Wong G, Briscoe S, McWhinney B, et al: Therapeutic drug monitoring of β -lactam antibiotics in the critically ill: Direct

- measurement of unbound drug concentrations to achieve appropriate drug exposures. *J Antimicrob Chemother* 2018; 73:3087–3094
257. Williams P, Beall G, Cotta MO, et al: Antimicrobial dosing in critical care: A pragmatic adult dosing nomogram. *Int J Antimicrob Agents* 2020; 55:105837
258. Williams P, Cotta MO, Roberts JA: Pharmacokinetics/pharmacodynamics of β -lactams and therapeutic drug monitoring: From theory to practical issues in the intensive care unit. *Semin Respir Crit Care Med* 2019; 40:476–487
259. Nation RL, Garonzik SM, Thamlikitkul V, et al: Dosing guidance for intravenous colistin in critically-ill patients. *Clin Infect Dis* 2017; 64:565–571
260. Roberts JA, Taccone FS, Udy AA, et al: Vancomycin dosing in critically ill patients: Robust methods for improved continuous-infusion regimens. *Antimicrob Agents Chemother* 2011; 55:2704–2709
261. Sinnollareddy M, Peake SL, Roberts MS, et al: Using pharmacokinetics and pharmacodynamics to optimise dosing of antifungal agents in critically ill patients: A systematic review. *Int J Antimicrob Agents* 2012; 39:1–10
262. Jimenez MF, Marshall JC; International Sepsis Forum: Source control in the management of sepsis. *Intensive Care Med* 2001; 27 Suppl 1:S49–S62
263. Kim H, Chung SP, Choi SH, et al; Korean Shock Society (KoSS) Investigators: Impact of timing to source control in patients with septic shock: A prospective multi-center observational study. *J Crit Care* 2019; 53:176–182
264. Martínez ML, Ferrer R, Torrents E, et al; Edusepsis Study Group: Impact of source control in patients with severe sepsis and septic shock. *Crit Care Med* 2017; 45:11–19
265. Azuhata T, Kinoshita K, Kawano D, et al: Time from admission to initiation of surgery for source control is a critical determinant of survival in patients with gastrointestinal perforation with associated septic shock. *Crit Care* 2014; 18:R87
266. Bloos F, Thomas-Rüddel D, Rüddel H, et al; MEDUSA Study Group: Impact of compliance with infection management guidelines on outcome in patients with severe sepsis: A prospective observational multi-center study. *Crit Care* 2014; 18:R42
267. Buck DL, Vester-Andersen M, Møller MH; Danish Clinical Register of Emergency Surgery: Surgical delay is a critical determinant of survival in perforated peptic ulcer. *Br J Surg* 2013; 100:1045–1049
268. Chao WN, Tsai CF, Chang HR, et al: Impact of timing of surgery on outcome of *Vibrio vulnificus*-related necrotizing fasciitis. *Am J Surg* 2013; 206:32–39
269. Karvellas CJ, Abraldes JG, Zepeda-Gomez S, et al; Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group: The impact of delayed biliary decompression and anti-microbial therapy in 260 patients with cholangitis-associated septic shock. *Aliment Pharmacol Ther* 2016; 44:755–766
270. Moss RL, Musemeche CA, Kosloske AM: Necrotizing fasciitis in children: Prompt recognition and aggressive therapy improve survival. *J Pediatr Surg* 1996; 31:1142–1146
271. Wong CH, Chang HC, Pasupathy S, et al: Necrotizing fasciitis: Clinical presentation, microbiology, and determinants of mortality. *J Bone Joint Surg Am* 2003; 85:1454–1460
272. Solomkin JS, Mazuski JE, Bradley JS, et al: Diagnosis and management of complicated intra-abdominal infection in adults and children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. *Clin Infect Dis* 2010; 50:133–164
273. Mermel LA, Allon M, Bouza E, et al: Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. *Clin Infect Dis* 2009; 49:1–45
274. Rijnders BJ, Peetermans WE, Verwaest C, et al: Watchful waiting versus immediate catheter removal in ICU patients with suspected catheter-related infection: A randomized trial. *Intensive Care Med* 2004; 30:1073–1080
275. Garnacho-Montero J, Aldabó-Pallás T, Palomar-Martínez M, et al: Risk factors and prognosis of catheter-related bloodstream infection in critically ill patients: A multicenter study. *Intensive Care Med* 2008; 34:2185–2193
276. Lorente L, Martín MM, Vidal P, et al; Working Group on Catheter Related Infection Suspicion Management of GTEIS/SEMICYUC: Should central venous catheter be systematically removed in patients with suspected catheter related infection? *Crit Care* 2014; 18:564
277. Tabah A, Bassetti M, Kollef MH, et al: Antimicrobial de-escalation in critically ill patients: A position statement from a task force of the European Society of *Int Care Medicine* (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP). *Int Care Med* 2020; 46:245–265
278. Leone M, Bechis C, Baumstarck K, et al; AZUREA Network Investigators: De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: A multicenter non-blinded randomized noninferiority trial. *Intensive Care Med* 2014; 40:1399–1408
279. Tabah A, Cotta MO, Garnacho-Montero J, et al: A systematic review of the definitions, determinants, and clinical outcomes of antimicrobial de-escalation in the intensive care unit. *Clin Infect Dis* 2016; 62:1009–1017
280. De Bus L, Depuydt P, Steen J, et al; DIANA study group: Antimicrobial de-escalation in the critically ill patient and assessment of clinical cure: The DIANA study. *Intensive Care Med* 2020; 46:1404–1417
281. Fernandez-Lazaro CI, Brown KA, Langford BJ, et al: Late-career physicians prescribe longer courses of antibiotics. *Clin Infect Dis* 2019; 69:1467–1475
282. Hanretty AM, Gallagher JC: Shortened courses of antibiotics for bacterial infections: A systematic review of randomized controlled trials. *Pharmacotherapy* 2018; 38:674–687
283. Royer S, DeMerle KM, Dickson RP, et al: Shorter versus longer courses of antibiotics for infection in hospitalized patients: A systematic review and meta-analysis. *J Hosp Med* 2018; 13:336–342
284. Spellberg B: The new antibiotic mantra—“shorter is better”. *JAMA Intern Med* 2016; 176:1254–1255
285. Wald-Dickler N, Spellberg B: Short-course antibiotic therapy-replacing constantine units with “shorter is better”. *Clin Infect Dis* 2019; 69:1476–1479
286. Chastre J, Wolff M, Fagon JY, et al; PneumA Trial Group: Comparison of 8 vs 15 days of antibiotic therapy for

- ventilator-associated pneumonia in adults: A randomized trial. *JAMA* 2003; 290:2588–2598
287. Choudhury G, Mandal P, Singanayagam A, et al: Seven-day antibiotic courses have similar efficacy to prolonged courses in severe community-acquired pneumonia—a propensity-adjusted analysis. *Clin Microbiol Infect* 2011; 17:1852–1858
 288. Kalil AC, Metersky ML, Klompas M, et al: Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. *Clin Infect Dis* 2016; 63:e61–e111
 289. Vaughn VM, Flanders SA, Snyder A, et al: Excess antibiotic treatment duration and adverse events in patients hospitalized with pneumonia: A multihospital cohort study. *Ann Intern Med* 2019; 171:153–163
 290. Eliakim-Raz N, Yahav D, Paul M, et al: Duration of antibiotic treatment for acute pyelonephritis and septic urinary tract infection—7 days or less versus longer treatment: Systematic review and meta-analysis of randomized controlled trials. *J Antimicrob Chemother* 2013; 68:2183–2191
 291. Runyon BA, McHutchison JG, Antillon MR, et al: Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients. *Gastroenterology* 1991; 100:1737–1742
 292. Yahav D, Franceschini E, Koppel F, et al; Bacteremia Duration Study Group: Seven versus 14 days of antibiotic therapy for uncomplicated gram-negative bacteremia: A noninferiority randomized controlled trial. *Clin Infect Dis* 2019; 69:1091–1098
 293. Sawyer RG, Claridge JA, Nathens AB, et al; STOP-IT Trial Investigators: Trial of short-course antimicrobial therapy for intraabdominal infection. *N Engl J Med* 2015; 372:1996–2005
 294. Corona A, Bertolini G, Ricotta AM, et al: Variability of treatment duration for bacteraemia in the critically ill: A multinational survey. *J Antimicrob Chemother* 2003; 52:849–852
 295. Burnham JP, Olsen MA, Stwalley D, et al: Infectious diseases consultation reduces 30-day and 1-year all-cause mortality for multidrug-resistant organism infections. *Open Forum Infect Dis* 2018; 5:ofy026
 296. Macheda G, Dyar OJ, Luc A, et al; ESGAP and SPILF: Are infection specialists recommending short antibiotic treatment durations? An ESCMID international cross-sectional survey. *J Antimicrob Chemother* 2018; 73:1084–1090
 297. Madaline T, Wadskier Montagne F, Eisenberg R, et al: Early infectious disease consultation is associated with lower mortality in patients with severe sepsis or septic shock who complete the 3-hour sepsis treatment bundle. *Open Forum Infect Dis* 2019; 6:ofz408
 298. Schmitt S, McQuillen DP, Nahass R, et al: Infectious diseases specialty intervention is associated with decreased mortality and lower healthcare costs. *Clin Infect Dis* 2014; 58:22–28
 299. Turner RB, Valcarlos E, Won R, et al: Impact of infectious diseases consultation on clinical outcomes of patients with staphylococcus aureus bacteremia in a community health system. *Antimicrob Agents Chemother* 2016; 60:5682–5687
 300. Viale P, Tedeschi S, Scudeller L, et al: Infectious diseases team for the early management of severe sepsis and septic shock in the emergency department. *Clin Infect Dis* 2017; 65:1253–1259
 301. Pugh R, Grant C, Cooke RP, et al: Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. *Cochrane Database Syst Rev* 2015:CD007577
 302. Havey TC, Fowler RA, Daneman N: Duration of antibiotic therapy for bacteremia: A systematic review and meta-analysis. *Crit Care* 2011; 15:R267
 303. Dimopoulos G, Matthaiou DK, Karageorgopoulos DE, et al: Short- versus long-course antibacterial therapy for community-acquired pneumonia: A meta-analysis. *Drugs* 2008; 68:1841–1854
 304. Tansarli GS, Andreatos N, Pliakos EE, et al: A systematic review and meta-analysis of antibiotic treatment duration for bacteremia due to enterobacteriaceae. *Antimicrob Agents Chemother* 2019; 63:e02495–e02418
 305. Montravers P, Tubach F, Lescot T, et al; DURAPOP Trial Group: Short-course antibiotic therapy for critically ill patients treated for postoperative intra-abdominal infection: The DURAPOP randomised clinical trial. *Intensive Care Med* 2018; 44:300–310
 306. Mazuski JE, Sawyer RG, Nathens AB, et al; Therapeutic Agents Committee of the Surgical Infections Society: The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: Evidence for the recommendations. *Surg Infect (Larchmt)* 2002; 3:175–233
 307. van Engelen TSR, Wiersinga WJ, Scicluna BP, et al: Biomarkers in Sepsis. *Crit Care Clin* 2018; 34:139–152
 308. Annane D, Maxime V, Faller JP, et al: Procalcitonin levels to guide antibiotic therapy in adults with non-microbiologically proven apparent severe sepsis: A randomised controlled trial. *BMJ Open* 2013; 3:e002186
 309. Bloos F, Trips E, Nierhaus A, et al; for SepNet Critical Care Trials Group: Effect of sodium selenite administration and procalcitonin-guided therapy on mortality in patients with severe sepsis or septic shock: A randomized clinical trial. *JAMA Intern Med* 2016; 176:1266–1276
 310. Bouadma L, Luyt CE, Tubach F, et al; PRORATA trial group: Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): A multicentre randomised controlled trial. *Lancet* 2010; 375:463–474
 311. de Jong E, van Oers JA, Beishuizen A, et al: Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: A randomised, controlled, open-label trial. *Lancet Infect Dis* 2016; 16:819–827
 312. Deliberato RO, Marra AR, Sanches PR, et al: Clinical and economic impact of procalcitonin to shorten antimicrobial therapy in septic patients with proven bacterial infection in an intensive care setting. *Diagn Microbiol Infect Dis* 2013; 76:266–271
 313. Hochreiter M, Köhler T, Schweiger AM, et al: Procalcitonin to guide duration of antibiotic therapy in intensive care patients: A randomized prospective controlled trial. *Crit Care* 2009; 13:R83
 314. Liu BH, Li HF, Lei Y, et al: [Clinical significance of dynamic monitoring of procalcitonin in guiding the use of antibiotics

- in patients with sepsis in ICU]. *Zhonghua Wei Zhong Bing Ji Jiu Yi Xue* 2013; 25:690–693
315. Nobre V, Harbarth S, Graf JD, et al: Use of procalcitonin to shorten antibiotic treatment duration in septic patients: A randomized trial. *Am J Respir Crit Care Med* 2008; 177:498–505
 316. Oliveira CF, Botoni FA, Oliveira CR, et al: Procalcitonin versus C-reactive protein for guiding antibiotic therapy in sepsis: A randomized trial. *Crit Care Med* 2013; 41:2336–2343
 317. Qu R, Ji Y, Ling Y, et al: Procalcitonin is a good tool to guide duration of antibiotic therapy in patients with severe acute pancreatitis. A randomized prospective single-center controlled trial. *Saudi Med J* 2012; 33:382–387
 318. Schroeder S, Hochreiter M, Koehler T, et al: Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: Results of a prospective randomized study. *Langenbecks Arch Surg* 2009; 394:221–226
 319. Shehabi Y, Sterba M, Garrett PM, et al; ProGUARD Study Investigators; ANZICS Clinical Trials Group: Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. *Am J Respir Crit Care Med* 2014; 190:1102–1110
 320. Stolz D, Smyrniotis N, Eggimann P, et al: Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: A randomised study. *Eur Respir J* 2009; 34:1364–1375
 321. Xu XL, Yan FD, Yu JQ, et al: [Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment of sepsis patients]. *Zhonghua Yi Xue Za Zhi* 2017; 97:343–346
 322. Arulkumaran N, Khpal M, Tam K, et al: Effect of antibiotic discontinuation strategies on mortality and infectious complications in critically ill septic patients: A meta-analysis and trial sequential analysis. *Crit Care Med* 2020; 48:757–764
 323. Collins CD, Brockhaus K, Sim T, et al: Analysis to determine cost-effectiveness of procalcitonin-guided antibiotic use in adult patients with suspected bacterial infection and sepsis. *Am J Health Syst Pharm* 2019; 76:1219–1225
 324. Lewis SR, Pritchard MW, Evans DJ, et al: Colloids versus crystalloids for fluid resuscitation in critically ill people. *Cochrane Database Syst Rev* 2018; 8:CD000567
 325. Awad S, Allison SP, Lobo DN: The history of 0.9% saline. *Clin Nutr* 2008; 27:179–188
 326. Chowdhury AH, Cox EF, Francis ST, et al: A randomized, controlled, double-blind crossover study on the effects of 2-L infusions of 0.9% saline and plasma-lyte® 148 on renal blood flow velocity and renal cortical tissue perfusion in healthy volunteers. *Ann Surg* 2012; 256:18–24
 327. Kellum JA: Fluid resuscitation and hyperchloremic acidosis in experimental sepsis: Improved short-term survival and acid-base balance with Hextend compared with saline. *Crit Care Med* 2002; 30:300–305
 328. Kellum JA, Song M, Almasri E: Hyperchloremic acidosis increases circulating inflammatory molecules in experimental sepsis. *Chest* 2006; 130:962–967
 329. Waters JH, Gottlieb A, Schoenwald P, et al: Normal saline versus lactated Ringer's solution for intraoperative fluid management in patients undergoing abdominal aortic aneurysm repair: An outcome study. *Anesth Analg* 2001; 93: 817–822
 330. Williams EL, Hildebrand KL, McCormick SA, et al: The effect of intravenous lactated Ringer's solution versus 0.9% sodium chloride solution on serum osmolality in human volunteers. *Anesth Analg* 1999; 88:999–1003
 331. Rochweg B, Alhazzani W, Sindi A, et al; Fluids in Sepsis and Septic Shock Group: Fluid resuscitation in sepsis: A systematic review and network meta-analysis. *Ann Intern Med* 2014; 161:347–355
 332. Young P, Bailey M, Beasley R, et al; SPLIT Investigators; ANZICS CTG: Effect of a buffered crystalloid solution vs saline on acute kidney injury among patients in the intensive care unit: The SPLIT randomized clinical trial. *JAMA* 2015; 314:1701–1710
 333. Semler MW, Wanderer JP, Ehrenfeld JM, et al; SALT Investigators * and the Pragmatic Critical Care Research Group; SALT Investigators: Balanced crystalloids versus saline in the intensive care unit. The SALT randomized trial. *Am J Respir Crit Care Med* 2017; 195:1362–1372
 334. Semler MW, Self WH, Wanderer JP, et al; SMART Investigators and the Pragmatic Critical Care Research Group: Balanced crystalloids versus saline in critically ill adults. *N Engl J Med* 2018; 378:829–839
 335. Brown RM, Wang L, Coston TD, et al: Balanced crystalloids versus saline in sepsis. A secondary analysis of the SMART clinical trial. *Am J Respir Crit Care Med* 2019; 200:1487–1495
 336. Myburgh J: Patient-centered outcomes and resuscitation fluids. *N Engl J Med* 2018; 378:862–863
 337. Zampieri FG, Azevedo LCP, Corrêa TD, et al; BaSICS Investigators and the BRICNet: Study protocol for the Balanced Solution versus Saline in Intensive Care Study (BaSICS): A factorial randomised trial. *Crit Care Resusc* 2017; 19:175–182
 338. Institute G: Plasma-Lyte 148® versus Saline Study (PLUS). 2020. ClinicalTrials.gov. Available at: <https://clinicaltrials.gov/ct2/show/NCT02721654>
 339. Caironi P, Tognoni G, Gattinoni L: Albumin replacement in severe sepsis or septic shock. *N Engl J Med* 2014; 371:84
 340. Martin GS, Bassett P: Crystalloids vs. colloids for fluid resuscitation in the intensive care unit: A systematic review and meta-analysis. *J Crit Care* 2019; 50:144–154
 341. Park CHL, de Almeida JP, de Oliveira GQ, et al: Lactated Ringer's versus 4% albumin on lactated Ringer's in early sepsis therapy in cancer patients: A pilot single-center randomized trial. *Crit Care Med* 2019; 47:e798–e805
 342. Kakaei FHS, Asheghvatan A, Zarrintan S, et al: Albumin as a resuscitative fluid in patients with severe sepsis: A randomized clinical trial. *Adv Biosci Clin Med* 2017; 5:9–16
 343. Haase N, Perner A, Hennings LI, et al: Hydroxyethyl starch 130/0.38–0.45 versus crystalloid or albumin in patients with sepsis: Systematic review with meta-analysis and trial sequential analysis. *BMJ* 2013; 346:f839
 344. Annane D, Siami S, Jaber S, et al; CRISTAL Investigators: Effects of fluid resuscitation with colloids vs crystalloids on mortality in critically ill patients presenting with

- hypovolemic shock: The CRISTAL randomized trial. *JAMA* 2013; 310:1809–1817
345. Rochweg B, Alhazzani W, Gibson A, et al; FISSH Group (Fluids in Sepsis and Septic Shock): Fluid type and the use of renal replacement therapy in sepsis: A systematic review and network meta-analysis. *Intensive Care Med* 2015; 41:1561–1571
 346. Moeller C, Fleischmann C, Thomas-Rueddel D, et al: How safe is gelatin? A systematic review and meta-analysis of gelatin-containing plasma expanders vs crystalloids and albumin. *J Crit Care* 2016; 35:75–83
 347. Avni T, Lador A, Lev S, et al: Vasopressors for the treatment of septic shock: Systematic review and meta-analysis. *PLoS One* 2015; 10:e0129305
 348. Regnier B, Safran D, Carlet J, et al: Comparative haemodynamic effects of dopamine and dobutamine in septic shock. *Intensive Care Med* 1979; 5:115–120
 349. De Backer D, Creteur J, Silva E, et al: Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock: Which is best? *Crit Care Med* 2003; 31:1659–1667
 350. Cui J, Wei X, Lv H, et al: The clinical efficacy of intravenous IgM-enriched immunoglobulin (pentaglobin) in sepsis or septic shock: A meta-analysis with trial sequential analysis. *Ann Intensive Care* 2019; 9:27
 351. Myburgh JA, Higgins A, Jovanovska A, et al; CAT Study investigators: A comparison of epinephrine and norepinephrine in critically ill patients. *Intensive Care Med* 2008; 34:2226–2234
 352. Holmes CL, Patel BM, Russell JA, et al: Physiology of vasopressin relevant to management of septic shock. *Chest* 2001; 120:989–1002
 353. Landry DW, Levin HR, Gallant EM, et al: Vasopressin deficiency contributes to the vasodilation of septic shock. *Circulation* 1997; 95:1122–1125
 354. Gordon AC, Mason AJ, Thirunavukkarasu N, et al; VANISH Investigators: Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: The VANISH randomized clinical trial. *JAMA* 2016; 316:509–518
 355. Dünser MW, Mayr AJ, Tür A, et al: Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: Incidence and risk factors. *Crit Care Med* 2003; 31:1394–1398
 356. Russell JA, Walley KR, Singer J, et al; VASST Investigators: Vasopressin versus norepinephrine infusion in patients with septic shock. *N Engl J Med* 2008; 358:877–887
 357. Ukor IF, Walley KR: Vasopressin in vasodilatory shock. *Crit Care Clin* 2019; 35:247–261
 358. McIntyre WF, Um KJ, Alhazzani W, et al: Association of vasopressin plus catecholamine vasopressors vs catecholamines alone with atrial fibrillation in patients with distributive shock: A systematic review and meta-analysis. *JAMA* 2018; 319:1889–1900
 359. Nagendran M, Russell JA, Walley KR, et al: Vasopressin in septic shock: An individual patient data meta-analysis of randomised controlled trials. *Intensive Care Med* 2019; 45:844–855
 360. Gamper G, Havel C, Arrich J, et al: Vasopressors for hypotensive shock. *Cochrane Database Syst Rev* 2016; 2:CD003709
 361. Akinaga J, Lima V, Kiguti LR, et al: Differential phosphorylation, desensitization, and internalization of α 1A-adrenoceptors activated by norepinephrine and oxy-metazoline. *Mol Pharmacol* 2013; 83:870–881
 362. Belletti A, Benedetto U, Biondi-Zoccai G, et al: The effect of vasoactive drugs on mortality in patients with severe sepsis and septic shock. A network meta-analysis of randomized trials. *J Crit Care* 2017; 37:91–98
 363. Russell JA, Vincent JL, Kjølbye AL, et al: Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients. *Crit Care* 2017; 21:213
 364. Laterre PF, Berry SM, Blemings A, et al; SEPSIS-ACT Investigators: Effect of selepressin vs placebo on ventilator- and vasopressor-free days in patients with septic shock: The SEPSIS-ACT randomized clinical trial. *JAMA* 2019; 322:1476–1485
 365. Chawla LS, Busse L, Brasha-Mitchell E, et al: Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): A pilot study. *Crit Care* 2014; 18:534
 366. Khanna A, English SW, Wang XS, et al; ATHOS-3 Investigators: Angiotensin II for the treatment of vasodilatory shock. *N Engl J Med* 2017; 377:419–430
 367. Liu ZM, Chen J, Kou Q, et al; Study Group of investigators: Terlipressin versus norepinephrine as infusion in patients with septic shock: A multicentre, randomised, double-blinded trial. *Intensive Care Med* 2018; 44:1816–1825
 368. Walley KR: Sepsis-induced myocardial dysfunction. *Curr Opin Crit Care* 2018; 24:292–299
 369. Cunha-Goncalves D, Perez-de-Sa V, Larsson A, et al: Inotropic support during experimental endotoxemic shock: Part II. A comparison of levosimendan with dobutamine. *Anesth Analg* 2009; 109:1576–1583
 370. Dubin A, Lattanzio B, Gatti L: The spectrum of cardiovascular effects of dobutamine - from healthy subjects to septic shock patients. *Rev Bras Ter Intensiva* 2017; 29:490–498
 371. Wilkman E, Kaukonen KM, Pettilä V, et al: Association between inotrope treatment and 90-day mortality in patients with septic shock. *Acta Anaesthesiol Scand* 2013; 57:431–442
 372. Dünser MW, Festic E, Dondorp A, et al; Global Intensive Care Working Group of European Society of Intensive Care Medicine: Recommendations for sepsis management in resource-limited settings. *Intensive Care Med* 2012; 38:557–574
 373. Gordon AC, Perkins GD, Singer M, et al: Levosimendan for the prevention of acute organ dysfunction in sepsis. *N Engl J Med* 2016; 375:1638–1648
 374. Bhattacharjee S, Soni KD, Maitra S, et al: Levosimendan does not provide mortality benefit over dobutamine in adult patients with septic shock: A meta-analysis of randomized controlled trials. *J Clin Anesth* 2017; 39:67–72
 375. Araghi A, Bander JJ, Guzman JA: Arterial blood pressure monitoring in overweight critically ill patients: Invasive or noninvasive? *Crit Care* 2006; 10:R64

376. Bur A, Hirschl MM, Herkner H, et al: Accuracy of oscillometric blood pressure measurement according to the relation between cuff size and upper-arm circumference in critically ill patients. *Crit Care Med* 2000; 28:371–376
377. Kaur B, Kaur S, Yaddanapudi LN, et al: Comparison between invasive and noninvasive blood pressure measurements in critically ill patients receiving inotropes. *Blood Press Monit* 2019; 24:24–29
378. Lehman LW, Saeed M, Talmor D, et al: Methods of blood pressure measurement in the ICU. *Crit Care Med* 2013; 41:34–40
379. Riley LE, Chen GJ, Latham HE: Comparison of noninvasive blood pressure monitoring with invasive arterial pressure monitoring in medical ICU patients with septic shock. *Blood Press Monit* 2017; 22:202–207
380. Vincent J: Arterial, central venous, and pulmonary artery catheters. *In: Critical care medicine: principles and diagnosis and management in the adult*. Fifth edition. Parrilla JE, editor. Philadelphia, PA, Elsevier, 2019. pp 40–49
381. Scheer B, Perel A, Pfeiffer UJ: Clinical review: Complications and risk factors of peripheral arterial catheters used for haemodynamic monitoring in anaesthesia and intensive care medicine. *Crit Care* 2002; 6:199–204
382. Bhattacharjee S, Maitra S, Baidya DK: Comparison between ultrasound guided technique and digital palpation technique for radial artery cannulation in adult patients: An updated meta-analysis of randomized controlled trials. *J Clin Anesth* 2018; 47:54–59
383. Gu WJ, Wu XD, Wang F, et al: Ultrasound guidance facilitates radial artery catheterization: A meta-analysis with trial sequential analysis of randomized controlled trials. *Chest* 2016; 149:166–179
384. O'Horo JC, Maki DG, Krupp AE, et al: Arterial catheters as a source of bloodstream infection: A systematic review and meta-analysis. *Crit Care Med* 2014; 42:1334–1339
385. Delaney A, Finnis M, Bellomo R, et al: Initiation of vasopressor infusions via peripheral versus central access in patients with early septic shock: A retrospective cohort study. *Emerg Med Australas* 2020; 32:210–219
386. Ricard JD, Salomon L, Boyer A, et al: Central or peripheral catheters for initial venous access of ICU patients: A randomized controlled trial. *Crit Care Med* 2013; 41:2108–2115
387. Cardenas-Garcia J, Schaub KF, Belchikov YG, et al: Safety of peripheral intravenous administration of vasoactive medication. *J Hosp Med* 2015; 10:581–585
388. Tian DH, Smyth C, Keijzers G, et al: Safety of peripheral administration of vasopressor medications: A systematic review. *Emerg Med Australas* 2020; 32:220–227
389. Loubani OM, Green RS: A systematic review of extravasation and local tissue injury from administration of vasopressors through peripheral intravenous catheters and central venous catheters. *J Crit Care* 2015; 30:653.e9–653.17
390. Beck V, Chateau D, Bryson GL, et al; Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group: Timing of vasopressor initiation and mortality in septic shock: A cohort study. *Crit Care* 2014; 18:R97
391. Black LP, Puskarich MA, Smotherman C, et al: Time to vasopressor initiation and organ failure progression in early septic shock. *J Am Coll Emerg Physicians Open* 2020; 1:222–230
392. Edaigbini SAAM, Delia IZ, Ibrahim A, et al: Clinical competence with central venous lines by resident doctors in a Nigerian teaching hospital. *Sub-Saharan Afr J Med* 2017; 4:47–51
393. Rivers E, Nguyen B, Havstad S, et al; Early Goal-Directed Therapy Collaborative Group: Early goal-directed therapy in the treatment of severe sepsis and septic shock. *N Engl J Med* 2001; 345:1368–1377
394. Alphonsus CS, Rodseth RN: The endothelial glycocalyx: A review of the vascular barrier. *Anaesthesia* 2014; 69:777–784
395. Boyd JH, Forbes J, Nakada TA, et al: Fluid resuscitation in septic shock: A positive fluid balance and elevated central venous pressure are associated with increased mortality. *Crit Care Med* 2011; 39:259–265
396. Marik PE, Linde-Zwirble WT, Bittner EA, et al: Fluid administration in severe sepsis and septic shock, patterns and outcomes: An analysis of a large national database. *Intensive Care Med* 2017; 43:625–632
397. Chen C, Kollef MH: Targeted fluid minimization following initial resuscitation in septic shock: A pilot study. *Chest* 2015; 148:1462–1469
398. Corl KA, Prodromou M, Merchant RC, et al: The restrictive IV fluid trial in severe sepsis and septic shock (RIFTS): A randomized pilot study. *Crit Care Med* 2019; 47:951–959
399. Hjortrup PB, Haase N, Bundgaard H, et al; CLASSIC Trial Group; Scandinavian Critical Care Trials Group: Restricting volumes of resuscitation fluid in adults with septic shock after initial management: The CLASSIC randomised, parallel-group, multicentre feasibility trial. *Intensive Care Med* 2016; 42:1695–1705
400. Macdonald SPJ, Keijzers G, Taylor DM, et al; REFRESH trial investigators: Restricted fluid resuscitation in suspected sepsis associated hypotension (REFRESH): A pilot randomised controlled trial. *Intensive Care Med* 2018; 44:2070–2078
401. Semler MW, Janz DR, Casey JD, et al: Conservative fluid management after sepsis resuscitation: A pilot randomized trial. *J Int Care Med* 2019; 35:1374–1382
402. Meyhoff TS, Hjortrup PB, Møller MH, et al: Conservative vs liberal fluid therapy in septic shock (CLASSIC) trial-Protocol and statistical analysis plan. *Acta Anaesthesiol Scand* 2019; 63:1262–1271
403. Self WH, Semler MW, Bellomo R, et al; CLOVERS Protocol Committee and NHLBI Prevention and Early Treatment of Acute Lung Injury (PETAL) Network Investigators: Liberal versus restrictive intravenous fluid therapy for early septic shock: Rationale for a randomized trial. *Ann Emerg Med* 2018; 72:457–466
404. Girardis M, Busani S, Damiani E, et al: Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: The oxygen-ICU randomized clinical trial. *JAMA* 2016; 316:1583–1589
405. ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group; Mackle D, Bellomo R, Bailey M, et al: Conservative oxygen therapy

- during mechanical ventilation in the ICU. *N Engl J Med* 2020; 382:989–998
406. Panwar R, Hardie M, Bellomo R, et al; CLOSE Study Investigators; ANZICS Clinical Trials Group: Conservative versus liberal oxygenation targets for mechanically ventilated patients. A pilot multicenter randomized controlled trial. *Am J Respir Crit Care Med* 2016; 193:43–51
 407. Chu DK, Kim LH, Young PJ, et al: Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): A systematic review and meta-analysis. *Lancet* 2018; 391:1693–1705
 408. Young P, Mackle D, Bellomo R, et al; ICU-ROX Investigators the Australian New Zealand Intensive Care Society Clinical Trials Group: Conservative oxygen therapy for mechanically ventilated adults with sepsis: A post hoc analysis of data from the intensive care unit randomized trial comparing two approaches to oxygen therapy (ICU-ROX). *Intensive Care Med* 2020; 46:17–26
 409. Barrot L, Asfar P, Mauny F, et al; LOCO2 Investigators and REVA Research Network: Liberal or conservative oxygen therapy for acute respiratory distress syndrome. *N Engl J Med* 2020; 382:999–1008
 410. Mauri T, Turrini C, Eronia N, et al: Physiologic effects of high-flow nasal cannula in acute hypoxemic respiratory failure. *Am J Respir Crit Care Med* 2017; 195:1207–1215
 411. Frat JP, Thille AW, Mercat A, et al; FLORALI Study Group; REVA Network: High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. *N Engl J Med* 2015; 372:2185–2196
 412. Ni YN, Luo J, Yu H, et al: The effect of high-flow nasal cannula in reducing the mortality and the rate of endotracheal intubation when used before mechanical ventilation compared with conventional oxygen therapy and noninvasive positive pressure ventilation. A systematic review and meta-analysis. *Am J Emerg Med* 2018; 36:226–233
 413. Ou X, Hua Y, Liu J, et al: Effect of high-flow nasal cannula oxygen therapy in adults with acute hypoxemic respiratory failure: A meta-analysis of randomized controlled trials. *CMAJ* 2017; 189:E260–E267
 414. Rochweg B, Granton D, Wang DX, et al: High-flow nasal cannula compared with conventional oxygen therapy for acute hypoxemic respiratory failure: Author's reply. *Intensive Care Med* 2019; 45:1171
 415. Demoule A, Chevret S, Carlucci A, et al; oVNI Study Group; REVA Network (Research Network in Mechanical Ventilation): Changing use of noninvasive ventilation in critically ill patients: Trends over 15 years in francophone countries. *Intensive Care Med* 2016; 42:82–92
 416. Demoule A, Girou E, Richard JC, et al: Benefits and risks of success or failure of noninvasive ventilation. *Intensive Care Med* 2006; 32:1756–1765
 417. Bellani G, Laffey JG, Pham T, et al; LUNG SAFE Investigators; ESICM Trials Group: Noninvasive ventilation of patients with acute respiratory distress syndrome. Insights from the LUNG SAFE study. *Am J Respir Crit Care Med* 2017; 195:67–77
 418. Antonelli M, Conti G, Rocco M, et al: A comparison of non-invasive positive-pressure ventilation and conventional mechanical ventilation in patients with acute respiratory failure. *N Engl J Med* 1998; 339:429–435
 419. Honrubia T, García López FJ, Franco N, et al: Noninvasive vs conventional mechanical ventilation in acute respiratory failure: A multicenter, randomized controlled trial. *Chest* 2005; 128:3916–3924
 420. Belenguer-Muncharaz A, Cubedo-Bort M, Blasco-Asensio D, et al: Non-invasive ventilation versus invasive mechanical ventilation in patients with hypoxemic acute respiratory failure in an intensive care unit. A randomized controlled study. *Minerva Pneumologica* 2017; 56:1–10
 421. Tonelli R, Fantini R, Tabbi L, et al: Early inspiratory effort assessment by esophageal manometry predicts noninvasive ventilation outcome in de novo respiratory failure. A pilot study. *Am J Respir Crit Care Med* 2020; 202:558–567
 422. Bernard GR, Artigas A, Brigham KL, et al: The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. *Am J Respir Crit Care Med* 1994; 149:818–824
 423. Ranieri VM, Rubenfeld GD, Thompson BT, et al; ARDS Definition Task Force: Acute respiratory distress syndrome: The Berlin Definition. *JAMA* 2012; 307:2526–2533
 424. Brower RG, Matthay MA, Morris A, et al; Acute Respiratory Distress Syndrome Network: Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. *N Engl J Med* 2000; 342:1301–1308
 425. Amato MB, Barbas CS, Medeiros DM, et al: Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. *N Engl J Med* 1998; 338:347–354
 426. Brochard L, Roudot-Thoraval F, Roupie E, et al: Tidal volume reduction for prevention of ventilator-induced lung injury in acute respiratory distress syndrome. The Multicenter Trial Group on Tidal Volume reduction in ARDS. *Am J Respir Crit Care Med* 1998; 158:1831–1838
 427. Brower RG, Shanholtz CB, Fessler HE, et al: Prospective, randomized, controlled clinical trial comparing traditional versus reduced tidal volume ventilation in acute respiratory distress syndrome patients. *Crit Care Med* 1999; 27:1492–1498
 428. Eichacker PQ, Gerstenberger EP, Banks SM, et al: Meta-analysis of acute lung injury and acute respiratory distress syndrome trials testing low tidal volumes. *Am J Respir Crit Care Med* 2002; 166:1510–1514
 429. Marini JJ, Gattinoni L: Ventilatory management of acute respiratory distress syndrome: A consensus of two. *Crit Care Med* 2004; 32:250–255
 430. Tobin MJ: Culmination of an era in research on the acute respiratory distress syndrome. *N Engl J Med* 2000; 342:1360–1361
 431. Hager DN, Krishnan JA, Hayden DL, et al; ARDS Clinical Trials Network: Tidal volume reduction in patients with acute lung injury when plateau pressures are not high. *Am J Respir Crit Care Med* 2005; 172:1241–1245
 432. Checkley W, Brower R, Korpak A, et al; Acute Respiratory Distress Syndrome Network Investigators: Effects of a clinical trial on mechanical ventilation practices in patients with acute lung injury. *Am J Respir Crit Care Med* 2008; 177:1215–1222
 433. Amato MB, Meade MO, Slutsky AS, et al: Driving pressure and survival in the acute respiratory distress syndrome. *N Engl J Med* 2015; 372:747–755

434. Papazian L, Aubron C, Brochard L, et al: Formal guidelines: Management of acute respiratory distress syndrome. *Ann Intensive Care* 2019; 9:69
435. Laffey JG, Bellani G, Pham T, et al; LUNG SAFE Investigators and the ESICM Trials Group: Potentially modifiable factors contributing to outcome from acute respiratory distress syndrome: The LUNG SAFE study. *Intensive Care Med* 2016; 42:1865–1876
436. Villar J, Martín-Rodríguez C, Domínguez-Berrot AM, et al; Spanish Initiative for Epidemiology, Stratification and Therapies for ARDS (SIESTA) Investigators Network: A quantile analysis of plateau and driving pressures: Effects on mortality in patients with acute respiratory distress syndrome receiving lung-protective ventilation. *Crit Care Med* 2017; 45:843–850
437. Hodgson CL, Cooper DJ, Arabi Y, et al: Maximal recruitment open lung ventilation in acute respiratory distress syndrome (PHARLAP). A phase II, multicenter randomized controlled clinical trial. *Am J Respir Crit Care Med* 2019; 200:1363–1372
438. Cavalcanti AB, Suzumura ÉA, Laranjeira LN, et al; Writing Group for the Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial (ART) Investigators: Effect of lung recruitment and titrated positive end-expiratory pressure (PEEP) vs low PEEP on mortality in patients with acute respiratory distress syndrome: A randomized clinical trial. *JAMA* 2017; 318:1335–1345
439. Brower RG, Lanken PN, MacIntyre N, et al; National Heart, Lung, and Blood Institute ARDS Clinical Trials Network: Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. *N Engl J Med* 2004; 351:327–336
440. Meade MO, Cook DJ, Guyatt GH, et al; Lung Open Ventilation Study Investigators: Ventilation strategy using low tidal volumes, recruitment maneuvers, and high positive end-expiratory pressure for acute lung injury and acute respiratory distress syndrome: A randomized controlled trial. *JAMA* 2008; 299:637–645
441. Mercat A, Richard JC, Vielle B, et al: Positive end-expiratory pressure setting in adults with acute lung injury and acute respiratory distress syndrome: A randomized controlled trial. *JAMA* 2008; 299:646–655
442. Kacmarek RM, Villar J, Sulemanji D, et al; Open Lung Approach Network: Open lung approach for the acute respiratory distress syndrome: A pilot, randomized controlled trial. *Crit Care Med* 2016; 44:32–42
443. Briel M, Meade M, Mercat A, et al: Higher vs lower positive end-expiratory pressure in patients with acute lung injury and acute respiratory distress syndrome: Systematic review and meta-analysis. *JAMA* 2010; 303:865–873
444. Goligher EC, Kavanagh BP, Rubenfeld GD, et al: Oxygenation response to positive end-expiratory pressure predicts mortality in acute respiratory distress syndrome. A secondary analysis of the LOVS and ExPress trials. *Am J Respir Crit Care Med* 2014; 190:70–76
445. Amato MB, Barbas CS, Medeiros DM, et al: Beneficial effects of the “open lung approach” with low distending pressures in acute respiratory distress syndrome. A prospective randomized study on mechanical ventilation. *Am J Respir Crit Care Med* 1995; 152:1835–1846
446. Gattinoni L, Caironi P, Cressoni M, et al: Lung recruitment in patients with the acute respiratory distress syndrome. *N Engl J Med* 2006; 354:1775–1786
447. Beitler JR, Sarge T, Banner-Goodspeed VM, et al; EPVent-2 Study Group: Effect of titrating positive end-expiratory pressure (PEEP) with an esophageal pressure-guided strategy vs an empirical high PEEP-Fio₂ strategy on death and days free from mechanical ventilation among patients with acute respiratory distress syndrome: A randomized clinical trial. *JAMA* 2019; 321:846–857
448. Talmor D, Sarge T, Malhotra A, et al: Mechanical ventilation guided by esophageal pressure in acute lung injury. *N Engl J Med* 2008; 359:2095–2104
449. Turbil E, Galerneau LM, Terzi N, et al: Positive-end expiratory pressure titration and transpulmonary pressure: The EPVENT 2 trial. *J Thorac Dis* 2019; 11(Suppl 15):S2012–S2017
450. Serpa Neto A, Cardoso SO, Manetta JA, et al: Association between use of lung-protective ventilation with lower tidal volumes and clinical outcomes among patients without acute respiratory distress syndrome: A meta-analysis. *JAMA* 2012; 308:1651–1659
451. Pipeling MR, Fan E: Therapies for refractory hypoxemia in acute respiratory distress syndrome. *JAMA* 2010; 304:2521–2527
452. Cavalcanti AB, Suzumura ÉA, Laranjeira LN, et al: Effect of lung recruitment and titrated positive end-expiratory pressure (PEEP) vs low PEEP on mortality in patients with acute respiratory distress syndrome: A randomized clinical trial. *JAMA* 2017; 318:1335–1345
453. Fan E, Wilcox ME, Brower RG, et al: Recruitment maneuvers for acute lung injury: A systematic review. *Am J Respir Crit Care Med* 2008; 178:1156–1163
454. Munshi L, Del Sorbo L, Adhikari NKJ, et al: Prone position for acute respiratory distress syndrome. A systematic review and meta-analysis. *Ann Am Thorac Soc* 2017; 14(Suppl 4):S280–S288
455. Sud S, Friedrich JO, Taccone P, et al: Prone ventilation reduces mortality in patients with acute respiratory failure and severe hypoxemia: Systematic review and meta-analysis. *Intensive Care Med* 2010; 36:585–599
456. Guérin C, Reignier J, Richard JC, et al; PROSEVA Study Group: Prone positioning in severe acute respiratory distress syndrome. *N Engl J Med* 2013; 368:2159–2168
457. Jolliet P, Bulpa P, Chevrolet JC: Effects of the prone position on gas exchange and hemodynamics in severe acute respiratory distress syndrome. *Crit Care Med* 1998; 26:1977–1985
458. Lamm WJ, Graham MM, Albert RK: Mechanism by which the prone position improves oxygenation in acute lung injury. *Am J Respir Crit Care Med* 1994; 150:184–193
459. Stocker R, Neff T, Stein S, et al: Prone positioning and low-volume pressure-limited ventilation improve survival in patients with severe ARDS. *Chest* 1997; 111:1008–1017
460. Gattinoni L, Tognoni G, Pesenti A, et al; Prone-Supine Study Group: Effect of prone positioning on the survival of patients with acute respiratory failure. *N Engl J Med* 2001; 345:568–573
461. Guerin C, Gaillard S, Lemasson S, et al: Effects of systematic prone positioning in hypoxemic acute respiratory

- failure: A randomized controlled trial. *JAMA* 2004; 292: 2379–2387
462. Klessig HT, Geiger HJ, Murray MJ, et al: A national survey on the practice patterns of anesthesiologist intensivists in the use of muscle relaxants. *Crit Care Med* 1992; 20:1341–1345
463. Murray MJ, Cowen J, DeBlock H, et al; Task Force of the American College of Critical Care Medicine (ACCM) of the Society of Critical Care Medicine (SCCM), American Society of Health-System Pharmacists, American College of Chest Physicians: Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. *Crit Care Med* 2002; 30:142–156
464. Hansen-Flaschen JH, Brazinsky S, Basile C, et al: Use of sedating drugs and neuromuscular blocking agents in patients requiring mechanical ventilation for respiratory failure. A national survey. *JAMA* 1991; 266:2870–2875
465. Forel JM, Roch A, Marin V, et al: Neuromuscular blocking agents decrease inflammatory response in patients presenting with acute respiratory distress syndrome. *Crit Care Med* 2006; 34:2749–2757
466. Gainnier M, Roch A, Forel JM, et al: Effect of neuromuscular blocking agents on gas exchange in patients presenting with acute respiratory distress syndrome. *Crit Care Med* 2004; 32:113–119
467. Papazian L, Forel JM, Gacouin A, et al; ACURASYS Study Investigators: Neuromuscular blockers in early acute respiratory distress syndrome. *N Engl J Med* 2010; 363:1107–1116
468. Alhazzani W, Alshahrani M, Jaeschke R, et al: Neuromuscular blocking agents in acute respiratory distress syndrome: A systematic review and meta-analysis of randomized controlled trials. *Crit Care* 2013; 17:R43
469. Guervilly C, Bisbal M, Forel JM, et al: Effects of neuromuscular blockers on transpulmonary pressures in moderate to severe acute respiratory distress syndrome. *Intensive Care Med* 2017; 43:408–418
470. Lyu G, Wang X, Jiang W, et al: [Clinical study of early use of neuromuscular blocking agents in patients with severe sepsis and acute respiratory distress syndrome]. *Zhonghua Wei Zhong Bing Ji Jiu Yi Xue* 2014; 26:325–329
471. National Heart, Lung, and Blood Institute PETAL Clinical Trials Network; Moss M, Huang DT, Brower RG, et al: Early neuromuscular blockade in the acute respiratory distress syndrome. *N Engl J Med* 2019; 380:1997–2008
472. Alhazzani W, Belley-Cote E, Møller MH, et al: Neuromuscular blockade in patients with ARDS: A rapid practice guideline. *Intensive Care Med* 2020; 46:1977–1986
473. Tarazan N, Alshehri M, Sharif S, et al; GUIDE Group: Neuromuscular blocking agents in acute respiratory distress syndrome: Updated systematic review and meta-analysis of randomized trials. *Intensive Care Med Exp* 2020; 8:61
474. Johnson KL, Cheung RB, Johnson SB, et al: Therapeutic paralysis of critically ill trauma patients: Perceptions of patients and their family members. *Am J Crit Care* 1999; 8:490–498
475. Munshi L, Walkey A, Goligher E, et al: Venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome: A systematic review and meta-analysis. *Lancet Respir Med* 2019; 7:163–172
476. Combes A, Hajage D, Capellier G, et al; EOLIA Trial Group, REVA, and ECMONet: Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. *N Engl J Med* 2018; 378:1965–1975
477. Peek GJ, Mugford M, Tiruvoipati R, et al; CESAR trial collaboration: Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): A multicentre randomised controlled trial. *Lancet* 2009; 374:1351–1363
478. Annane D, Renault A, Brun-Buisson C, et al; CRICS-TRIGGERSEP Network: Hydrocortisone plus fludrocortisone for adults with septic shock. *N Engl J Med* 2018; 378:809–818
479. Venkatesh B, Finfer S, Cohen J, et al; ADRENAL Trial Investigators and the Australian–New Zealand Intensive Care Society Clinical Trials Group: Adjunctive glucocorticoid therapy in patients with septic shock. *N Engl J Med* 2018; 378:797–808
480. Rygård SL, Butler E, Granholm A, et al: Low-dose corticosteroids for adult patients with septic shock: A systematic review with meta-analysis and trial sequential analysis. *Intensive Care Med* 2018; 44:1003–1016
481. Dellinger RP, Bagshaw SM, Antonelli M, et al; EUPHRATES Trial Investigators: Effect of targeted polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level: The EUPHRATES randomized clinical trial. *JAMA* 2018; 320:1455–1463
482. Zhou F, Peng Z, Murugan R, et al: Blood purification and mortality in sepsis: A meta-analysis of randomized trials. *Crit Care Med* 2013; 41:2209–2220
483. David S, Bode C, Putensen C, et al; EXCHANGE study group: Adjuvant therapeutic plasma exchange in septic shock. *Intensive Care Med* 2021; 47:352–354
484. Hébert PC, Wells G, Blajchman MA, et al: A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. *N Engl J Med* 1999; 340:409–417
485. Holst LB, Haase N, Wetterslev J, et al; TRISS Trial Group; Scandinavian Critical Care Trials Group: Lower versus higher hemoglobin threshold for transfusion in septic shock. *N Engl J Med* 2014; 371:1381–1391
486. Hirano Y, Miyoshi Y, Kondo Y, et al: Liberal versus restrictive red blood cell transfusion strategy in sepsis or septic shock: A systematic review and meta-analysis of randomized trials. *Crit Care* 2019; 23:262
487. Bergamin FS, Almeida JP, Landoni G, et al: Liberal versus restrictive transfusion strategy in critically ill oncologic patients: The transfusion requirements in critically ill oncologic patients randomized controlled trial. *Crit Care Med* 2017; 45:766–773
488. Hotchkiss RS, Monneret G, Payen D: Immunosuppression in sepsis: A novel understanding of the disorder and a new therapeutic approach. *Lancet Infect Dis* 2013; 13: 260–268
489. Madsen MB, Hjortrup PB, Hansen MB, et al: Immunoglobulin G for patients with necrotising soft tissue infection (INSTINCT): A randomised, blinded, placebo-controlled trial. *Intensive Care Med* 2017; 43:1585–1593

490. Welte T, Dellinger RP, Ebel H, et al: Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: A randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study). *Intensive Care Med* 2018; 44:438–448
491. Alejandria MM, Lansang MA, Dans LF, et al: Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. *Cochrane Database Syst Rev* 2013; 2013:Cd001090.
492. Busani S, Damiani E, Cavazzuti I, et al: Intravenous immunoglobulin in septic shock: Review of the mechanisms of action and meta-analysis of the clinical effectiveness. *Minerva Anestesiol* 2016; 82:559–572
493. Cook DJ, Fuller HD, Guyatt GH, et al: Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. *N Engl J Med* 1994; 330:377–381
494. Krag M, Marker S, Perner A, et al; SUP-ICU trial group: Pantoprazole in patients at risk for gastrointestinal bleeding in the ICU. *N Engl J Med* 2018; 379:2199–2208
495. D'Silva KM, Mehta R, Mitchell M, et al: Proton pump inhibitor use and risk for recurrent Clostridioides difficile infection: A systematic review and meta-analysis. *Clin Microbiol Infect* 2021:S1198-1743X(21)00035-5
496. Granholm A, Zeng L, Dionne JC, et al; GUIDE Group: Predictors of gastrointestinal bleeding in adult ICU patients: A systematic review and meta-analysis. *Intensive Care Med* 2019; 45:1347–1359
497. Cook D, Crowther M, Meade M, et al: Deep venous thrombosis in medical-surgical critically ill patients: Prevalence, incidence, and risk factors. *Crit Care Med* 2005; 33:1565–1571
498. Alhazzani W, Lim W, Jaeschke RZ, et al: Heparin thromboprophylaxis in medical-surgical critically ill patients: A systematic review and meta-analysis of randomized trials. *Crit Care Med* 2013; 41:2088–2098
499. Kahn SR, Lim W, Dunn AS, et al: Prevention of VTE in non-surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012; 141:e195S–e226S
500. Arabi YM, Al-Hameed F, Burns KEA, et al; Saudi Critical Care Trials Group: Adjunctive intermittent pneumatic compression for venous thromboprophylaxis. *N Engl J Med* 2019; 380:1305–1315
501. Kellum JA, Angus DC, Johnson JP, et al: Continuous versus intermittent renal replacement therapy: A meta-analysis. *Intensive Care Med* 2002; 28:29–37
502. Tonelli M, Manns B, Feller-Kopman D: Acute renal failure in the intensive care unit: A systematic review of the impact of dialytic modality on mortality and renal recovery. *Am J Kidney Dis* 2002; 40:875–885
503. Zha J, Li C, Cheng G, et al: The efficacy of renal replacement therapy strategies for septic-acute kidney injury: A PRISMA-compliant network meta-analysis. *Medicine (Baltimore)* 2019; 98:e15257
504. Zhao Y, Chen Y: Effect of renal replacement therapy modalities on renal recovery and mortality for acute kidney injury: A PRISMA-compliant systematic review and meta-analysis. *Semin Dial* 2020; 33:127–132
505. Zarbock A, Kellum JA, Schmidt C, et al: Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: The ELAIN randomized clinical trial. *JAMA* 2016; 315:2190–2199
506. Gaudry S, Hajage D, Schortgen F, et al; AKIKI Study Group: Initiation strategies for renal-replacement therapy in the intensive care unit. *N Engl J Med* 2016; 375:122–133
507. Barbar SD, Clere-Jehl R, Bourredjem A, et al; IDEAL-ICU Trial Investigators and the CRICS TRIGGERSEP Network: Timing of renal-replacement therapy in patients with acute kidney injury and sepsis. *N Engl J Med* 2018; 379:1431–1442
508. STARRT-AKI Investigators; Canadian Critical Care Trials Group; Australian and New Zealand Intensive Care Society Clinical Trials Group; United Kingdom Critical Care Research Group; Canadian Nephrology Trials Network; Irish Critical Care Trials Group; Bagshaw SM, Wald R, Adhikari NKJ; et al: Timing of initiation of renal-replacement therapy in acute kidney injury. *N Engl J Med* 2020; 383:240–251
509. Badawi O, Waite MD, Fuhrman SA, et al: Association between intensive care unit-acquired dysglycemia and in-hospital mortality. *Crit Care Med* 2012; 40:3180–3188
510. Krinsley JS: Glycemic variability: A strong independent predictor of mortality in critically ill patients. *Crit Care Med* 2008; 36:3008–3013
511. Siegelar SE, Hermanides J, Oudemans-van Straaten HM, et al: Mean glucose during ICU admission is related to mortality by a U-shaped curve in surgical and medical patients: A retrospective cohort study. *Crit Care* 2010; 14:R224
512. American Diabetes Association: 14. Diabetes care in the hospital: Standards of medical care in diabetes—2018. *Diabetes Care* 2018; 41(Suppl 1):S144–S151
513. van den Berghe G, Wouters P, Weekers F, et al: Intensive insulin therapy in critically ill patients. *N Engl J Med* 2001; 345:1359–1367
514. Brunkhorst FM, Engel C, Bloos F, et al; German Competence Network Sepsis (SepNet): Intensive insulin therapy and pentastarch resuscitation in severe sepsis. *N Engl J Med* 2008; 358:125–139
515. Preiser JC, Devos P, Ruiz-Santana S, et al: A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: The Glucontrol study. *Intensive Care Med* 2009; 35:1738–1748
516. Griesdale DE, de Souza RJ, van Dam RM, et al: Intensive insulin therapy and mortality among critically ill patients: A meta-analysis including NICE-SUGAR study data. *CMAJ* 2009; 180:821–827
517. Song F, Zhong LJ, Han L, et al: Intensive insulin therapy for septic patients: A meta-analysis of randomized controlled trials. *Biomed Res Int* 2014; 2014:698265. doi: 10.1155/2014/698265
518. NICE-SUGAR Study Investigators; Finfer S, Chittock DR, Su SY, et al: The NICE-SUGAR Study Investigators: Intensive versus conventional glucose control in critically ill patients. *N Engl J Med* 2009; 360:1283–1297.
519. Yatabe T, Inoue S, Sakaguchi M, et al: The optimal target for acute glycemic control in critically ill patients: A network meta-analysis. *Intensive Care Med* 2017; 43:16–28

520. Kuhn SO, Meissner K, Mayes LM, et al: Vitamin C in sepsis. *Curr Opin Anaesthesiol* 2018; 31:55–60
521. Marik PE, Khangoora V, Rivera R, et al: Hydrocortisone, vitamin C, and thiamine for the treatment of severe sepsis and septic shock: A retrospective before-after study. *Chest* 2017; 151:1229–1238
522. Putzu A, Daems AM, Lopez-Delgado JC, et al: The effect of vitamin C on clinical outcome in critically ill patients: A systematic review with meta-analysis of randomized controlled trials. *Crit Care Med* 2019; 47:774–783
523. Fowler AA III, Truitt JD, Hite RD, et al: Effect of vitamin C infusion on organ failure and biomarkers of inflammation and vascular injury in patients with sepsis and severe acute respiratory failure: The CITRIS-ALI randomized clinical trial. *JAMA* 2019; 322:1261–1270
524. Fujii T, Luethi N, Young PJ, et al; VITAMINS Trial Investigators: Effect of vitamin C, hydrocortisone, and thiamine vs hydrocortisone alone on time alive and free of vasopressor support among patients with septic shock: The VITAMINS randomized clinical trial. *JAMA* 2020; 323:423–431
525. Moskowitz A, Huang DT, Hou PC, et al; ACTS Clinical Trial Investigators: Effect of ascorbic acid, corticosteroids, and thiamine on organ injury in septic shock: The ACTS randomized clinical trial. *JAMA* 2020; 324:642–650
526. Cooper DJ, Walley KR, Wiggs BR, et al: Bicarbonate does not improve hemodynamics in critically ill patients who have lactic acidosis. A prospective, controlled clinical study. *Ann Intern Med* 1990; 112:492–498
527. Mathieu D, Neviere R, Billard V, et al: Effects of bicarbonate therapy on hemodynamics and tissue oxygenation in patients with lactic acidosis: A prospective, controlled clinical study. *Crit Care Med* 1991; 19:1352–1356
528. Jaber S, Paugam C, Futier E, et al; BICAR-ICU Study Group: Sodium bicarbonate therapy for patients with severe metabolic acidemia in the intensive care unit (BICAR-ICU): A multicentre, open-label, randomised controlled, phase 3 trial. *Lancet* 2018; 392:31–40
529. Kudsk KA: Current aspects of mucosal immunology and its influence by nutrition. *Am J Surg* 2002; 183:390–398
530. McClave SA, Heyland DK: The physiologic response and associated clinical benefits from provision of early enteral nutrition. *Nutr Clin Pract* 2009; 24:305–315
531. Reignier J, Boisramé-Helms J, Brisard L, et al; NUTRIREA-2 Trial Investigators; Clinical Research in Intensive Care and Sepsis (CRICS) group: Enteral versus parenteral early nutrition in ventilated adults with shock: A randomised, controlled, multicentre, open-label, parallel-group study (NUTRIREA-2). *Lancet* 2018; 391:133–143
532. Ibrahim EH, Mehlinger L, Prentice D, et al: Early versus late enteral feeding of mechanically ventilated patients: Results of a clinical trial. *JPEN J Parenter Enteral Nutr* 2002; 26:174–181
533. Malhotra A, Mathur AK, Gupta S: Early enteral nutrition after surgical treatment of gut perforations: A prospective randomised study. *J Postgrad Med* 2004; 50:102–106
534. Pupelis G, Austrums E, Jansone A, et al: Randomised trial of safety and efficacy of postoperative enteral feeding in patients with severe pancreatitis: Preliminary report. *Eur J Surg* 2000; 166:383–387
535. Singh G, Ram RP, Khanna SK: Early postoperative enteral feeding in patients with nontraumatic intestinal perforation and peritonitis. *J Am Coll Surg* 1998; 187:142–146
536. Ely EW: The ABCDEF bundle: Science and philosophy of how ICU liberation serves patients and families. *Crit Care Med* 2017; 45:321–330
537. Brinkman-Stoppelenburg A, Rietjens JA, van der Heide A: The effects of advance care planning on end-of-life care: A systematic review. *Palliat Med* 2014; 28:1000–1025
538. White DB, Angus DC, Shields AM, et al; PARTNER Investigators: A randomized trial of a family-support intervention in intensive care units. *N Engl J Med* 2018; 378:2365–2375
539. Schneiderman LJ, Gilmer T, Teetzel HD: Impact of ethics consultations in the intensive care setting: A randomized, controlled trial. *Crit Care Med* 2000; 28:3920–3924
540. Schneiderman LJ, Gilmer T, Teetzel HD, et al: Effect of ethics consultations on nonbeneficial life-sustaining treatments in the intensive care setting: A randomized controlled trial. *JAMA* 2003; 290:1166–1172
541. Chen C, Michaels J, Meeker MA: Family outcomes and perceptions of end-of-life care in the intensive care unit: A mixed-methods review. *J Palliat Care* 2020; 35:143–153
542. Andereck WS, McGaughey JW, Schneiderman LJ, et al: Seeking to reduce nonbeneficial treatment in the ICU: An exploratory trial of proactive ethics intervention*. *Crit Care Med* 2014; 42:824–830
543. Carson SS, Cox CE, Wallenstein S, et al: Effect of palliative care-led meetings for families of patients with chronic critical illness: A randomized clinical trial. *JAMA* 2016; 316:51–62
544. Picker D, Dans M, Heard K, et al: A randomized trial of palliative care discussions linked to an automated early warning system alert. *Crit Care Med* 2017; 45:234–240
545. Cheung W, Aggarwal G, Fugaccia E, et al: Palliative care teams in the intensive care unit: A randomised, controlled, feasibility study. *Crit Care Resusc* 2010; 12:28–35
546. Curtis JR, Nielsen EL, Treece PD, et al: Effect of a quality-improvement intervention on end-of-life care in the intensive care unit: A randomized trial. *Am J Respir Crit Care Med* 2011; 183:348–355
547. Lautrette A, Darmon M, Megarbane B, et al: A communication strategy and brochure for relatives of patients dying in the ICU. *N Engl J Med* 2007; 356:469–478
548. Ma J, Chi S, Buettner B, et al: Early palliative care consultation in the medical ICU: A cluster randomized crossover trial. *Crit Care Med* 2019; 47:1707–1715
549. Clark E, MacCrosain A, Ward NS, et al: The key features and role of peer support within group self-management interventions for stroke? A systematic review. *Disabil Rehabil* 2020; 42:307–316
550. Govindan S, Iwashyna TJ, Watson SR, et al: Issues of survivorship are rarely addressed during intensive care unit stays. Baseline results from a statewide quality improvement collaborative. *Ann Am Thorac Soc* 2014; 11:587–591
551. Wobma R, Nijland RH, Ket JC, et al: Evidence for peer support in rehabilitation for individuals with acquired brain injury: A systematic review. *J Rehabil Med* 2016; 48:837–840

552. McPeake J, Hirshberg EL, Christie LM, et al: Models of peer support to remediate post-intensive care syndrome: A report developed by the society of critical care medicine thrive international peer support collaborative. *Crit Care Med* 2019; 47:e21–e27
553. Mikkelsen ME, Jackson JC, Hopkins RO, et al: Peer support as a novel strategy to mitigate post-intensive care syndrome. *AACN Adv Crit Care* 2016; 27:221–229
554. Halm MA: Effects of support groups on anxiety of family members during critical illness. *Heart Lung* 1990; 19:62–71
555. Fridlund B, Stener-Bengtsson A, Wännman AL: Social support and social network after acute myocardial infarction; the critically ill male patient's needs, choice and motives. *Intensive Crit Care Nurs* 1993; 9:88–94
556. McPeake J, Shaw M, Iwashyna TJ, et al: Intensive care syndrome: Promoting independence and return to employment (InS:PIRE). Early evaluation of a complex intervention. *PLoS One* 2017; 12:e0188028
557. Sabo KA, Kraay C, Rudy E, et al: ICU family support group sessions: Family members' perceived benefits. *Appl Nurs Res* 1989; 2:82–89
558. Parent N, Fortin F: A randomized, controlled trial of vicarious experience through peer support for male first-time cardiac surgery patients: Impact on anxiety, self-efficacy expectation, and self-reported activity. *Heart Lung* 2000; 29:389–400
559. Damianakis T, Tough A, Marziali E, et al: Therapy online: A web-based video support group for family caregivers of survivors with traumatic brain injury. *J Head Trauma Rehabil* 2016; 31:E12–E20
560. Harvey C, Dixon M, Padberg N: Support group for families of trauma patients: A unique approach. *Crit Care Nurse* 1995; 15:59–63
561. Jones C, Macmillan RR, Griffiths RD: Providing psychological support for patients after critical illness. *Clin Intensive Care* 1994; 5:176–179
562. Peskett M, Gibb P: Developing and setting up a patient and relatives intensive care support group. *Nurs Crit Care* 2009; 14:4–10
563. Sacco TL, Stapleton MF, Ingersoll GL: Support groups facilitated by families of former patients: Creating family-inclusive critical care units. *Crit Care Nurse* 2009; 29:36–45
564. Haines KJ, Beesley SJ, Hopkins RO, et al: Peer support in critical care: A systematic review. *Crit Care Med* 2018; 46:1522–1531
565. Danesh V: A prospective, 2-arm, single-blind, randomized controlled clinical feasibility trial design is planned. Forty CCI survivors will be randomized (1:1) to either the PS-PICS (peer support) intervention or usual care (control) group. 2019. NCT03788096. Available at: <https://clinicaltrials.gov/ct2/show/study/NCT03788096>
566. Haines KJ, Holdsworth C, Cranwell K, et al: Development of a peer support model using experience-based co-design to improve critical care recovery. *Crit Care Explor* 2019; 1:e0006
567. Matthaues-Kraemer CT, Thomas-Rueddel DO, Schwarzkopf D, et al: Crossing the handover chasm: Clinicians' perceptions of barriers to the early detection and timely management of severe sepsis and septic shock. *J Crit Care* 2016; 36:85–91
568. Parent B, LaGrone LN, Albirair MT, et al: Effect of standardized handoff curriculum on improved clinician preparedness in the intensive care unit: A stepped-wedge cluster randomized clinical trial. *JAMA Surg* 2018; 153:464–470
569. Nanchal R, Aebly B, Graves G, et al: Controlled trial to improve resident sign-out in a medical intensive care unit. *BMJ Qual Saf* 2017; 26:987–992
570. Hess DR, Tokarczyk A, O'Malley M, et al: The value of adding a verbal report to written handoffs on early readmission following prolonged respiratory failure. *Chest* 2010; 138:1475–1479
571. Hoffman RL, Saucier J, Dasani S, et al: Development and implementation of a risk identification tool to facilitate critical care transitions for high-risk surgical patients. *Int J Qual Health Care* 2017; 29:412–419
572. Chaboyer W, Lin F, Foster M, et al: Redesigning the ICU nursing discharge process: A quality improvement study. *Worldviews Evid Based Nurs* 2012; 9:40–48
573. Medlock S, Eslami S, Askari M, et al: Improved communication in post-ICU care by improving writing of ICU discharge letters: A longitudinal before-after study. *BMJ Qual Saf* 2011; 20:967–973
574. Griffiths J, Hatch RA, Bishop J, et al: An exploration of social and economic outcome and associated health-related quality of life after critical illness in general intensive care unit survivors: A 12-month follow-up study. *Crit Care* 2013; 17:R100
575. Donnelly JP, Lakkur S, Judd SE, et al: Association of neighborhood socioeconomic status with risk of infection and sepsis. *Clin Infect Dis* 2018; 66:1940–1947
576. Koch K, Nørgaard M, Schönheyder HC, et al; Danish Collaborative Bacteremia Network: Effect of socioeconomic status on mortality after bacteremia in working-age patients. A Danish population-based cohort study. *PLoS One* 2013; 8:e70082
577. Ho KM, Dobb GJ, Knuiman M, et al: The effect of socioeconomic status on outcomes for seriously ill patients: A linked data cohort study. *Med J Aust* 2008; 189:26–30
578. Ogundipe F, Kodadhala V, Ogundipe T, et al: Disparities in sepsis mortality by region, urbanization, and race in the USA: A multiple cause of death analysis. *J Racial Ethn Health Disparities* 2019; 6:546–551
579. Goodwin AJ, Nadig NR, McElligott JT, et al: Where you live matters: The impact of place of residence on severe sepsis incidence and mortality. *Chest* 2016; 150:829–836
580. Prescott HC, Angus DC: Enhancing recovery from sepsis: A review. *JAMA* 2018; 319:62–75
581. Gruther W, Pieber K, Steiner I, et al: Can early rehabilitation on the general ward after an intensive care unit stay reduce hospital length of stay in survivors of critical illness?: A randomized controlled trial. *Am J Phys Med Rehabil* 2017; 96:607–615
582. Huang CY, Daniels R, Lembo A, et al; Sepsis Survivors Engagement Project (SSEP): Life after sepsis: An international survey of survivors to understand the post-sepsis syndrome. *Int J Qual Health Care* 2019; 31:191–198

583. Azoulay E, Pochard F, Chevret S, et al: Impact of a family information leaflet on effectiveness of information provided to family members of intensive care unit patients: A multicenter, prospective, randomized, controlled trial. *Am J Respir Crit Care Med* 2002; 165:438–442
584. Bench S, Day T, Heelas K, et al: Evaluating the feasibility and effectiveness of a critical care discharge information pack for patients and their families: A pilot cluster randomised controlled trial. *BMJ Open* 2015; 5:e006852
585. Demircelik MB, Cakmak M, Nazli Y, et al: Effects of multimedia nursing education on disease-related depression and anxiety in patients staying in a coronary intensive care unit. *Appl Nurs Res* 2016; 29:5–8
586. Fleischer S, Berg A, Behrens J, et al: Does an additional structured information program during the intensive care unit stay reduce anxiety in ICU patients?: A multicenter randomized controlled trial. *BMC Anesthesiol* 2014; 14:48
587. Gehrke-Beck S, Bänfer M, Schilling N, et al: The specific needs of patients following sepsis: A nested qualitative interview study. *BJGP Open* 2017; 1:bjgpopen17X100725
588. Schmidt K, Worrack S, Von Korff M, et al; SMOOTH Study Group: Effect of a primary care management intervention on mental health-related quality of life among survivors of sepsis: A randomized clinical trial. *JAMA* 2016; 315:2703–2711
589. Oermann MH, McInerney SM: An evaluation of sepsis Web sites for patient and family education. *Plast Surg Nurs* 2007; 27:192–196
590. Légaré F, Adekpedjou R, Stacey D, et al: Interventions for increasing the use of shared decision making by health-care professionals. *Cochrane Database Syst Rev* 2018; 7:CD006732
591. Anderson WG, Arnold RM, Angus DC, et al: Passive decision-making preference is associated with anxiety and depression in relatives of patients in the intensive care unit. *J Crit Care* 2009; 24:249–254
592. Bokinskie JC: Family conferences: A method to diminish transfer anxiety. *J Neurosci Nurs* 1992; 24:129–133
593. Choi J, Lingler JH, Donahoe MP, et al: Home discharge following critical illness: A qualitative analysis of family caregiver experience. *Heart Lung* 2018; 47:401–407
594. Moss KO, Douglas SL, Baum E, et al: Family surrogate decision-making in chronic critical illness: A qualitative analysis. *Crit Care Nurse* 2019; 39:e18–e26
595. Austin CA, Mohottige D, Sudore RL, et al: Tools to promote shared decision making in serious illness: A systematic review. *JAMA Intern Med* 2015; 175:1213–1221
596. Bell CM, Brener SS, Gunraj N, et al: Association of ICU or hospital admission with unintentional discontinuation of medications for chronic diseases. *JAMA* 2011; 306:840–847
597. Fabes J, Seligman W, Barrett C, et al: Does the implementation of a novel intensive care discharge risk score and nurse-led inpatient review tool improve outcome? A prospective cohort study in two intensive care units in the UK. *BMJ Open* 2017; 7:e018322
598. Mekonnen AB, McLachlan AJ, Brien JA: Pharmacy-led medication reconciliation programmes at hospital transitions: A systematic review and meta-analysis. *J Clin Pharm Ther* 2016; 41:128–144
599. Morandi A, Vasilevskis E, Pandharipande PP, et al: Inappropriate medication prescriptions in elderly adults surviving an intensive care unit hospitalization. *J Am Geriatr Soc* 2013; 61:1128–1134
600. Scales DC, Fischer HD, Li P, et al: Unintentional continuation of medications intended for acute illness after hospital discharge: A population-based cohort study. *J Gen Intern Med* 2016; 31:196–202
601. Stelfox HT, Bastos J, Niven DJ, et al: Critical care transition programs and the risk of readmission or death after discharge from ICU. *Intensive Care Med* 2016; 42:401–410
602. Tomichek JE, Stollings JL, Pandharipande PP, et al: Antipsychotic prescribing patterns during and after critical illness: A prospective cohort study. *Crit Care* 2016; 20:378
603. Ball C, Kirkby M, Williams S: Effect of the critical care outreach team on patient survival to discharge from hospital and readmission to critical care: Non-randomised population based study. *BMJ* 2003; 327:1014
604. Baxter AD, Cardinal P, Hooper J, et al: Medical emergency teams at The Ottawa Hospital: The first two years. *Can J Anaesth* 2008; 55:223–231
605. Choi S, Lee J, Shin Y, et al: Effects of a medical emergency team follow-up programme on patients discharged from the medical intensive care unit to the general ward: A single-centre experience. *J Eval Clin Pract* 2016; 22:356–362
606. Elliott D, McKinley S, Alison J, et al: Health-related quality of life and physical recovery after a critical illness: A multicentre randomised controlled trial of a home-based physical rehabilitation program. *Crit Care* 2011; 15:R142
607. Garcea G, Thomasset S, McClelland L, et al: Impact of a critical care outreach team on critical care readmissions and mortality. *Acta Anaesthesiol Scand* 2004; 48:1096–1100
608. Green A, Edmonds L: Bridging the gap between the intensive care unit and general wards—the ICU Liaison Nurse. *Intensive Crit Care Nurs* 2004; 20:133–143
609. Leary T, Ridley S: Impact of an outreach team on readmissions to a critical care unit. *Anaesthesia* 2003; 58:328–332
610. Pittard AJ: Out of our reach? Assessing the impact of introducing a critical care outreach service. *Anaesthesia* 2003; 58:882–885
611. Williams TA, Leslie G, Finn J, et al: Clinical effectiveness of a critical care nursing outreach service in facilitating discharge from the intensive care unit. *Am J Crit Care* 2010; 19:e63–e72
612. Pronovost P, Weast B, Schwarz M, et al: Medication reconciliation: A practical tool to reduce the risk of medication errors. *J Crit Care* 2003; 18:201–205
613. Ravn-Nielsen LV, Duckert ML, Lund ML, et al: Effect of an in-hospital multifaceted clinical pharmacist intervention on the risk of readmission: A randomized clinical trial. *JAMA Intern Med* 2018; 178:375–382
614. Taylor SP, Chou SH, Sierra MF, et al: Association between adherence to recommended care and outcomes for adult survivors of sepsis. *Ann Am Thorac Soc* 2020; 17:89–97
615. Etesse B, Jaber S, Mura T, et al; AzuRéa Group: How the relationships between general practitioners and intensivists

- can be improved: The general practitioners' point of view. *Crit Care* 2010; 14:R112
616. Kripalani S, LeFevre F, Phillips CO, et al: Deficits in communication and information transfer between hospital-based and primary care physicians: Implications for patient safety and continuity of care. *JAMA* 2007; 297:831–841
 617. Robelia PM, Kashiwagi DT, Jenkins SM, et al: Information transfer and the hospital discharge summary: National primary care provider perspectives of challenges and opportunities. *J Am Board Fam Med* 2017; 30:758–765
 618. Weissman GE, Harhay MO, Lugo RM, et al: Natural language processing to assess documentation of features of critical illness in discharge documents of acute respiratory distress syndrome survivors. *Ann Am Thorac Soc* 2016; 13:1538–1545
 619. Needham DM, Davidson J, Cohen H, et al: Improving long-term outcomes after discharge from intensive care unit: Report from a stakeholders' conference. *Crit Care Med* 2012; 40:502–509
 620. Iwashyna TJ, Ely EW, Smith DM, et al: Long-term cognitive impairment and functional disability among survivors of severe sepsis. *JAMA* 2010; 304:1787–1794
 621. König C, Matt B, Kortgen A, et al: What matters most to sepsis survivors: A qualitative analysis to identify specific health-related quality of life domains. *Qual Life Res* 2019; 28:637–647
 622. Dietz BW, Jones TK, Small DS, et al: The relationship between index hospitalizations, sepsis, and death or transition to hospice care during 30-day hospital readmissions. *Med Care* 2017; 55:362–370
 623. Ortego A, Gaieski DF, Fuchs BD, et al: Hospital-based acute care use in survivors of septic shock. *Crit Care Med* 2015; 43:729–737
 624. Mayr FB, Talisa VB, Balakumar V, et al: Proportion and cost of unplanned 30-day readmissions after sepsis compared with other medical conditions. *JAMA* 2017; 317:530–531
 625. Hernandez AF, Greiner MA, Fonarow GC, et al: Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. *JAMA* 2010; 303:1716–1722
 626. Field TS, Ogarek J, Garber L, et al: Association of early post-discharge follow-up by a primary care physician and 30-day rehospitalization among older adults. *J Gen Intern Med* 2015; 30:565–571
 627. Shen E, Koyama SY, Huynh DN, et al: Association of a dedicated post-hospital discharge follow-up visit and 30-day readmission risk in a medicare advantage population. *JAMA Intern Med* 2017; 177:132–135
 628. Douglas SL, Daly BJ, Kelley CG, et al: Chronically critically ill patients: Health-related quality of life and resource use after a disease management intervention. *Am J Crit Care* 2007; 16:447–457
 629. Jónasdóttir RJ, Jónsdóttir H, Gudmundsdóttir B, et al: Psychological recovery after intensive care: Outcomes of a long-term quasi-experimental study of structured nurse-led follow-up. *Intensive Crit Care Nurs* 2018; 44:59–66
 630. Kansagara D, Ramsay RS, Labby D, et al: Post-discharge intervention in vulnerable, chronically ill patients. *J Hosp Med* 2012; 7:124–130
 631. Deb P, Murtaugh CM, Bowles KH, et al: Does early follow-up improve the outcomes of sepsis survivors discharged to home health care? *Med Care* 2019; 57:633–640
 632. Annane D, Sharshar T: Cognitive decline after sepsis. *Lancet Respir Med* 2015; 3:61–69
 633. Jackson JC, Ely EW, Morey MC, et al: Cognitive and physical rehabilitation of intensive care unit survivors: Results of the RETURN randomized controlled pilot investigation. *Crit Care Med* 2012; 40:1088–1097
 634. Brummel NE, Girard TD, Ely EW, et al: Feasibility and safety of early combined cognitive and physical therapy for critically ill medical and surgical patients: The activity and cognitive therapy in ICU (ACT-ICU) trial. *Intensive Care Med* 2014; 40:370–379
 635. Zhao J, Yao L, Li M, et al: [Effects of early intervention training on cognitive impairment in critical patients]. *Zhonghua Wei Zhong Bing Ji Jiu Yi Xue* 2019; 31:298–302
 636. Wong GKC, Mak JSY, Wong A, et al: Minimum Clinically Important Difference of Montreal Cognitive Assessment in aneurysmal subarachnoid hemorrhage patients. *J Clin Neurosci* 2017; 46:41–44
 637. Teixeira C, Rosa RG: Post-intensive care outpatient clinic: Is it feasible and effective? A literature review. *Rev Bras Ter Intensiva* 2018; 30:98–111
 638. Cuthbertson BH, Rattray J, Campbell MK, et al; PRaCTICaL study group: The PRaCTICaL study of nurse led, intensive care follow-up programmes for improving long term outcomes from critical illness: A pragmatic randomised controlled trial. *BMJ* 2009; 339:b3723
 639. Jensen JF, Egerod I, Bestle MH, et al: A recovery program to improve quality of life, sense of coherence and psychological health in ICU survivors: A multicenter randomized controlled trial, the RAPIT study. *Intensive Care Med* 2016; 42:1733–1743
 640. Schofield-Robinson OJ, Lewis SR, Smith AF, et al: Follow-up services for improving long-term outcomes in intensive care unit (ICU) survivors. *Cochrane Database Syst Rev* 2018; 11:CD012701
 641. Kowalkowski M, Chou SH, McWilliams A, et al; Atrium Health ACORN Investigators: Structured, proactive care coordination versus usual care for Improving Morbidity during Post-Acute Care Transitions for Sepsis (IMPACTS): A pragmatic, randomized controlled trial. *Trials* 2019; 20:660
 642. Paratz JD, Kenardy J, Mitchell G, et al: IMPOSE (IMProving Outcomes after Sepsis)-the effect of a multidisciplinary follow-up service on health-related quality of life in patients postsepsis syndromes-a double-blinded randomised controlled trial: Protocol. *BMJ Open* 2014; 4:e004966
 643. Prescott HC, Iwashyna TJ, Blackwood B, et al: Understanding and enhancing sepsis survivorship. Priorities for research and practice. *Am J Respir Crit Care Med* 2019; 200:972–981
 644. Batterham AM, Bonner S, Wright J, et al: Effect of supervised aerobic exercise rehabilitation on physical fitness and quality-of-life in survivors of critical illness: An exploratory minimized controlled trial (PIX study). *Br J Anaesth* 2014; 113:130–137

645. Battle C, James K, Temblett P, et al: Supervised exercise rehabilitation in survivors of critical illness: A randomised controlled trial. *J Intensive Care Soc* 2019; 20:18–26
646. Connolly B, Thompson A, Douiri A, et al: Exercise-based rehabilitation after hospital discharge for survivors of critical illness with intensive care unit-acquired weakness: A pilot feasibility trial. *J Crit Care* 2015; 30:589–598
647. Jones C, Skirrow P, Griffiths RD, et al: Rehabilitation after critical illness: A randomized, controlled trial. *Crit Care Med* 2003; 31:2456–2461
648. Jones TK, Fuchs BD, Small DS, et al: Post-acute care use and hospital readmission after sepsis. *Ann Am Thorac Soc* 2015; 12:904–913
649. McDowell K, O'Neill B, Blackwood B, et al: Effectiveness of an exercise programme on physical function in patients discharged from hospital following critical illness: A randomised controlled trial (the REVIVE trial). *Thorax* 2017; 72:594–595
650. McWilliams DJ, Benington S, Atkinson D: Outpatient-based physical rehabilitation for survivors of prolonged critical illness: A randomized controlled trial. *Physiother Theory Pract* 2016; 32:179–190
651. Walsh TS, Salisbury LG, Merriweather JL, et al; RECOVER Investigators: Increased hospital-based physical rehabilitation and information provision after intensive care unit discharge: The RECOVER randomized clinical trial. *JAMA Intern Med* 2015; 175:901–910
652. Health Nif; Excellence C: Rehabilitation after critical illness in adults: NICE Reino Unido. 2014. Available at: <https://www.nice.org.uk/guidance/qs158/resources/rehabilitation-after-critical-illness-in-adults-pdf-75545546693317>. Accessed March 17, 2021
653. Major ME, Kwakman R, Kho ME, et al: Surviving critical illness: What is next? An expert consensus statement on physical rehabilitation after hospital discharge. *Crit Care* 2016; 20:354